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ABSTRACT 
Megan Clarke Roberts: Racial Variation in the Use of Oncotype DX Testing among Women with 
Breast Cancer 
(Under the direction of Morris Weinberger) 
 
 Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy 
decision-making. While ODX has the potential to improve quality of care, <50% of eligible women 
receive it. If there is differential ODX testing by race, well-documented disparities in quality of cancer 
care may persist or worsen. Thus, we had three research objectives: (1) examine racial variation in 
ODX test uptake, (2) examine racial variation in subsequent adjuvant chemotherapy initiation, and (3) 
explore how oncologists use the test, identifying barriers and facilitators. 
 We used mixed methods to explore these objectives. We used data from the Carolina Breast 
Cancer Study Phase III (n=2,998), a population-based cohort study of women diagnosed with breast 
cancer in 2008-2014. We used modified Poisson regression to determine the associations between 
race and (1) ODX testing (stratified by node status), and (2) adjuvant chemotherapy initiation 
(stratified by ODX risk group). We also conducted semi-structured interviews with oncologists (n=15). 
Interview transcripts were double-coded using template analysis. 
 Overall, 42% of women (n=1468) had ODX testing. We found no racial disparities in the 
uptake of ODX testing among node negative patients. However, among node positive patients, Black 
patients were 46% less likely to receive testing than non-Black women after controlling for clinical 
factors (aRR: 0.54, 95%CI:0.35-0.84, p=0.006). Among women who underwent ODX testing (n=541), 
54.2%, 37.5%, and 8.3% of women had low-, intermediate- and high-risk tumors, respectively. We did 
not observe racial variation in adjuvant chemotherapy initiation. Several themes emerged from our 
provider interviews, including organizational, interpersonal, and intrapersonal factors that influenced 
ODX testing.  
 Overall, we did not find racial disparities in ODX testing for node negative patients for whom 
the test is guideline-recommended and widely covered by insurers; however, our findings suggested 
iv 
that a newer application of ODX testing for node positive breast cancer was accessed less often by 
Black than non-Black women. This finding indicates more guideline-concordant treatment, but also 
may signal slower diffusion of newer test-applications among Black patients. As treatment decision-
making becomes increasingly targeted with the use of genetic technologies, it may be important to 
examine their use across racial subgroups during early adoption.  
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CHAPTER 1. ONCOTYPE DX TESTING IN WOMEN WITH BREAST CANCER: OVERVIEW 
Specific Aims 
Breast cancer remains the second leading cause of cancer death among women, and while 
the incidence of breast cancer is lower among Black women, their breast cancer mortality is 37% 
higher compared to white women.[1, 2] Transformative research and technology have improved the 
prognosis and treatment of breast cancer in the past decade. However, even when controlling for 
known differences in tumor biology, racial disparities in breast cancer care processes and outcomes 
continue to grow[3, 4], suggesting that this racial disparity can be partially explained by access to high 
quality cancer treatment.[5, 6] In 2004, a genomic innovation in breast cancer treatment, Oncotype 
DX® (ODX), became commercially available [7]. ODX uses tumor genetics to predict not only risk of 
recurrence, but also the benefit of chemotherapy among early-stage, estrogen receptor positive 
breast cancer patients.[7] [8, 9] ODX began to be included in clinical guidelines in 2007 and 
reimbursed by CMS in 2006. ODX can improve treatment decision-making by avoiding the costs and 
risks associated with adjuvant chemotherapy among women with low risk scores [10-13]. However, 
some evidence suggests that eligible Black patients are less likely to utilize ODX testing compared to 
white patients [14-16]. Reasons for these disparities and whether these disparities persist across 
diverse health care settings and insurers remain unclear. Furthermore, it is unknown whether ODX 
testing impacts chemotherapy use equally across racial subgroups. Genomic diffusion research 
suggests that organizational, provider, and patient level characteristics contribute to racial disparities 
in genetic testing uptake across diverse health care settings [17]. However, to my knowledge, no 
studies have explored racial disparities in ODX uptake and subsequent adjuvant chemotherapy 
initiation across a diversity of health care settings and insurance types.  
The long-term goal of this research is to narrow racial disparities in breast cancer treatment 
and outcomes by developing interventions that increase access to genomic technologies, such as 
ODX testing, among minority cancer patients. The objective of this study is to identify whether racial 
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disparities exist in ODX test use and to identify modifiable factors that (1) contribute to racial 
disparities in ODX uptake and subsequent adjuvant chemotherapy initiation and (2) inform future 
interventions. The central hypothesis of this work is that Black women are less likely to receive ODX 
testing compared to white women and that ODX testing impacts chemotherapy behaviors 
differentially by racial subgroup. Literature has demonstrated that racial disparities in breast cancer 
care emerge not only due to access to innovative technologies, but also during the treatment 
decision-making process.[17] The rationale for this study is to close a gap in our current 
understanding of how race influences ODX uptake and adjuvant chemotherapy use across diverse 
health organizations in North Carolina. Identifying these factors will move the field forward by 
providing an evidence base to inform future interventions aimed at increasing patients’ access to and 
the appropriate use of ODX testing and other genetic technologies among minority populations. This 
leads to the following three aims and hypotheses to be tested using Carolina Breast Cancer Study 
(CBCS-III), a unique and rich dataset that includes survey and medical record abstraction data for 
2998 women across North Carolina, as well as interviews with oncologists in North Carolina: 
 Aim 1: Determine whether ODX test use varies by racial subgroup. Hypothesis: ODX 
testing is lower among Black patients compared to white patients. I will build multivariate regression 
models using CBCS-III data.  
 Aim 2: Determine the independent and interactive effects of race with ODX risk score 
on the initiation of guideline-concordant adjuvant chemotherapy. Hypothesis 2a: Black women 
will be less likely to receive guideline-concordant chemotherapy within the low and high-risk groups 
compared to white women. Hypothesis 2b: Black women will be less likely to initiate adjuvant 
chemotherapy within the intermediate risk group compared to white women. I will use CBCS-III data 
to elucidate the relationship between race and ODX risk score on adjuvant chemotherapy use among 
NC breast cancer patients. 
Aim 3: Identify the perceived organizational and provider barriers and facilitators 
among oncologists for recommending ODX, as well as how results are used in breast cancer 
care, among eligible women with breast cancer. I will conduct semi-structured phone interviews 
with up to 20 oncologists sampled across a range of health care settings in NC. 
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As genomic technologies shift cancer treatment towards personalized therapies, it is critical 
to understand utilization patterns across patient populations and health care settings and to identify 
factors that can increase access to high quality cancer care for all patients. I seek to elucidate 
whether race influences the use of transformative genomic technologies, such as ODX testing (Aim 
1). Furthermore, I expect to identify whether ODX risk score influences adjuvant chemotherapy 
initiation differentially by race (Aim 2). Qualitative interviews with oncologists across diverse settings 
will compliment current understanding of ODX use and subsequent treatment decision-making by 
focusing on factors that cannot be studied using secondary data sources (Aim 3). Taken as a whole, 
results from these three aims can inform future interventions and policies aimed to provide high 
quality care to all breast cancer patients. 
Executive Summary 
Breast cancer remains the second leading cause of cancer death among women. Although 
the incidence of breast cancer is lower among Black women, they are more likely to experience 
worse breast cancer care processes and outcomes compared to white women. New and developing 
genetic technologies and targeted therapies hold great potential to guide individualized high-quality 
cancer care; however, an unintended consequence could be increased disparities if such innovative 
technologies are not equally accessible across racial subgroups.  
In 2004, a genomic innovation in breast cancer treatment, Oncotype DX® (ODX), became 
commercially available. For women with early-stage, estrogen receptor positive breast cancer, ODX 
predicts not only risk of breast cancer recurrence, but also the benefit of chemotherapy. ODX has 
already been incorporated into the clinical guidelines for node negative patients and is widely 
reimbursed by insurers, including Medicare and Medicaid. ODX results, which categorize women into 
low-, intermediate-, or high-risk groups, can improve treatment decision-making by avoiding the costs 
and risks associated with overuse of adjuvant chemotherapy among women who are unlikely to 
benefit from chemotherapy. Mixed evidence suggests that eligible Black patients may be less likely to 
utilize ODX testing compared to white patients. Reasons for these disparities and whether these 
disparities persist across diverse health care settings and insurers remain unclear. Furthermore, it is 
unclear whether subsequent chemotherapy initiation varies across racial subgroups in the presence 
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of ODX test results. This study contributes to the literature by exploring racial disparities in ODX 
uptake and subsequent adjuvant chemotherapy use across a large cohort of women treated in the 
community. Specifically, this dissertation has three objectives: 1) to characterize racial variation in the 
uptake of ODX among women with node negative and node positive breast cancer, 2) to characterize 
racial variation in adjuvant chemotherapy initiation among women receiving ODX testing, and 3) to 
understand the nuances in ODX and adjuvant chemotherapy decision making among oncologists 
caring for breast cancer patients.  
To achieve these objectives, we used modified Poisson regression to examine the 
association between race and ODX testing and between race and adjuvant chemotherapy initiation 
among women in the Carolina Breast Cancer Study, Phase III cohort. We also conducted 15 semi-
structured telephone interviews with oncologists to further understand provider and organizational 
level factors that influence the use of ODX testing and adjuvant chemotherapy initiation. 
We found that ODX testing does not vary by race among node negative patients. However 
among node positive patients, Black women are less likely to receive ODX testing compared to White 
women. Currently, clinical and insurance guidelines recommend ODX testing only among eligible 
women with node negative, not node positive, breast cancer. Our qualitative work suggested that 
providers often order ODX testing for node positive within the context of an ongoing clinical trial. It is 
possible that racial differences among node positive women occur due lower clinical trial enrollment 
by minority patients, less favorable insurance policies, patient preferences or provider 
recommendation patterns. This racial difference in node positive patients reflects more guideline 
concordant care among African American women. Future research should examine more the role of 
these factors on racial variation in ODX test uptake for node positive patients. Specifically, it is 
unclear whether racial differences in the use of ODX testing by race are important and lead to 
differential quality of care and outcomes. Distinguishing between racial disparities verses racial 
differences in the uptake of newly emerging genetic technologies will be a challenge moving forward 
in the era of “precision medicine.”  
Among women receiving ODX, race does not influence uptake of adjuvant chemotherapy 
across ODX risk groups. Instead, the ODX risk score, tumor characteristics and age influence 
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adjuvant chemotherapy uptake within risk groups. It is possible that the additional objective 
information provided by ODX reduces racial variation in chemotherapy uptake. Alternatively, the lack 
of racial differences may reflect broader recent research that has suggested narrowing racial 
disparities in adjuvant chemotherapy initiation.  
Finally, oncologists identified organizational, interpersonal and intrapersonal factors that 
influence ODX use in clinical practice. Providers did not report variation in ODX testing by 
socioeconomic or racial characteristics. Instead, they discussed how clinical characteristics and 
patient preferences influence ODX test recommendations and chemotherapy initiation. Additionally, 
multi-level factors influenced the uptake of ODX testing in clinical practice. These factors appeared to 
vary across providers and their health care settings. Furthermore, providers reported that barriers to 
ODX testing that existed during early adoption have diminished over time. For example, we identified 
targets for facilitating the incorporation of this genetic technology into breast cancer care: 
Organizational structures, insurance coverage, and medical guidelines emerged as important 
organizational levers for facilitating the use of ODX testing, especially during early adoption. Future 
research should examine the association between organizational and provider level factors with ODX 
testing. 
ODX testing offered an interesting model to study how rapidly expanding genetic tests can be 
used to guide precision medicine across racial subgroups. Overall, results from this study can inform 
key stakeholders about racial variation in the uptake of ODX testing and subsequent treatment 
decisions. Fortunately, ODX testing was equally accessed among node negative patients, for whom 
the test is covered and guideline concordant. Interestingly, African American women were less likely 
to receive ODX testing compared to non-African American women among node positive patients for 
whom the test is not yet widely covered nor included in clinical guidelines. This racial difference is 
interesting as it suggests potential racial differences in the early adoption of genetic technologies, yet 
also reflects more guideline concordant care among African American women. Taken together with 
qualitative results, insurance coverage and medical guidelines will be important policy levers for 
facilitating the use of genetic technology among all patients. 
  
6 
REFERENCES 
1. Atlas, S.J., et al., A cluster-randomized trial of a primary care informatics-based system for 
breast cancer screening. J Gen Intern Med, 2011. 26(2): p. 154-61. 
2. Jemal, A., et al., Annual report to the nation on the status of cancer, 1975-2005, featuring 
trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst, 2008. 100(23): p. 
1672-94. 
3. Schneider, E.C., A.M. Zaslavsky, and A.M. Epstein, Racial disparities in the quality of care for 
enrollees in medicare managed care. JAMA, 2002. 287(10): p. 1288-94. 
4. Du, X.L., S. Fang, and T.E. Meyer, Impact of treatment and socioeconomic status on racial 
disparities in survival among older women with breast cancer. Am J Clin Oncol, 2008. 31(2): 
p. 125-32. 
5. Racial disparities in breast cancer mortality are not driven by estrogen receptor status alone, 
2011, National Institutes of Health. 
6. Wheeler, S.B., K.E. Reeder-Hayes, and L.A. Carey, Disparities in breast cancer treatment 
and outcomes: biological, social, and health system determinants and opportunities for 
research. Oncologist, 2013. 18(9): p. 986-93. 
7. Paik, S., et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative 
breast cancer. N Engl J Med, 2004. 351(27): p. 2817-26. 
8. Marchionni, L., et al., Impact of gene expression profiling tests on breast cancer outcomes. 
Evid Rep Technol Assess (Full Rep), 2007(160): p. 1-105. 
9. Recommendations from the EGAPP Working Group: can tumor gene expression profiling 
improve outcomes in patients with breast cancer? Genet Med, 2009. 11(1): p. 66-73. 
10. Asad, J., et al., Does oncotype DX recurrence score affect the management of patients with 
early-stage breast cancer? Am J Surg, 2008. 196(4): p. 527-9. 
11. Joh, J.E., et al., The effect of Oncotype DX recurrence score on treatment recommendations 
for patients with estrogen receptor-positive early stage breast cancer and correlation with 
estimation of recurrence risk by breast cancer specialists. Oncologist, 2011. 16(11): p. 1520-
6. 
12. Ademuyiwa, F.O., et al., The effects of oncotype DX recurrence scores on chemotherapy 
utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat, 2011. 126(3): 
p. 797-802. 
13. Henry, L.R., et al., The influence of a gene expression profile on breast cancer decisions. J 
Surg Oncol, 2009. 99(6): p. 319-23. 
14. Hassett, M.J., et al., Adoption of gene expression profile testing and association with use of 
chemotherapy among women with breast cancer. J Clin Oncol, 2012. 30(18): p. 2218-26. 
15. Lund, M.J., et al., 21-Gene recurrence scores: racial differences in testing, scores, treatment, 
and outcome. Cancer, 2012. 118(3): p. 788-96. 
16. Haas, J.S., et al., Genomic testing and therapies for breast cancer in clinical practice. Am J 
Manag Care, 2011. 17(5 Spec No): p. e174-81. 
7 
17. Institute of Medicine (US) Roundtable on Translating Genomic-Based Research for Health, 
2008, Institute of Medicine: Washington (DC). 
 
 
 
 
 
 
 
8 
CHAPTER 2. ONCOTYPE DX TESTING IN WOMEN WITH BREAST CANCER: STUDY 
RATIONALE 
Background  
Health Disparities in Cancer Care 
National focus on health disparities came into the forefront following the 2003 Institute of 
Medicine’s (IOM) report, Unequal Treatment, which brought attention to disparities in health care 
quality and outcomes among racial/ethnic minorities, low-income and other vulnerable populations.[1] 
From this report, IOM developed a working definition for health disparities “the difference in treatment 
or access not justified by the differences in health status or preferences of the groups.”[1] This 
definition acknowledges a distinction between health differences and disparities, where a health 
difference fails to account for patient preferences and clinical appropriateness. Additionally as a result 
of Unequal Treatment, the National Health Disparities Report began providing an annual national 
view of health disparities in the US. The 2013 report demonstrated that health disparities persist 
across quality and access measures among all priority populations, including racial/ethnic minorities, 
low-income groups, women, children, the elderly, lesbian, gay, bisexual and transgender populations, 
disabled, and uninsured and rural populations.[1] Moreover, the majority of identified disparities in 
these groups have remained from year to year, demonstrating a need for innovative approaches for 
improving documented disparities.[2] 
Racial disparities in cancer-specific mortality have persisted over the past 20 years.[3] In 
breast cancer, evidence suggests that racial disparities have not only persisted, but actually widened 
over time.[3] Biological factors may partially explain these disparities. Improvements in treatments 
that target certain types of breast cancer may partially contribute to widening disparities. While 
targeted therapies, such as trastazumab and endocrine therapy have been developed for human 
epidermal growth factor receptor 2 (HER2) positive and estrogen receptor/progesterone receptor 
(ER/PR) positive breast cancers, respectively, few new treatments have emerged for triple negative 
cancers, which are more common among Black women compared to white women.[3] Black women 
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are more likely to present with more aggressive tumor types [4]. However, even upon controlling for 
disease stage and treatment, disparities persist.[3] [5-9] For example, among hormone receptor 
positive breast cancers, Black women are more likely to experience poor health outcomes [10]. This 
is of particular interest, as hormone receptor positive breast cancer is associated with an improved 
prognosis compared to other breast cancer subtypes, yet disparities in health outcomes among Black 
women persist even upon controlling for tumor biology [10]. Thus, studies have demonstrated that 
even when controlling for biological differences, Black women still fare worse, suggesting that access 
and quality of care may contribute to existing disparities.  
Racial disparities in breast cancer care processes and outcomes likely arise from a 
combination of biological, social and health system factors.[11] From screening to survivorship or 
mortality, racial/ethnic minorities fare worse on many quality and access measures.[2] The National 
Health Disparities Report demonstrated that racial/ethnic minorities, low-income populations, and 
those with public insurance (v. private) were less likely to have recommended mammogram 
screening;[2] even upon controlling for screening mammography and stage at diagnosis, racial 
disparities persist.[12, 13] This may be explained by concurrent differences in quality and access of 
care among breast cancer patients. Among women who develop breast cancer, multiple treatment 
quality and access disparities have been identified.[5, 10, 14-17] These treatment disparities may 
reflect differential access to, and quality of, cancer care among Black women. Black women were less 
likely to receive guideline concordant radiation therapy [2] and chemotherapy [5, 18] compared to 
white women. Furthermore, racial and socioeconomic disparities have been found among the use of 
targeted therapies such as trastazumab [19] for HER2 positive patients with metastatic breast cancer, 
and endocrine therapy for hormone receptor positive breast cancer patients [20]. This suggests that 
racial/ethnic minorities and low socioeconomic patients are less likely to reap the benefits of new 
targeted therapies compared to their white counterparts. 
Genetic Technologies in Cancer Care 
Increasingly, tumor genetics are being used to guide high quality cancer care. Cancer care is 
becoming increasingly personalized through the use of targeted therapies that are informed through 
the use of genetic technologies. These technologies have the potential to improve quality of care for 
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all women. Furthermore, if equally accessible to all racial/ethnic minorities, these technologies have 
the potential to account for biological differences in cancer etiology between racial/ethnic subgroups, 
potentially narrowing disparities in breast cancer processes and outcomes. However, if these 
technologies are not equally accessible across racial/ethnic subgroups, we risk widening existing 
disparities [21-23]. Thus, moving forward, health disparities researchers must also consider 
disparities in access to and use of genetic technologies in breast cancer care. 
Evidence suggests that racial/ethnic minorities have lower access to innovative technologies 
compared to whites, including lower use of cancer predisposition genetic tests among Blacks 
compared to whites [22-24]. For example, Black women are less likely to access BRCA1/2 testing for 
breast and ovarian cancer prevention compared to white women [25]. These disparities in test receipt 
partially result from characteristics of the providers seen by racial/ethnic minorities: For example, 
Blacks are more likely to see providers or health care centers that are less likely to use these 
innovations [26, 27]. A qualitative study found that providers, patient advocates, executives and 
insurers identified similar barriers to the use of cancer predisposition genetic tests (e.g., BRCA1 test) 
and prognostic genetic tests (e.g., tumor gene expression panels for the management of breast 
cancer) [28]. Thus, it is also important to explore whether racial disparities exist in the uptake of tumor 
gene expression panels for the management of cancer. 
Oncotype DX for the Management of Early Breast Cancer 
Traditionally, decision tools have been crude for determining which early-stage breast cancer 
patients would most likely receive benefit from adjuvant chemotherapy, leading to its underuse or 
overuse relative to the associated costs and risks. A new genomic technology, Oncotype DX (ODX) 
was developed by Genomic Health (Redwood City, CA). Researchers examined the relationship 
between the expression of 250 candidate genes and the recurrence of breast cancer using tumor 
tissue from three clinical trials [29]. The candidate genes were selected because of their potential 
involvement in carcinogenesis, from evidence in the cancer literature, microarray data, genomic 
databases and molecular biology research. Gene expression was quantified using rt-PCR techniques 
from fixed, paraffin-embedded tumor tissue. Sixteen genes were found to be the strongest predictors 
of 10-year distant recurrence. Five control genes were chosen to normalize gene expression data: 
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these genes are not associated with carcinogenesis. Together, an algorithm was based around the 
expression of these 21 genes to compute a recurrence score that quantifies the likelihood of 10-year 
distance recurrence in patients with node negative, estrogen receptor positive breast cancer [29, 30]. 
This algorithm was validated to predict 10 year distant recurrence using data from the National 
Surgical Adjuvant Breast and Bowel Project Trial B-14 [30]. 
ODX leverages tumor gene expression patterns using the validated algorithm to predict risk 
of 10 year distant recurrence: The algorithm groups genes into functional groups (i.e., reference (or 
control genes), proliferation, invasion, HER2, GSTM1, CD68, BAG1 and Estrogen) and calculates a 
“risk of recurrence score” which correlates to a percent risk of distant recurrence at ten years. These 
risk scores are divided into three risk groups: low (score<18), intermediate (score 18-30) and high 
(score >30). The test not only predicts a woman’s risk of breast cancer recurrence, but also the 
benefit to chemotherapy; thus, it may be a useful tool for providers and patients during adjuvant 
chemotherapy decision-making [29, 30]. Women with low risk tumors are unlikely to receive any 
clinical benefit for using adjuvant chemotherapy, whereas women with high risk scores receive a 
significant improvement in ten-year distant recurrence outcomes.[29] The benefit for adjuvant 
chemotherapy in the intermediate risk group is less clear: for these women, clinical-pathological and 
preference based decision-making may be appropriate. The Trial Assigning IndividuaLized Options 
for Treatment (Rx) (TAILORx) is currently in progress to acquire more information about women in 
the intermediate risk group. The TAILORx trial is randomizing women with intermediate ODX risk 
scores (defined as ODX risk score=11-25 for the trial) to anti-estrogen therapy (i.e., tamoxifen, 
aromatase inhibitors) only or antiestrogen therapy plus adjuvant chemotherapy.[31]  
Currently, evidence is building for ODX testing not only for node negative patients, but also 
for women with early stage, lymph node positive disease [32-34]: An ongoing trial RxPONDER will 
provide more definitive evidence around whether ODX should be used among women with one to 
three positive lymph nodes [35]. It is important to note, that development and validation of ODX 
occurred from the tumors of women taking Tamoxifen [29, 30, 36]. Because these women were on 
Tamoxifen, it is unclear whether the Oncotype DX algorithm predicts the natural history, 10-year 
distant recurrence, or if the algorithm predicts a woman’s responsiveness to endocrine therapy.  
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Since the original study validating ODX, evidence has mounted to support the prognostic [37] 
and predictive value of the test [38]. Exempt from FDA approval, ODX became commercially 
available in 2004. Insurance reimbursement for the test began in 2005 by a commercial insurer [39], 
and by 2006 CMS began reimbursing the test [40]. ODX was subsequently added to the guidelines in 
2007 and 2008 by ASCO and NCCN, respectively.[39] Today, many large insurers cover the test [39], 
as evidence suggests prognostic and predictive validity for the test and potential cost savings [39, 41-
45]. On a population level, evidence suggests that ODX influences chemotherapy treatment decision-
making [46-54], reducing the overuse of chemotherapy [52-55]. ODX may increase providers’ 
confidence in the chemotherapy decision-making process [47], and patients have reported that they 
would recommend ODX to other breast cancer patients [56].  
Uptake of Oncotype DX (Aim 1) 
About half of all women with invasive breast cancer may be eligible for and benefit from ODX 
[57]. However, uptake of ODX varies across study settings, ranging from 10%-50% of eligible women 
receiving the test. This suggests potentially suboptimal use of the test among eligible patients.[58, 59] 
[60] Unfortunately, early descriptive evidence suggests that Black women are less likely to receive 
this test compared to white women [58, 60, 61], even when controlling for disease characteristics.[61] 
To my knowledge, only five studies describe the uptake of ODX by race.[27, 58, 59, 61, 62] Of these 
five studies, three reported racial disparities in its use, with the proportion of Black women who 
received ODX being an average of 10% lower compared to white women.[58, 60, 61] Two studies 
found no racial differences in ODX testing; however, the generalizability may be limited as one was 
conducted within a single academic, comprehensive cancer center [59] and the other was conducted 
among women ages 65 or older with Medicare [62]. Only two studies directly examined racial 
disparities in ODX testing as part of their primary analyses. [58, 60] Unfortunately, the generalizability 
of these studies is also limited as they examine patient-level factors within a homogeneous patient 
population: one within a single urban population [60] and the other within three academic medical 
centers [58]. Furthermore, while several articles have investigated racial variation in the uptake of 
ODX testing, little is known about why these racial disparities in test uptake exist. One study suggests 
that Black women may more likely be seen in hospitals with low uptake of ODX,[60] suggesting that 
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system-level factors influence the ODX testing among patients. However, it is likely that additional 
patient level factors influence the ODX testing. Reasons for racial disparities in ODX testing may 
consist of biological (e.g., more aggressive tumor biology) and social factors (e.g., access to care) on 
the patient level. Studies investigating patient level factors that influence ODX test receipt and 
disparities will fill a gap in the literature regarding who has access to genomic technologies in cancer 
care.  
Chemotherapy Decision-Making with Oncotype DX (Aim 2) 
In addition to potential disparities in the uptake of ODX, it is unclear whether racial variation 
exists in adjuvant chemotherapy decision-making when ODX test results are available to the provider. 
A number of studies indicate that minority women are less likely to receive guideline-concordant, 
primary course of treatment for breast cancer.[63] Similar results have been found for adjuvant care. 
Black women across health care insurers appear to be less likely to receive guideline-concordant 
adjuvant chemotherapy compared to their white counterparts.[5, 8, 18, 64] Differences in adjuvant 
chemotherapy use may emerge during the treatment decision-making process. Thus, it is of interest 
to understand whether a technology, such as ODX testing, influences adjuvant chemotherapy 
decision-making differentially among racial subgroups. Only one study has examined racial 
differences in chemotherapy use among women who receive ODX score results.[58] Interestingly, the 
study found no racial differences in chemotherapy use within ODX risk groups. However these results 
may not be generalizable, as the study was conducted within three academic-affiliated Atlanta 
hospitals. Furthermore, this study’s evaluation of treatment outcomes was limited by small sample 
size. Studies conducted in diverse settings are necessary to characterize how ODX scores impact 
adjuvant chemotherapy initiation across racial subgroups in order to inform policy and interventions 
which aim to improve adjuvant chemotherapy decision-making.  
Multilevel Factors Associated with Oncotype DX Use (Aim 3) 
Prior genomic research indicates that the diffusion of genomic innovations is influenced by 
organizational (i.e., health care system), interpersonal (i.e., provider) and intrapersonal (i.e., patient) 
level factors [65]. Thus, it is important to consider not only patient characteristics’ influence on ODX 
test receipt and adjuvant chemotherapy initiation, but also provider and organizational characteristics. 
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The lack of a multilevel framework to model ODX testing is partially due to data-constraints, as 
secondary datasets rarely include provider and organizational level factors that influence the receipt 
of ODX testing across diverse health settings (i.e., public/private, academic/non-academic, and 
urban/rural health care centers) [58, 60, 61, 66]. To date, two studies have examined whether site of 
care influences ODX receipt.[27, 61] The authors found that women treated at municipal hospitals 
were less likely to receive ODX testing compared to those being seen at tertiary hospitals.[27] 
Interestingly, Black women were more likely to be seen at municipal facilities, suggesting that site of 
care is a partial source of the racial disparity in receiving ODX testing. Another study found that 
women who were seen at a comprehensive cancer center were more likely to receive gene 
expression profiling tests compared to those seen in the community.[61] These studies provide 
supporting evidence for taking multilevel approaches in examining disparities in the use of ODX 
testing.  
Two qualitative studies have used provider interviews to examine provider and system-level 
factors that influence the ODX testing in clinical care.[28, 67] Study findings indicated that 
characteristics of the test (i.e., interpreting intermediate results)[67], test coordination (including 
reimbursement) [28], patient out-of-pocket costs [28], and the use of multidisciplinary teams [67] 
created barriers to the use of this technology in clinical practice. Furthermore, oncologists worried that 
testing could be used inappropriately [67] or result in treatment delays [28]. One study focused on 
barriers to the ordering ODX testing, while the other study focused on how the test is used in clinical 
practice [28]. However, neither explored both issues of uptake and use of the test results, nor were 
conceptual frameworks used to explicitly examine provider and organizational factors. Ordering ODX 
testing and subsequent adjuvant chemotherapy is a nuanced decision process, and quantitative 
analyses alone may not capture how ODX is used in decision-making. Thus a need remains to 
conduct a theory driven, qualitative study that explores both why the test is ordered/not ordered and 
how the test result is used in clinical decision-making.  
Rationale 
Significance 
Advances in genetics have improved our understanding of the molecular basis for cancer. 
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Today, we recognize that breast cancer is not one single disease, but rather a complex set of 
diseases that can be characterized by genetic markers. The genetic characteristics of a tumor can 
predict risk of recurrence and can be used to tailor therapeutics to the individual, providing high-
quality, patient-centered cancer care [68]. However, if genomic innovations are not accessed equally 
and used appropriately across racial groups, an unintended consequence of this technology may be 
to exacerbate current racial disparities in the process and outcomes of cancer care [58].  
ODX, an example of such a genomic technology, has demonstrated prognostic and predictive 
validity [69-71]. Thus, ODX was added to the American Society of Clinical Oncology guidelines in 
2007 and National Comprehensive Cancer Network Breast Cancer Treatment guidelines in 2008; in 
addition, Medicare began reimbursing for ODX in 2006. By personalizing cancer treatment plans, 
ODX testing has the potential to improve overall processes and outcomes of care for women with 
breast cancer. However, research demonstrates that Black women are less likely to receive ODX 
testing compared to white women with similar disease characteristics [58, 60, 61], which may 
exacerbate racial disparities in cancer care. Current literature regarding race and ODX testing is 
largely descriptive and has not identified factors that are associated with racial disparities across 
different health care systems, nor has the literature demonstrated that this innovation impacts 
adjuvant chemotherapy initiation equivalently across racial subgroups.  
This project seeks to address this gap in knowledge by identifying whether racial disparities 
exist in the uptake of ODX testing, as well as adjuvant chemotherapy initiation based upon ODX 
results. This contribution will be significant as it can inform evidence-based interventions and policies 
that increase access to genomic technologies (such as ODX) and improve quality of, and access to, 
cancer care for minority patients. The goal of this study is aligned with the mission of the NCI “to 
assess the incorporation of state-of-the-art cancer treatments into clinical practice.[72]” Although this 
study focuses solely on ODX testing, genomic technologies will continue to become available to 
personalize treatment and to improve the outcomes of cancer patients, particularly as the federal 
government moves forward with “precision medicine” efforts. Understanding if and why these uptake 
disparities exist and how test results are used to inform treatment decisions can help to identify 
strategies that attenuate chasms in the process and outcomes of cancer care.  
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Innovation  
The proposed research is innovative in four important ways. First, it is the first study to 
examine uptake of ODX testing by racial subgroup across diverse health settings (i.e., public/private, 
academic/non-academic, and urban/rural health care centers) and insurers [58, 60, 61, 66]. Although 
two published studies examined racial disparities in the uptake of ODX testing [58, 60], their 
generalizability is limited as they examine patient-level factors within a single urban population [60] 
and within academic medical centers [58]. This is problematic, because prior genomic research 
indicates that the diffusion of genomic innovations is influenced by organizational, provider and 
patient level factors [65]. The lack of diverse patient populations and care settings is partially due to 
secondary datasets rarely including data about ODX testing and results across diverse health care 
settings and insurers. Second, it is the first study to determine whether ODX risk score is associated 
with similar probabilities of adjuvant chemotherapy initiation by racial subgroup across a diverse 
patient population. Only one other study has examined racial disparities and adjuvant chemotherapy 
use among women receiving ODX testing. The study was underpowered and only examined health 
care use among patients seen within three academic medical centers, limiting the generalizability of 
study findings.[58] Third, the proposed study analyzes data from a rich and unique dataset that 
includes diverse health care settings and insurance plans throughout North Carolina to examine racial 
disparities in genomic testing in cancer care. To date, secondary data analyses have utilized claims-
based datasets, which often restrict the sample to a single payer population or medical records from a 
single medical center. Instead, we levered the phase III, Carolina Breast Cancer Study (CBCS-III) 
data to examine racial disparities. This data set includes both survey and medical record abstraction 
data for women across NC. Both ODX testing and results have been abstracted from the medical 
record, allowing for the analysis of racial disparities in the uptake of ODX and its use in treatment in a 
diverse patient population. Also, CBCS-III oversamples Black breast cancer patients, making this 
dataset ideal to examine racial disparities in breast cancer care. Finally, the approach uses mixed-
methods to capture multilevel factors that influence ODX uptake and use in clinical practice. In-depth 
interviews with oncologists who deliver care across diverse health care settings provide important 
insights about strategies to increase ODX uptake when caring for women with breast cancer. Taken 
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together, this study elucidates factors that future clinical and policy interventions can target to 
increase the use of genomic technologies, such as ODX testing, among minority populations. 
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CHAPTER 3: METHODS 
 I have organized the Methods section by Specific Aims. First, I have described the Methods 
for Aims 1 and 2, including the General Approach, Conceptual Model, Hypotheses, Data Sources, 
and Analytical Plans. Second, I have described Aim 3, using the same structure. The rationale for 
organizing the Methods in this way is that Aims 1 and 2 are quantitative analyses of CBCS-III, while 
Aim 3 uses qualitative methods: Such a structure should reduce redundancy. 
Aims 1 and 2 Methodology 
General Approach 
 Aim 1: Characterizing which patients received ODX testing provides information regarding 
who has access to genomic technologies in clinical practices across health care settings. In 
particular, I sought to examine whether ODX test uptake varies by race; if so, this may contribute to 
our understanding of racial disparities in breast cancer care and outcomes. The objective of aim 1 
was to determine whether differences in ODX test receipt in clinical practice have occurred by race. 
To attain this objective, I tested the working hypothesis that white women were more likely to receive 
ODX testing compared to Black women. To this end, my approach was to model the uptake of ODX 
testing using a multivariate regression model and controlling for patient level factors. The rationale for 
this aim was to fill a gap in current knowledge about the uptake of ODX across racial groups and 
across diverse health care settings. In the age of precision medicine and targeted therapies, we must 
elucidate the relationship between the uptake of genomic innovations and race in order to better 
understand how these new technologies may influence racial disparities in cancer processes and 
outcomes. From this study, I expected to understand whether racial disparities emerge in the receipt 
of ODX testing among early-stage breast cancer patients in North Carolina. The results from this aim 
can inform clinicians, policy makers and researchers about whether there is a need to implement 
interventions to increase patients’ access to genomic technologies, particularly among certain racial 
subgroups. 
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Aim 2: Determining the effects of race and ODX risk group on adjuvant chemotherapy 
initiation will elucidate whether there are racial differences in how the test results are used in 
treatment initiation. The objective of this aim sought to identify whether racial differences occur in 
adjuvant chemotherapy initiation among women with similar ODX risk scores. For this objective, I 
tested two working hypotheses: (1) Black women in the low and high risk groups would be less likely 
to initiate guideline-concordant adjuvant chemotherapy compared to white women and (2) Black 
women in the intermediate risk group would be less likely to initiate adjuvant chemotherapy compared 
to white women. I tested these hypotheses using the approach of multivariate modeling techniques to 
elucidate chemotherapy initiation within the CBCS-III dataset. The rationale for this aim was to 
identify whether racial differences existed in treatment decisions in the presence of ODX risk 
information. This information is critical in understanding the impact of ODX test results on racial 
differences in breast cancer processes, and may inform interventions that improve the use of test 
results across racial groups. When completed, my expectation was to have identified whether there 
are racial differences in chemotherapy initiation, accounting for ODX risk score. This evidence would 
allow policy makers to create interventions that impact how genomic technologies are used among 
breast cancer patients, particularly minority patients. 
Conceptual Model: Andersen’s Behavioral Model 
Andersen’s behavioral model of health care utilization guided the analysis for Aims 1 and 2 
(Figure 1) [1]. Andersen’s behavioral model of health services use demonstrates how environmental 
factors and population characteristics influence health care utilization.[1] In particular, the model 
suggests population characteristics, including predisposing characteristics, enabling resources, and 
needs, influence ODX test receipt. A woman’s need for ODX testing is determined by predisposing 
factors and mediated by enabling resources.  
 Predisposing Characteristics. A large body of evidence has demonstrated that race 
influences breast cancer processes and outcomes.[2] More specifically, studies demonstrate that 
Black women are less likely to receive ODX testing compared to white women. [3-5] Predisposing 
factors also include socio-cultural factors that are associated with race and health care utilization, for 
example, attitudes and beliefs, mistrust of the medical system, and structural racism. [2, 6-8]  
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 Enabling Resources. The ODX test is a complex and expensive tumor gene expression test. 
Thus, education, income, employment, insurance status and social support [2, 9-11] may act as 
enabling resources for the use of ODX, where more educated women and women with more financial 
and social resources might be more likely to access ODX. According to the IOM’s definition of health 
disparities, both measures of SES and race/ethnicity together measure health disparities in the US. 
 Need. Clinical characteristics such as tumor size, stage, grade, receptor subtype, nodal 
involvement and treatment type influence the perceived need for ODX testing. These characteristics 
influence a patient’s need for chemotherapy decision-making support through the use of ODX 
testing.[9] Black women are more likely to have more aggressive tumor characteristics and this may 
impact whether a patient receives ODX testing. For example, if a provider observes high-risk tumor 
characteristics, then he/she may bypass ODX testing and automatically recommend adjuvant 
chemotherapy. Other clinical predisposing factors such as age [12] and comorbidities [10] may also 
influence chemotherapy decision-making, where women who are very frail or who suffer from 
extensive co-morbidities may be less likely to receive ODX testing, as chemotherapy may be 
contraindicated, negating a need for the test. On the other hand, it is possible that women who are 
frail or who suffer from co-morbidities may be in higher need of ODX testing to provide reassurance 
that chemotherapy is not necessary. Either way, it is likely that these clinical characteristics influence 
ODX testing in one direction or another.  
 Other factors. Andersen’s model also describes how external factors influence health care 
use. We did not control for factors arising from the environment and outcomes. However, we did 
control for year of breast cancer diagnosis, as the year may influence whether ODX was being widely 
used by providers. By 2008, when recruitment into CBCS-III began, ODX had been added to clinical 
guidelines and was being covered widely by CMS and private insurers [13]. Roger’s theory of 
diffusion, suggests that the use of an innovation changes over time, where diffusion of the innovation 
across time can be depicted by an “S-shaped” curve. Along this curve, individuals represent the (1) 
early adopters, (2) early majority, (3) late majority, (4) laggards and non-adopters of the technology 
[14]. Thus, it was important to control for year of diagnosis, as the uptake of ODX has increased over 
time [15].  
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Figure 1. Andersen's behavioral model (adapted) for health care utilization informed empirical models 
for Aims 1 and 2.[1] 
 
 
 Just as the model frames how race, a predisposing characteristic, influences whether a 
patient receives ODX testing, the model frames how race may influence adjuvant chemotherapy 
initiation (Aim 2). Researchers have documented lower rates of guideline-concordant chemotherapy 
among Black women [8, 10, 12, 16], suggesting that Black women may be more likely to forgo 
chemotherapy. The aforementioned predisposing, enabling and need variables, influence not only 
ODX test receipt, but also chemotherapy initiation. Predisposing characteristics, including 
socioeconomic factors (such as education, income, employment status, insurance) [9]and social 
support, may influence chemotherapy use.  
In Aim 2, ODX test results were added to the analytic model. The ODX test result, a need 
variable, reflects a patient’s need for adjuvant chemotherapy. Thus, race interacted with ODX risk 
scores would demonstrate whether racial differences in chemotherapy initiation occur by risk score 
(where risk scores are categorized into three groups: low-, intermediate, and high- risk groups).  
Hypotheses  
Question 1: To what extent is race associated with the uptake of ODX? Hypothesis 1: ODX 
test receipt are lower among Black patients compared to white patients, controlling for clinical 
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characteristics. 
Question 2a: To what extent is race associated with the initiation of guideline-concordant 
adjuvant chemotherapy? Hypothesis 2a: Black women are less likely to receive guideline-concordant 
chemotherapy within the low and high-risk groups compared to white women.  
Question 2b: Is race associated with the initiation of guideline concordant adjuvant 
chemotherapy among women with intermediate risk scores? Hypothesis 2b: Black women are less 
likely to initiate adjuvant chemotherapy within the intermediate risk group compared to white women.   
Data Source  
Data included baseline, pathology report, and medical record abstraction data from phase III 
of the Carolina Breast Cancer Study (CBCS-III) (NIH 8389741). This dataset contains data on 2.998 
women, age 20-74 years with invasive breast cancer who were enrolled in the study between 2008 
and 2013. Participants were identified through rapid case ascertainment in collaboration with the 
North Carolina Cancer Registry[17]. Women were included in the study if they had an incident 
primary invasive breast cancer diagnosed, and if they were North Carolina residents at the time of 
diagnosis. These women were enrolled across the state of North Carolina, representing 44 counties, 
including both rural and urban counties.  
Patients were randomly sampled from four strata: Black women under 50 years old, Black 
women 50 years or older, non-Black women under 50 years old, and non-Black women 50 years or 
older, where the sampling fraction (ƒ=n/N, n=sample size and N equals the population size) was 
100%, 60%, 40% and 15%, respectively [18]. Thus half of this cohort was composed of Black women, 
and the remaining half was non-Black. This makes these data particularly amenable to racial health 
disparities research. CBCS-III data are unique as they include both survey and medical record 
abstraction data for women who are being treated across diverse health care settings (i.e., 
public/private, academic/non-academic, urban/rural) and insurance types (i.e., public, private, 
uninsured). In the study, a nurse interviewed participants at baseline, and the patients completed a 
quality of life questionnaire and provided consent for medical record abstraction, providing both self-
reported and abstracted medical record data [17, 18]. Two abstraction forms capture medical record 
data: the medical record abstraction form and the medical record abstraction pathology report form 
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(Table 1). Thus, these rich data provided a comprehensive look at how ODX testing has been used, 
across a diverse population in North Carolina.  
Eligibility Criteria  
Eligibility criteria for women in the CBCS-III dataset were: (1) estrogen receptor positive 
(ER+) breast cancer, as ODX testing has been approved for use within this patient population[19], 
and (2) early, non-metastatic disease (i.e., AJCC stage III-IV patients were excluded), because 
chemotherapy decision-making process is quite different in this patient population and ODX testing 
has not been validated within this patient population, (3) HER2 negative, because ODX testing is not 
approved for these patients, (4) patients with undetermined tumor grade, and (5) patients with 
missing data.[20] We estimated that 1439 women (602 Black women, 837 white women) would meet 
these eligibility criteria. Given this sample size, our preliminary sample size calculation suggested that 
we would be able to detect effect sizes of 10-15% with 80% power; this effect size reflected a minimal 
clinically significant difference. Our total sample size was 1468 women; thus, we had enough power 
to detect 10% differences in ODX test receipt by race. This supports the AHRQ definition of health 
disparities, which detects racial disparities as differences of 10% or greater [21]. 
Aim 2 analyses were further limited to those women who received ODX testing and had an 
ODX test result abstracted from their pathology records. We estimated that 651 women (417 Black 
women, 234 white women) would meet these criteria. A preliminary sample size calculation 
suggested that we would be able to detect crude effect sizes of 15-25% with 80% power. Our total 
samples size was 544 women; we have enough power to detect effect sizes of ~15% in the 
intermediate group, and ~20% in the low risk group, and ~35% in the high risk group. 
Descriptive Analyses 
 Aim 1. Descriptive statistics were calculated using population weights to account for the 
stratified sampling strategy used to collect CBCS-III data. We also accounted for clustering at the 
provider. We described clinical and demographic differences between (1) women who received ODX 
testing compared to those who did not, and (2) Black women and white women in the sample using 
weighted linear regression for continuous variables and weighted chi2 test for binary/categorical 
variables.  
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Aim 2. Descriptive statistics were calculated using population weights to account for the 
stratified sampling design. We also accounted for clustering at the provider. Weighted linear 
regression for continuous variables and weighted chi2 test for binary/categorical variables compared 
the characteristics (especially race) of women who initiated adjuvant chemotherapy compared to 
those who did not initiate adjuvant chemotherapy, by ODX risk group. Also, we plotted the distribution 
of raw ODX risk scores by race within each risk group in order to describe the distribution of raw risk 
scores within each risk group by race. Finally, we plotted the distribution of raw ODX risk scores by 
nodal status. 
Primary Analyses 
 Aim 1. For the primary analysis, we used a modified Poisson regression with robust standard 
errors. We explored logistic regression modeling to determine whether race influences the likelihood 
that an individual receives ODX. Logistic regression models address out of range predictions and 
heteroskedasticity that can result from using ordinary least squares approaches (linear probability 
modeling) when the outcome variable is binary. However, model convergence can be difficult with 
logistic regression models, furthermore, logistic regression models produce odds ratios, which can be 
difficult for readers to interpret. As such, we considered several other models. First we considered 
reverting back to the linear probability model: However, this model yielded predictions that were out of 
range (that is predicted probabilities that were greater than 1 or less than 0) over 8% of the time. 
Second, we considered the Poisson and Binomial models. Like logistic regression, the Binomial 
models (generalized linear model with the Binomial family and log link) can experience problems with 
model convergence: This was the case in our study. Poisson regression with a sandwich error term 
estimates relative risk consistently and efficiently with correlated binary outcomes.[22, 23] 
Furthermore, this approach easily produces a risk ratio, which is a more intuitive result to report to lay 
audiences. Thus, this approach was used to estimate the effect of race on ODX test receipt. It is 
important to note that all models yielded similar regression results. 
 Complex survey design was addressed through sample weights and design effects using 
Taylor Series Approximations in STATA (StataCorps, College Station, TX): both sampling weights 
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and strata were implemented. Using sample weights provided parameter estimates that represent the 
population, not just the sample.  
 Theory suggested that it may be necessary to stratify analyses for node status, as the 
reasons for ordering ODX testing may vary by node status. In order to do this, I tested the null 
hypothesis that H0= Pr(y=1|x, Z)node positive=Pr(y=1|x, Z)node negative. We failed to reject the null 
hypothesis: Risk ratios for the association between race and ODX testing differed by nodal status. 
Furthermore, qualitative data suggested that providers used different criteria when deciding to use 
ODX for node positive compared to node negative patients. Thus, models were stratified by nodal 
status for Aim 1. 
 IOM’s definition of health disparities is “the difference in treatment or access not justified by 
the differences in health status or preferences of the groups”.[24, 25] This definition acknowledges 
race as a social construct [24, 25]. Thus, SES variables were not included in our primary models for 
identifying racial disparities: These models were referred to as the “primary models.” “Secondary 
models” were run, which included SES variables. 
The empirical models are below:  
Primary Model: ODX test receipt = β0 + β1Race+ β2tumor characteristics+ β3treatment 
characteristics + β4comorbidities + u 
 
Secondary Model: ODX test receipt = β0 + β1Race+ β2tumor characteristics+ β3treatment 
characteristics + β4comorbidities + β5socioeconomic factors + u 
 
 for y=0,1 
 
The key dependent variable in Aim 1 is receipt of ODX testing (Table 1), which was abstracted from 
the medical pathology reports. This begs the assumption that if ODX testing was ordered, it was 
noted in the pathology reports. The key independent variable in this aim was a binary indicator for 
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race (i.e., Black and non-Black (i.e., White, Asian, other), which was obtained from the baseline 
survey. Covariates included the following: tumor characteristics (such as tumor stage, size, grade, 
progesterone receptor status), treatment characteristics (i.e., surgery type and radiation), 
comorbidities (i.e., diabetes, obesity, COPD, hypertension and heart disease), and year of diagnosis. 
Socioeconomic variables (i.e., income, insurance status, education, age) were included in our 
secondary model.  
Prior to inclusion in the model, we used pair-wise correlations to determine whether 
significant multicollinearity occurred between certain variables (e.g., tumor stage and tumor size). 
Decisions on which variable to exclude were made based on which variables were the most clinically 
and theoretically appropriate for the construct of interest. Tumor stage, size and grade were highly 
correlated. Thus, tumor stage was removed from the model, as it incorporates size and grade and 
therefore does not account for new information to the model. Instead tumor stage was only used to 
determine inclusion criteria (Stage I and II were included in Aims 1 and 2). Radiation receipt and 
surgery type (i.e., binary variable: lumpectomy vs. mastectomy) were highly correlated, as the vast 
majority of women receiving a lumpectomy also received radiation per NCCN guidelines. For this 
reason, radiation was not included in the final analysis, however we did look at radiation initiation 
descriptively (Table 1). Finally, we used sensitivity analyses to evaluate whether the race-ODX test 
association varied in smaller (<0.5 cm) verses larger (>=0.5 cm) tumors, and found no substantial 
differences between strata. While some guidelines do not recommend ODX testing on<0.5cm tumors, 
we included women with <0.5cm tumors in our analysis, as we wanted to retain as much of our 
sample as possible.  
Aim 2. For the primary analysis, we used the modified Poisson regression with robust 
standard errors to determine whether race influenced the likelihood that an individual initiated 
adjuvant chemotherapy, controlling for the ODX test result (see empirical models below). We 
stratified our analyses by ODX risk groups, as reasons for taking adjuvant chemotherapy would likely 
vary by risk group given differential treatment guidelines for each stratum. This decision was 
supported by sensitivity analyses, which indicated that a pooled analysis would be inappropriate. 
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Thus, three models assessed adjuvant chemotherapy initiation across the three risk strata. Models A 
and B assessed the impact of race on the initiation of adjuvant chemotherapy in the low and high risk 
groups, respectively, where there are clear guidelines regarding adjuvant chemotherapy decision-
making (i.e., women with low risk scores are recommended to forgo chemotherapy, women with high 
risk scores are recommended to initiate chemotherapy). Model C assessed the association between 
race and the initiation of adjuvant chemotherapy among women with intermediate ODX risk scores, 
for whom chemotherapy guidelines are less clear. For the reasons described above (Aim 1), modified 
Poisson regression was used, accounting for complex survey design with sample weights and design 
effects using Taylor Series Approximations in STATA. Risk ratios were reported.  
Sensitivity analyses suggested that node negative and node positive patients could be pooled 
for analysis. Analyses within the high-risk group were exploratory due to small sample size (n=53), 
and only a crude model was reported. Below are the empirical models: 
Models A and B, Primary Model: Chemotherapy Initiation = β0 + β1Race+ β2ODX risk group+ 
β3treatment characteristics + β4comorbidities + u 
Models A and B, Secondary Model: Chemotherapy Initiation = β0 + β1Race+ β2ODX risk 
group+ β3treatment characteristics + β4comorbidities + β5socioeconomic factors + u for y=0,1 
 
Model C, Primary Model: Chemotherapy Initiation = β0 + β1Race+ β2ODX risk score+ 
β3treatment characteristics + β4comorbidities + u 
Model C, Secondary Model: Chemotherapy Initiation = β0 + β1Race+ β2ODX risk score+ 
β3treatment characteristics + β4comorbidities + β5socioeconomic factors + u for y=0,1 
The key dependent variable in Aim 2 was adjuvant chemotherapy initiation (Table 1), which was 
abstracted from each patient’s medical record. The key independent variable was a binary indicator 
for race (i.e., Black and non-Black).  
Covariates included those used in Aim 1, as these factors influence not only whether a 
patient receives ODX, but also whether they receive adjuvant chemotherapy. These covariates 
included the following: tumor characteristics (such as tumor size, grade, progesterone receptor 
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status), treatment characteristics (i.e., surgery type), comorbidities (i.e., diabetes, obesity, COPD, 
hypertension and heart disease), and year of diagnosis. Socioeconomic factors (i.e., income, 
insurance status, education, age, ethnicity) were not included in the Primary Models, but were 
included in the Secondary Models. As previously mentioned, covariates were tested for 
multicollinearity using pair-wise correlations: tumor stage and radiation initiation were excluded from 
the models as described in Aim 1. Due to sample size constraints, we did not further stratify analyses 
by nodal status; however, nodal status was included as a covariate in these models. Also, ODX risk 
score was added as a covariate within each stratified analysis. 
Secondary Analyses 
 Aim 1. We employed propensity weighted models to determine the average treatment effect 
of race on receiving ODX testing. Propensity score weighting may address small sample size and 
large number of covariates. This approach prevents the loss of degrees of freedom by allowing the 
inclusion of all of the covariates in one measure. Because the mode of implementation of propensity 
scores can yield different results, we conducted sensitivity analyses comparing propensity score 
weighting with matching (using the Greedy matching technique [26], using STATA code gmatch). 
Results from propensity score weighting and matching can differ due to limited availability of matches 
and sensitivity of weighted estimates to outliers.[27] In our analyses, results were consistent across 
propensity score weighting and matching (Appendix 1). To allow us to use all observations in the 
sample, we implemented propensity score weighting for our analysis. 
 Aim 2. As a secondary analysis, we employed propensity weighted models to determine the 
average treatment effect of race on ODX use. As a sensitivity analysis, we also conducted propensity 
matched models, using the Greedy Matching method, and found similar results to those found using 
propensity weighted models (Appendix 1).  
 As an exploratory aim, we compared endocrine therapy initiation across racial subgroups and 
by ODX risk group using weighted chi-square tests.  
 Expected Outcomes. The expected outcomes of this study were to understand (1) whether 
the likelihood of ODX test receipt varies by race, and (2) how ODX results are used in making 
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treatment decisions for Black versus non-Black women with breast cancer across different risks. This 
outcome attains this study’s objective of determining whether differences in ODX testing in clinical 
practice have occurred by race, and whether there are racial differences in adjuvant chemotherapy 
initiation among those with ODX test results. This helps attain this proposal’s overall goal, as the 
expected outcomes elucidate whether race influences ODX test receipt and can be targeted in future 
interventions that aim to increase access to ODX testing and subsequent guideline concordant 
adjuvant chemotherapy use.  
Table 1. Variables of Interest 
Variables in Models & Descriptive Stats 
  Aim Variable 
CBCS3 
Code name 
Original 
Coding/Categori
es 
Data 
Source 
Variable/Sample 
Specification 
C
lin
ic
a
l C
h
a
ra
c
te
ri
s
ti
c
s
 
1-2 
Year of 
Diagnosis 
of BC DX DATE 
Date 
(MM/DD/YYYY) 
Med Rec 
Abs 
Year: Dummy 
Variable (2008-
2013) (2012 and 
2013 were 
collapsed due to 
small cell size) 
1-2 
Age at 
Diagnosis AGESEL 20-74  Survey 
 Binary: above and 
below 50 years of 
age 
1-2 
Comorbiditi
es 
COMORB_ 
COMP_1-
10 
See attached 
Excel 
Med Rec 
Abs 
Count: Includes the 
number of ICD-9 
codes from the 
following 
categories: 
Obesity, Diabetes, 
Hypertension, 
COPD, Heart 
Disease  
  
2 
Nodal 
Status 
NODESTA
T 
1=Positive, 
0=Negative MA_VARS 
Binary: 
N0=negative, 
remainder positive 
(node positive were 
N1) 
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1-2 
Tumor Size ESTSIZE 
1 = < 2 cm, 2 = 
>2-5 cm, 3 = >5 
cm MA_VARS 
Dummy 
Categorical < 2 cm, 
>2-5 cm, >5 cm 
1-2 
Tumor 
Grade GRADE 
1 = Well 
differentiated, 2 
= Moderately 
differentiated, 3 
= Poorly 
differentiated, 4 
= 
Undifferentiated, 
9 = Not 
determined 
Med Rec 
Abs 
Dummy 
Categorical: 
Grade==9 
excluded; 
Combined 
Nottingham 
Histologic grade 
2 
Oncotype 
DX Score 
ONCO_DX
_SCORE Count Path 
Count: 1-100 & 
Group (Low score 
18 or less, 
Intermediate >18-
31, high score >31) 
1-2 
PR Status  PR_STS  
Negative, Weak 
Positive/Borderli
ne, Positive Path 
Binary: 
Pos=weak/borderlin
e & positive 
 Neg= Negative 
T
re
a
tm
e
n
t 
C
h
a
ra
c
te
ri
s
ti
c
s
 
1-2 
Surgery SURG 
See CBCS3 
Code Book for 
full list of 
surgery types 
Med Rec 
Abs 
Binary : 
Lumpectomy/Maste
ctomy: mastectomy 
= yes, if she has 
any first course 
SURG==30-80), 
lumpectomy==yes 
(if she has any first 
course SURG==20-
24 and has no 
SURG==30-80 
K
e
y
 I
n
d
e
p
e
n
d
e
n
t 
V
a
ri
a
b
le
 
1-2 
Race used 
in Sampling RACE 
1=non-
Black/0=Black Survey  Binary 
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D
e
p
e
n
d
e
n
t 
V
a
ri
a
b
le
s
 
1 
ODX 
Included? 
ONCO_DX
_ASSAY_I
NCLUDED Yes/No Path Binary: Yes/No  
2 Adjuvant 
Chemother
apy 
Initiation 
ADJCHEM
O2 Yes/No 
Med Rec 
Abs 
Binary: Yes/No 
First course adj 
chemo (after 
surgery) 
Variables for Descriptive Statistics 
  
 Variable 
CBCS3 
Code name 
Original 
Coding/Categori
es 
Data 
Source 
Variable/Sample 
Specification 
D
e
s
c
ri
p
tiv
e
 T
re
a
tm
e
n
t 
V
a
ri
a
b
le
s
 
1-2 Radiation 
Initiation 
RAD_STA
RT_DATE Date 
Med Rec 
Abs Binary: Yes/No 
1-2 
Adjuvant 
Chemother
apy 
Initiation 
CHEMO_S
TART_DAT
E & 
Diagnosis 
Date MM/DD/YYYY 
Med Rec 
Abs 
Binary: Yes/No, 
Adjuvant chemo, 
chemo after first 
course surgery 
1-2 Hormonal 
Therapy 
Initiation 
HORM_ST
ART_DAT
E MM/DD/YYYY 
Med Rec 
Abs 
Binary: Yes/No 
First course 
therapy 
D
e
s
c
ri
p
tiv
e
/S
E
S
 V
a
ri
a
b
le
s
 
1-2 
Income 2 MONEY 
1 = 15-30K 
Survey Dummy Categorical 
2 = 30-50K 
3 = >50K 
4 = <15K 
5= Not Reported 
1-2 
Insurance 
type 
P2I2, 
P3I3A, 
P3I3B, 
P3I3C, 
P3I3D, 
P3I3E, 
P3I3F 
Question I2: Do 
you currently 
have health 
insurance 
coverage? 
Survey 
Binary: Medicare, 
Private, Medicaid, 
Uninsured 
Question I3: 
What type of 
health insurance 
do you have 
now? (check all 
that apply). 
1-2 
Education 
2 EDUCAT 
1 = HS & Post 
HS 
Survey Dummy Categorical 
2 = College+ 
3 = < HS 
1-2 Employme
nt 
P3H7A, 
P3H7B 
Yes/No/Not 
reported Survey Binary: Yes/No 
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1-2 
Marital 
Status P3H1 
1 ___ Never 
married or lived 
as married, 2 
___ Married, or 
living as 
married, 3 ___ 
Widowed, 4 ___ 
Separated, 
divorced, or no 
longer living as 
married, 9 ___ 
NA  Survey 
Binary: 
Married=Married or 
living as married, 
Not Married = 
never/lived as 
married, widowed, 
separated, divorced 
or no longer living 
as married, NA 
From the baseline 
survey, item H1.  
Variables for Sample Selection and Stratification 
  
 Variable 
CBCS3 
Code name 
Original 
Coding/Categori
es 
Data 
Source 
Variable/Sample 
Specification 
S
a
m
p
le
 S
p
e
c
if
ic
a
ti
o
n
: 
C
lin
ic
a
l/T
u
m
o
r 
C
h
a
ra
c
te
ri
s
tic
s
 
1-2 
Tumor 
Stage 
AJCC_GR
P 
1 = Stage I, 1A 
= Stage IA, 1B = 
Stage IB, 2A = 
Stage IIA, 2B = 
Stage IIB, 3A = 
Stage IIIA, 3B = 
Stage IIIB, 4 = 
Stage IV, 88 = 
Not applicable, 
99 = Unknown 
Med Rec 
Abs 
FOR SAMPLE 
SPECIFICATION: 
Stage 1=1-1B, 
Stage 2=2A-2B 
1-2 
ER Status ER_STS  
Negative, Weak 
Positive/Borderli
ne, Positive Path 
FOR SAMPLE 
SPECIFICATION: : 
Pos=weak/borderlin
e & positive 
Neg= Negative 
1-2 
HER2 
Status HER2_STS  
Negative, Weak 
Positive/Borderli
ne, Positive Path 
Binary: 
Pos=weak/borderlin
e & positive 
Neg= Negative 
S
tr
a
ti
fic
a
ti
o
n
 1 
Nodal 
Status 
NODESTA
T 
1=Positive, 
0=Negative MA_VARS 
STRATIFICATION: 
Binary: 
N0=negative, 
remainder positive  
Variables used to account for complex survey design 
S
tu
d
y
 D
e
s
ig
n
 
1-2 
Strata STRATA 
Non-Black age 
<50, Non-Black 
age 50+, Black 
age <50, Black 
age 50+ Survey Categorical  
38 
1-2 Sampling 
Weights WT   Survey Continuous  
1-2 Physician 
ID 
NUM_PHY
SICIAN Physician Codes Path String  
Med Rec Abs= Medical Record Abstraction Form, Path=Medical Abstraction Pathology Form 
Aim 3 Methodology 
General Approach 
Patient, provider, and health system characteristics likely influence the uptake of ODX testing 
in breast cancer care.[28] While Aims 1 and 2 focused on patient-level factors obtained in CBCS-III, 
Aim 3 focused on provider and health system level factors that affect ODX recommendations and 
treatment decision-making. Specifically, to complement analyses of secondary datasets, Aim 3 used 
qualitative methods that provide a deeper understanding of factors influencing ODX testing practices. 
The objective of this aim was to identify oncologist-reported barriers and facilitators for ODX test 
uptake in clinical practice. I tested the working hypothesis that organizational facilitators, provider 
characteristics, attitudes towards ODX and social usage are associated with ODX test uptake. To this 
end, my approach involved semi-structured phone interviews with oncologists sampled across a 
range of health care settings in NC. The rationale for this aim was to elucidate factors that (1) 
influence ODX uptake and (2) have been understudied due to limitations in large secondary datasets. 
My expectation was that this research would contribute to indentifying factors that can be leveraged 
by policymakers to improve ODX test uptake, achieving the overall goal of this study. 
Conceptual Model: Individual Acceptance of an Innovation 
Aims 1 and 2 examined the influence of population characteristics on health services use. 
Aim 3 complements Aims 1 and 2 by exploring the influence of the environment. (Figure 2) 
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Figure 2. Andersen's Behavioral Model (adapted) describes how environmental factors, including 
health system factors influence health services use [1] (Aim 3)). 
 
The environment can be studied using Frambach and Schillewaert’s conceptual model. (Figure 3) In 
this study-context, individual acceptance of an innovation is equivalent to the recommendation of 
ODX testing for a patient[29]. Thus, it is important to understand a provider’s level of acceptance for 
ODX testing, as this describes whether a provider has adopted an innovation and will recommend it 
to his or her patients [30]. According to Frambach and Schillewaert’s conceptual model, individual 
acceptance is driven by organizational characteristics (e.g., organizational facilitators), provider 
characteristics (e.g., demographics), attitudes (e.g., beliefs about ODX), and social networks (e.g., 
peer usage of the test) (Figure 2). These represent organizational, interpersonal and intrapersonal 
level factors. For example, providers who believe that ODX testing is effective and informative for 
clinical decision-making have a higher likelihood of recommending ODX testing for a patient and 
using the test results in clinical decision-making. If a large proportion of the provider’s colleagues are 
actively using ODX test results, the provider may be more likely to use the test as well. Similarly, if the 
organization in which the provider works has had training or support for ordering the ODX test, then 
the provider may be more likely to recommend ODX testing for his or her patients. This conceptual 
model drives the approach (specifically, the semi-structured interview guide) in Aim #3, which not only 
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sought to understand why and when this test is used, but also how this test is being used.  
 
Figure 3. Provider acceptance of ODX test [29]   
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Table 2. Characteristics from the Electronic Provider Survey. 
Variable 
Variable 
Type 
Categories Source 
Provider 
Attitude 
Towards the 
Innovation 
Qualitative NA Interview 
Dispositional 
Innovativeness 
Categorical 
strongly disagree, disagree, 
neutral, agree, strongly 
agree 
Provider 
Survey 
Provider 
Characteristics 
      
Gender Binary Male/Female 
Provider 
Survey 
Age Categorical 
18-29, 30-39, 40-49, 50-59, 
60-69, 70-79, 80 or older 
Provider 
Survey 
Race Categorical 
White, Black, Asian, 
Hispanic, Native American, 
Other 
Provider 
Survey 
Role in patient 
care 
Binary Surgical/Medical Oncology 
Provider 
Survey 
Years since 
completing 
Training 
Count 0-40 
Provider 
Survey 
 
Health 
Organization 
Social Usage Qualitative NA Interview 
Attitude 
Towards the 
Innovation 
Qualitative NA Interview 
Organizational 
Characteristics 
      
Public Binary Public/Private 
Provider 
Survey 
Academic Binary Academic/Non-Academic 
Provider 
Survey 
Urban Categorical Urban/Suburban/Rural 
Provider 
Survey 
# providers in 
practice 
Count 0-100 
Provider 
Survey 
% breast cancer 
care in practice 
Continuous 0-100 
Provider 
Survey 
% breast cancer 
patients per 
provider 
Continuous 0-100 
Provider 
Survey 
# patients per 
week 
Count 0-100 
Provider 
Survey 
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% ER/PR+ 
patients 
Continuous 0-100 
Provider 
Survey 
# patients per 
week 
Count 0-100 
Provider 
Survey 
Patient mix       
% patients on 
Medicaid 
Count 0-100 
Provider 
Survey 
% Black 
patients 
Count 0-100 
Provider 
Survey 
 
Individual 
Acceptance 
Qualitative 
and Count 
How many times have you 
ordered ODX in the past 
month?  
Provider 
Survey and 
Interview 
 
Data Source/Eligibility Criteria 
Data were obtained through semi-structured interviews with oncologists in North Carolina 
who see at least five breast cancer patients (to establish care, undergo treatment, for follow-up, etc). 
Because the ODX test can be ordered and reimbursed by both medical and surgical oncologists, we 
interviewed both types of breast oncologists. No additional eligibility criteria were applied to the 
sample population. In addition to obtaining qualitative data through interviews, all participants 
completed a brief survey prior to the interview. 
Procedures 
To achieve this aim, I conducted 30-minute phone interviews with up to 20 oncologists. The 
interview guides were semi-structured and focused on factors that are associated with provider 
acceptance and use of ODX testing in clinical practice (Table 2) (Figure 3). I elicited participants’ 
beliefs and attitudes towards ODX as these perceptions likely influence a provider’s recommendation 
for ODX, as well as how the ODX test result is used during adjuvant chemotherapy decision-making.  
Recruitment 
Oncologists were sampled across a diversity of health care settings (e.g., urban and rural, 
academic and non-academic, inpatient and outpatient clinics etc.) in North Carolina until theme 
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saturation was reached. Oncologists were identified through the NC licensure and North Carolina 
Oncology Association websites. Following identification, we sent a letter (via email or fax) to the 
oncologists. [Appendix 2] Providers who were interested in participating contacted me via email. All 
providers who were interested in participating were given a written informed consent and survey by 
email using Qualtrics software (Provo, UT) prior to the phone interview.[31] Completion of the 
informed consent and survey served as the formal enrollment mechanism for participants. [Appendix 
3] Providers were compensated with a $100 VISA gift card for their participation in the survey and 
interview. (This was funded through Cancer Control Education Program research funds (R25-
CA57726). 
Data Collection Protocol 
Survey data were maintained using Qualtrics software (Provo, UT). Data were stored without 
provider identifiers. 30-minute phone interviews were conducted on a secured conference call line 
with audio recording capabilities using FreeConferenceCall.com.[32] Two researchers, Megan 
Roberts (MCR) and Amy Bryson (AB) conducted the interviews with a semi-structured interview guide 
[Appendix 4]; MCR conducted the interviews and AB took notes and identified recurring themes for 
probing and establishing saturation of themes. A transcriptionist transcribed all audio files such that 
no identifying information was included in the text for analysis. Data analyses were ongoing, and 
provider recruitment ended upon saturation of themes. All identifying provider information was kept in 
a separate file from the interview and survey data. Data were stored on a password-protected 
computer. 
Analysis 
Template analysis was used to analyze qualitative data.[33] This analysis method has 
previously been applied to health services research.[34-38] Template analysis is a qualitative analysis 
technique, which involves developing a coding ‘template’ that includes hierarchical coding to 
summarize themes, which are identified a priori and modified throughout data analysis. This method 
incorporates both deductive and inductive approaches, as it recognizes that research design often 
employs a conceptual framework. Thus, a purely inductive approach, such as grounded theory, is not 
appropriate. Template analysis uses a priori codes, however these codes may be modified, 
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dispensed or added to in order to create a template to serve as the basis for data interpretation.[33] 
Following Frambach and Schillewaert’s conceptual framework (Figure 2), organizational facilitators, 
provider characteristics, attitudes towards the innovation, social usage, and personal dispositional 
innovativeness were used as deductive, a priori codes. However an inductive approach was also 
used, and emergent codes were added to the analytical template (i.e., code book) as data analysis 
progressed. Furthermore, a priori codes were modified and dispensed as necessary.  
Implementation of template analysis involved several steps. First, the initial coding template 
was based off of a subset of provider interviews (n=5). First transcripts were transcribed and reviewed 
by two coders (MCR and AB). Next the initial template (i.e., codebook) was employed using only a 
priori codes from the conceptual framework. During this initial coding, a priori codes were modified, 
dispensed and augmented with inductive codes. This initial code list represented our initial template 
for the codebook. Codes were organized in a hierarchal fashion, and a final template was created that 
included both inductive and deductive codes. This final template was then used to analyze all 
transcripts, which were double coded (MCR and AB). Coding was conducted using Atlas.ti.[39] 
Coders checked for consistency in applying the coding template to the transcribed interviews through 
discussion and reconciliation for a subset of interviews (n=5). Once consistency was established, 
double coding was conducted and the coders’ analytic files were merged using Atlas.ti. Analysis was 
synthesized by organizational, interpersonal and intrapersonal level themes (Figure 4). 
Expected Outcomes 
The expected outcomes for this aim were to identify organizational and provider factors that 
are associated with ODX test uptake and to better understand how the test is being used in adjuvant 
chemotherapy decision-making. This expected outcome attains this aim’s objective of identifying 
factors that influence ODX uptake and subsequent adjuvant chemotherapy use. This helps attain this 
dissertation’s overall goal, as the outcomes elucidated modifiable factors that can be targeted in 
future interventions aimed at increasing ODX test uptake.  
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Figure 4. Conceptual model based on Frambach and Schillewaert 
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CHAPTER 4. RACIAL VARIATION IN THE UPTAKE OF ONCOTYPE DX FOR EARLY STAGE 
BREAST CANCER 
Background 
This year, an estimated 231,840 women will be diagnosed with invasive breast cancer [1], 
almost half with early stage, hormone receptor positive breast cancer [2, 3]. Among these women, 
some will reap benefit from chemotherapy in addition to endocrine therapy as part of their adjuvant 
therapy. Historically, clinicopathological features, such as tumor grade, size, age and comorbidities, 
drove adjuvant chemotherapy decision-making [4, 5]; however, commercially available genetic 
technologies, such as Oncotype DX (ODX), alleviate some of the remaining uncertainty associated 
with using only clinicopathological criteria to estimate adjuvant chemotherapy benefit.   
ODX became commercially available in 2004 for the management of early stage, node 
negative, estrogen receptor positive (ER+) breast cancer [6]. The test is a 21-tumor gene expression 
profiling panel that categorizes women into three risk groups (i.e., low, intermediate, high) based on 
10-year risk of distant recurrence [7]. Women with low risk scores are unlikely to benefit from the 
addition of chemotherapy to adjuvant endocrine therapy, whereas those with high scores derive 
considerably more benefit [7]. Evidence suggests that providers change adjuvant chemotherapy 
decision-making in about 30%-40% of patients in the presence of ODX results [8-12], reducing the 
overuse of adjuvant chemotherapy [5, 13]. Furthermore, this test appears to be cost-effective [5, 14, 
15]. Level I evidence of chemotherapy decision-making based on ODX in node-negative, ER+ 
disease awaits the results of the randomized TAILORx trial [16].  
The first private insurer began covering ODX for women with ER+, human epidermal growth 
factor receptor 2 negative (HER2-), early stage breast cancer in 2005 [6]. Medicare also began 
covering ODX testing for this patient group in 2006 [6]. Soon thereafter, medical guidelines began 
incorporating the use of ODX for adjuvant chemotherapy decision-making among node negative 
breast cancer patients with ER+, HER2-, and early stage (stage I-II) disease with tumors > 0.5cm [6]. 
Since the initial validation of ODX in node negative patients, several studies have demonstrated the 
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prognostic validity of ODX for women with 1-3 positive nodes as well [17-19]. The RxPONDER trial, is 
underway to verify observational findings and evaluate ODX for women with early stage, node 
positive, ER+ breast cancer [20]. Currently, ODX testing for women with positive lymph nodes is not 
guideline recommended or widely covered by insurance. 
 By helping clinicians make individualized evidence-based decisions regarding chemotherapy, 
ODX testing can contribute to targeted, high quality care for women with breast cancer. However, 
there also remains the potential for unintended consequences: If technologies, such as ODX, are not 
equally accessed by patients, they may exacerbate existing disparities in breast cancer care 
processes and outcomes [21]. Among guideline-eligible (i.e., node negative, ER+, stages I-II) 
patients, only 10-50% are receiving ODX testing [22, 23]. Understanding who has access to ODX 
testing will be important in targeting interventions to improve access to such technologies. The few 
studies that have examined the effect of race on ODX testing offer mixed evidence on racial 
disparities in testing uptake [22-26]; notably, these studies have limited generalizability as they have 
been conducted in academic settings [22, 24], hospitals within a single urban setting [22, 23], or 
among women with Medicare [26].  
We now seek to extend prior research by explicitly examining whether ODX use varies by 
race across diverse health care settings. Furthermore, we sought to disentangle the effect of race on 
ODX test use by lymph node status, as clinical guidelines and insurance guidelines for ODX testing 
vary among these two patient groups. 
Methods 
Data Source  
 The Carolina Breast Cancer Study (CBCS-III) (NIH 8389741) is a population-based study of 
women diagnosed with breast cancer across 44 counties in North Carolina between 2008 and 2013.. 
CBCS-III is among the largest cohort studies of breast cancer in Black women in the United States. 
Because it oversampled Black women, CBCS-III is particularly well-powered to examine racial health 
disparities in breast cancer. Between 2008 and 2013, CBCS-III enrolled 2,998 women, 20-74 years 
old with invasive breast cancer through rapid case ascertainment in collaboration with the North 
Carolina Cancer registry. Patients were sampled by randomized recruitment in four strata: Black 
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women < 50 years old, Black women > 50 years, non-Black women < 50 years old, and non-Black 
women > 50 years. For this study, we used baseline survey, medical record abstraction, and 
pathology report abstraction data.  
 
 
 
Figure 5. Sample population with exclusion criteria 
 
Subjects  
We included women whose breast cancer was: (1) ER+, (2) stage I-II, and (3) HER2-. 
Patients were further excluded patients if they had multiple tumors or undetermined tumor grade, 
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tumor size or progesterone receptor (PR) status (Figure 5). There were no significant differences in 
missing tumor data by race: 1.5% of Black had missing tumor information compared to 2.1% of non-
Black women (p=0.51). Our sample size calculations suggested that we would be able to detect crude 
effect sizes of 10% with 80% power. 
Measures  
 We used the IOM’s definition of health disparity: “the difference in treatment or access not 
justified by the differences in health status or preferences of the groups.” This definition implies that 
race is a social construct, thus controlling for socioeconomic variables that are associated with race 
may mask existing racial disparities [27] [28]. As such, socioeconomic variables (i.e., marital status, 
education, current employment (since diagnosis), family income, and insurance type) were not 
included in our primary model, which measured the reduced form effect of race on ODX testing. In 
order to observe the residual direct effect of race on ODX testing, we also developed a secondary 
model, which included socioeconomic status (SES) covariates, providing insight into contributing 
factors for racial disparities. 
 Dependent variable: Our dependent variable, ODX testing, was abstracted from pathology 
reports. Patients without ODX reports in their pathology records were assumed not to have received 
the test. 
 Independent variable: Race, abstracted from the baseline survey, was patient self-reported. 
Race was dichotomized as “non-Black” including White, Asian and other race, or “Black”, irrespective 
of ethnicity. 
 Covariates: Covariates included tumor (i.e., tumor stage, tumor size, tumor grade, and PR 
status), treatment (i.e., lumpectomy vs. mastectomy, radiation), and clinical characteristics (i.e., 
comorbidities and age). Age at diagnosis was dichotomized (< 50 versus >50 years old). Using 
comorbidities from baseline surveys, we calculated a count of comorbidities from five clinical 
categories: heart disease, hypertension, obesity, diabetes, and chronic obstructive pulmonary 
disease. Tumor and treatment characteristics were abstracted from the pathology report and medical 
reports, respectively. Tumor stage and radiation therapy were dropped due to multicollinearity with 
tumor size and surgery type, respectively. Endocrine therapy and adjuvant chemotherapy, which 
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were derived from the medical record abstraction, were each dichotomized as “ever starting therapy”. 
Adjuvant chemotherapy was defined as chemotherapy occurring after the first primary surgery (i.e., 
lumpectomy or mastectomy). Our secondary model also included socioeconomic variables, including 
marital status (i.e., married or living as married vs. other), education (i.e., less than high school, high 
school, or college and more), current employment since diagnosis (i.e., yes, no, not reported), family 
income (i.e., <15K, 15-30K, 30-50K, >50K per year, not reported), and insurance type (i.e., Medicaid, 
Medicare, private, and/or uninsured). 
Analyses  
 Descriptive statistics were calculated using population weights. We compared characteristics 
between Black and non-Black women, as well as those who did and did not receive ODX testing, 
using weighted linear regression for continuous variables and weighted chi-square tests for 
binary/categorical variables. For our multivariate analyses, we employed generalized linear models 
(GLM) with the Poisson family and log link to examine the association between race and ODX use. 
Modified Poisson regression with sandwich error terms estimates relative risk consistently and 
efficiently with correlated binary outcomes [29, 30]. Both descriptive and multivariate analyses 
addressed complex survey design through sample weights and design effects using Taylor Series 
Approximations: We also accounted for clustering at the provider level. Analyses were conducted 
using STATA software (StataCorps, College Station, TX).  
 Because factors that influence ODX testing may vary between women with lymph node 
positive verses lymph node negative breast cancer, we conducted sensitivity analyses. This 
uncovered a need to stratify analyses by lymph node status (N0 vs. N1). Thus, we present six 
models: crude, primary, and secondary models within each lymph node stratum. 
Results  
 Characteristics of patients by race and ODX uptake: Overall, non-Black women tended to 
have smaller, lower grade, and progesterone receptor positive tumors), fewer comorbidities, older 
age at diagnosis, and higher SES compared to Black women (Table 3). ODX use varied by race, with 
fewer Black women receiving ODX compared to non-Black women (33.9% vs. 43.2%, p=0.001). 
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However, upon stratifying the descriptive analysis by node status, this racial difference in ODX test 
receipt was only present among the node positive patients (14.4% vs. 34.0%, p<0.001).  
 Less than half of women who met criteria for ODX testing had ODX results reported in their 
pathology report. Node positive patients were less likely to receive ODX testing compared to node 
negative patients (30% vs. 45%, p=0.001), however this difference appears to diminish over time 
(Figure 6). Rates of ODX testing increased among node positive women in 2012/2013 compared to 
2008, while staying relatively stable in among node positive patients: Interestingly, rates of ODX 
testing among both sub-populations appear to be similar after 2008 (Figure 6). Patients receiving 
ODX testing tended to be younger, have fewer comorbidities, and have moderate tumor size and 
grade compared to patients who did not receive the test. Those receiving ODX were more likely to 
also receive adjuvant chemotherapy compared to those who did not receive ODX testing, and both 
groups were equally likely to initiate endocrine therapy (Table 4). 
 Table 3. Population-Weighted, Sample Characteristics (Mean with Standard Error/Proportion) by Race and Lymph Node Status 
 
  FULL SAMPLE  NODE POSITIVE NODE NEGATIVE 
  
Non-
Black 
Black   
Non-
Black 
Black   
Non-
Black 
Black   
  N = 859 N = 609 p N = 203 N = 180 p N = 656 N = 429 p 
  
Wgt. N = 
3,895 
Wgt. N = 
793 
  
Wgt. N = 
828 
Wgt. N = 
218 
  
Wgt. N = 
3,067 
Wgt. N = 
574 
  
O
D
X
 ODX Assay included? 43.2 33.9 0.001 34 14.4 <0.001 45.7 41.4 0.23 
ODX Recurrence Score 
17.7 
(8.3) 
19.0  
(16.2) 
0.17 
18.0 
(6.4) 
19.2 
(13.9) 
0.61 
17.7 
(8.7) 
19.0 
(16.7) 
0.20 
T
u
m
o
r
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 Stage 1 (v. 2) 65.9 55.3 <0.001 11.6 7.0 0.16 80.6 73.7 0.02 
Tumor size category     <0.001     0.22     0.01 
<2 cm 75.5 65.9   54.8 45.5   81.0 73.7   
2-5 cm 22.4 32.3   43.5 53.3   16.8 24.3   
>5 cm 2.1 1.8   1.7 1.2   2.2 2.0   
Grade     <0.001     0.003     0.004 
1 38.4 27.9   29.5 18.2   40.8 31.6   
2 46.0 47.2   48.8 43.8   45.2 48.5   
3 15.6 24.9   21.7 38.0   13.9 20.0   
PR Positive 89.9 80.8 <0.001 92.5 80.2 0.004 89.2 81.0 <0.001 
T
r
e
a
t
m
e
n
t
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
ET Initiation 90.7 87.1 0.06 93.7 88.2 0.08 89.8 86.7 0.15 
Adjuvant Chemotherapy 
Initiation 
27.5 36.7 <0.001 56.6 66.1 0.09 19.6 25.5 0.03 
Radiation 68.1 68.0 0.97 71.3 76.3 0.30 67.3 64.9 0.49 
Lumpectomy (v. 
Mastectomy) 
62.9 61.9   49.4 49.2 0.97 66.5 66.7 0.13 
C
l
i
n
i
c
a
l
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
Age at diagnosis 
57.7 
(8.7) 
55.5  
(16.9) 
0.003 
56.0 
(9.2) 
52.6 
(15.0) 
<0.001 
58.2 
(8.6) 
56.6 
(17.2) 
0.04 
Diagnosis Year      0.49     0.41       0.49 
2008 11.2 10.9  14.8 14.5  10.2 9.6  
2009 19.4 19.2  15.7 22.6  20.4 17.9  
2010 24.3 23.0  19.9 19.7  25.5 24.3  
2011 23.7 28.0  26.4 27.3  23.0 28.3  
2012/2013 21.4 18.8  23.2 12.2  20.9 20.0  
Comorbidities               
Diabetes 11.0 25.7 <0.001 12.5 20.8 0.06 10.6 27.6 <0.001 
5
5
 
 COPD 3.6 3.4 0.87 3.8 3.2 0.77 3.6 3.5 0.97 
Obesity 11.0 21.9 <0.001 10.0 19.5 0.02 11.3 22.8 <0.001 
Heart disease 6.7 7.2 0.73 7.8 5.5 0.43 6.4 7.9 0.41 
Hypertension 38.9 65.7 <0.001 39.4 61.4 <0.001 38.8 67.3 <0.001 
S
o
c
i
o
e
c
o
n
o
m
i
c
 
S
t
a
t
u
s
 
V
a
r
i
a
b
l
e
s
 
Family Income     <0.001     <0.001     <0.001 
<15K 7.1 25.1   8.2 30.7   6.8 23.0   
15-30K 12.3 25.0   9.4 29.6   13.1 23.3   
30-50K 17.1 19.3   18.0 15.7   16.8 20.6   
>50K 56.5 25.1   60.5 17.3   55.4 28.1   
Not reported 7.0 5.4   3.9 6.7   7.9 4.9   
Insurance                   
Private 78.9 63.7 <0.001 78.7 57.2 <0.001 79.0 66.0 <0.001 
Medicaid 6.0 23.5 <0.001 6.9 28.9 <0.001 5.8 21.6 <0.001 
Medicare 35.4 37.4 0.51 28.7 32.8 0.47 37.2 39.1 0.61 
Uninsured 2.9 9.7 <0.001 2.5 14.8 <0.001 3 7.7 0.001 
Married 71.1 39.4 <0.001 73.8 34.2 <0.001 70.3 41.4 <0.001 
Employed     0.12     0.16     0.35 
Unemployed 53.9 58.7   50.9 61.2   54.7 57.7   
Employed 45.4 39.9   47.7 36.8   44.8 41.1   
Not reported 0.7 1.4   1.4 2.0   0.5 1.2   
Education   <0.001     <0.001   <0.001 
HS & Post HS 49.0 55.9   39.0 60.9   51.7 54.0   
College+ 44.8 30.6   50.4 26.9   43.3 32.0   
<HS 6.1 13.5   10.6 12.2   4.9 14.0   
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 Table 4. Sample Characteristics (Mean with Standard Error/Proportion) by ODX Use and Lymph Node Status. 
 
  FULL SAMPLE NODE POSITIVE NODE NEGATIVE 
 ODX Test Receipt No ODX ODX   No ODX ODX   No ODX ODX   
 N 900 568 p 302 81 p 598 487 p 
 Weighted N 2734 1953   734 313   2001 1640   
T
u
m
o
r
 
 
 
Tumor Size 
 
  
 
  
 
0.04 
 
  
 
  
 
0.18 
 
  
 
  
 
<0.001 
<2 cm 74 73.6   49.4 61.1   83.1 75.9   
2-5 cm 22.9 25.8   48.7 38.1   13.5 23.4   
>5 cm 3 0.7   2 0.8   3.4 0.7   
Grade     0.003     0.03     <0.001 
1 40.7 31   26.6 28.4   45.9 31.5   
2 41.3 53.1   43.2 58.4   40.6 52   
3 18 16   30.2 13.2   13.5 16.5   
PR Positive 86.5 91.1 0.03 89.7 90.4 0.86 85.3 91.2 0.01 
T
r
e
a
t
m
e
n
t
 
 ET Initiation 87.1 94.1 <0.001 90.6 97 0.12 85.9 93.6 <0.001 
Adjuvant chemo 30.7 26.7 0.18 70.4 30.9 <0.001 16.1 25.9 <0.001 
Radiation 69.4 66.4 0.38 77.2 61.1 0.01 66.5 67.4 0.82 
Lumpectomy (v. 
Mastectomy) 
38.7 35.4 0.43 55.8 38.6 0.01 32.4 34.8 0.56 
C
l
i
n
i
c
a
l
 
 
Age at diagnosis 
57.6 
(10.9) 
56.9 
(9.9) 
0.28 
54.0 
(12.0) 
58.3 
(8.1) 
0.004 
58.9 
(10.1) 
56.6 
(10.3) 
0.002 
Diagnosis Year     >0.99      0.08       0.41 
2008 10.9 11.5  18.2 6.7  8.2 12.5  
2009 19 19.8  17.6 16.1  19.5 20.5  
2010 24.6 23.4  20.8 17.6  26 24.5  
2011 24.6 24.3  25.7 28.5  24.1 23.5  
2012/2013 20.9 21.0  17.2 29.8  21.9 18.9  
Comorbidites                   
Diabetes 15.5 10.6 0.03 15.7 10.6 0.39 15.4 10.6 0.06 
COPD 4.9 1.8 0.01 5.3 0 0.08 4.8 2.1 0.05 
Obesity 13 12.6 0.86 14.3 6.5 0.12 12.5 13.8 0.59 
Heart Disease 8.9 3.9 0.005 8.5 4.8 0.4 9 3.7 0.008 
Hypertension 45.3 40.8 0.19 41.8 49.3 0.28 46.7 39.2 0.07 
 
5
7
 
 S
o
c
i
o
e
c
o
n
o
m
i
c
 
 
Family Income     <0.001     0.002     0.006 
<15K 12.2 7.2   15.9 6.1   10.9 7.4   
15-30K 15.6 12.9   14.2 12.2   16.1 13   
30-50K 17.4 17.6   21 9.4   16 19.2   
>50K 46.2 58.1   43.2 70.7   47.3 55.7   
Not Reported 8.6 4.1   5.7 1.7   9.7 4.6   
Insurance                   
Private 74.6 79.1 0.13 72.8 79 0.39 75.3 79.1 0.26 
Medicaid 10.3 6.7 0.03 11.9 9.1 0.55 9.7 6.3 0.04 
Medicare 37.3 33.5 0.24 29 30.5 0.82 40.3 34.1 0.09 
Uninsured 4.7 3 0.06 6.1 2.7 0.08 4.2 3.1 0.3 
Married 62.7 70 0.02 62.1 73.6 0.06 62.8 69.3 0.06 
Employed     0.11     0.35     0.009 
Unemployed 57.4 50.9   53.1 53   59 50.5   
Employed 41.7 48.5   46.1 43.8   40 49.3   
Not Reported 0.9 0.7   0.8 3.2   1 0.2   
Education     0.07     0.56     0.09 
HS & Post HS 51 49.1   41.8 47.9   54.4 49.3   
College+ 40.3 45.4   46.1 44.1   38.2 45.6   
<HS 8.7 5.6   12.2 8   7.4 5.1   
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Figure 6. Proportion of ER+, HER2-, Stage I-II patients who had an ODX testing reported over time, 
by lymph node status (with population weights) 
 
 Race and other characteristics independently associated with receiving ODX test: Among 
node negative patients, race was not associated with receiving ODX testing, with similar results for 
the crude, primary and secondary models (Table 5). Tumor characteristics were independently 
associated with ODX test use: higher tumor grade, PR positivity, and moderate tumor size were 
associated with a greater likelihood of receiving ODX testing among node negative women. SES 
factors among node negative patients were not associated with ODX use. Year of diagnosis was not 
associated with receiving ODX testing among node negative women. 
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Year of Diagnosis
ODX Testing by Year of Diagnosis
Mean Node
Negative
Mean Node
Positive
 Table 5. Modified Poisson Regression Results of ODX Test Use for Node Negative Breast Cancer Patients 
 
n=1049  
Crude 
Model 
95% CI p 
Primary 
Model 
95% CI p 
Secondary 
Model 
95% CI p 
PSU=455  
Pop. Size=3641 
RR RR RR 
Black (v. non-Black) 
0.90 
0.77-
1.067 
0.23 0.91 
0.76-
1.094 
0.33 0.95 0.78-1.15 0.58 
Tumor Size  
(v. <2cm)          
2-5 cm 
   1.30 
1.083-
1.56 
0.005 1.31 1.10-1.56 0.003 
>5 cm 
   0.31 
0.089-
1.045 
0.059 0.31 
0.091-
1.019 
0.054 
Grade (v. 1)          
2    1.41 1.16-1.72 0.001 1.41 1.15-1.72 0.001 
3 
   1.42 
1.098-
1.83 
0.007 1.45 1.13-1.86 0.003 
PR Positive  
(v. negative)    1.48 
1.085-
2.029 
0.014 1.50 
1.099-
2.051 
0.011 
Mastectomy  
(v. lumpectomy)    1.031 0.86-1.23 0.74 1.05 0.88-1.25 0.58 
# Comorbidities 
   0.91 
0.83-
1.011 
0.080 0.95 
0.86-
1.060 
0.38 
< 50 Age at 
Diagnosis  
(v. >50)    1.13 0.95-1.33 0.16 1.074 0.90-1.28 0.42 
Diagnosis Year (v. 
2008)          
2009    0.86 0.66-1.12 0.26 0.84 0.65-1.10 0.22 
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 2010 
   0.84 
0.66-
1.072 
0.16 0.78 0.60-1.00 0.052 
2011 
   0.85 0.66-1.10 0.23 0.8 
0.62-
1.038 
0.093 
2012/2013 
   0.79 
0.58-
1.074 
0.13 0.74 
0.54-
1.011 
0.058 
Family Income (v. 
<15K)          
15-30K       0.97 0.66-1.43 0.89 
30-50K       1.12 0.77-1.62 0.56 
>50K       1.017 0.68-1.52 0.94 
Not reported 
      0.64 
0.39-
1.069 
0.088 
Uninsured  
(v. insured)       0.84 0.55-1.28 0.42 
Married  
(v. unmarried)       1.11 0.91-1.37 0.30 
Employment  
(v. unemployed)          
Employed       1.068 0.89-1.29 0.48 
Not reported       0.46 0.91-2.13 0.32 
Education  
(v. HS/HS+)          
College or more       1.082 0.92-1.27 0.33 
<HS       0.87 0.56-1.35 0.53 
Constant 0.46 0.41-0.51 <0.001 0.30 0.19-0.47 <0.001 0.26 0.15-0.45 <0.001 
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 Table 6. Modified Poisson Regression Results for the Association between Race and Covariates and ODX Testing in Node Positive Breast Cancer 
Patients 
 
n=360 Crude 
Model 
95% CI p 
Primary 
Model 
95% CI p 
Secondary 
Model 
95% CI p 
PSU=232 
Pop. Size=1047 
RR  RR RR  
 
Black (v. non-Black) 
0.42 0.27-0.66 <0.001 0.54 0.35-0.84 0.006 0.68 0.39-1.19 0.172 
Tumor Size  
(v. <2cm)          
2-5 cm    0.82 0.54-1.24 0.35 0.90 0.59-1.39 0.64 
>5 cm    0.86 0.13-5.57 0.88 1.30 0.20-8.26 0.79 
Grade (v. 1)          
2 
   1.19 0.77-1.83 0.44 1.24 
0.76-
2.035 
0.39 
3    0.57 0.26-1.24 0.16 0.56 0.27-1.16 0.12 
PR Positive  
(v. negative)    1.022 0.60-1.75 0.94 1.083 
0.58-
2.026 
0.80 
Mastectomy  
(v. lumpectomy)    0.84 0.56-1.27 0.41 0.93 0.62-1.39 0.71 
# Comorbidities 
   0.87 0.68-1.11 0.25 0.88 
0.71-
1.084 
0.23 
< 50 Age at Diagnosis  
(v. >50)  
 
 0.49 0.32-0.75 0.001 0.52 0.33-0.80 0.003 
 
Year of Diagnosis  
(v. 2008)          
2009    2.40 0.85-6.75 0.097 1.99 0.71-5.55 0.19 
2010    2.061 0.81-5.26 0.13 1.65 0.60-4.53 0.33 
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 2011 
   2.53 0.97-6.56 0.057 2.00 
0.80-
5.015 
0.14 
2012/2013 
 
 
 
.7 
 3.17 1.15-8.76 0.026 3.10 
1.088-
8.86 
0.034 
Family Income (v. 
<15K)          
15-30K       1.497 (0.790)  0.446 
30-50K       0.952 (0.558)  0.934 
>50K       2.516 (1.350)  0.087 
Not reported       0.802 (0.791)  0.791 
Uninsured  
(v. insured)       0.73 0.24-2.25 0.58 
Married  
(v. unmarried)       0.93 0.59-1.48 0.77 
Employment  
(v. unemployed)          
Employed       0.82 0.53-1.25 0.35 
NA       3.53 1.37-9.10 0.009 
Education  
(v. HS-Post HS)          
College or more 
      0.62 0.40-0.96 0.031 
<HS 
      0.74 
0.27-
2.033 
0.56 
Constant 
0.34 0.27-0.43 <0.001 0.22 
0.071-
0.71 
0.011 0.16 
0.032-
0.83 
0.029 
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 Among node positive patients, Black women were significantly less likely to receive ODX 
testing on their tumor compared to non-Black women (adjusted RR (aRR): 0.54, 95%CI:0.35-0.84, 
p=0.006) (Table 6). Furthermore, women under the age of 50 with positive nodes were significantly 
less likely to receive ODX testing compared to women over the age of 50 years, holding other factors 
constant (aRR=0.49, 95%CI: 0.32-0.75, p=0.001; aRR=0.052, 95%CI: 0.33-0.80, p=0.003). Women 
were significantly more likely to receive ODX in 2012-2013 compared to 2008, holding other factors 
constant (aRR=3.2, 95%CI: 1.15-8.76, p=0.03; aRR=3.1, 95%CI: 1.37-9.10, p=0.009). These findings 
were consistent across models: However, race was not statistically associated with receiving ODX 
testing in our secondary model, controlling for other factors, including SES variables (aRR=0.68, 
95%CI: 0.39-1.19, p=0.172). 
Discussion 
 In North Carolina between 2008 and 2013, less than half of women who were eligible for 
ODX testing (those with early stage, ER+, HER2-, node negative breast cancer) received ODX 
testing, and about one third of women with node positive breast cancer received ODX testing. 
However, these patterns changed over the course of the study, with increasing uptake of ODX testing 
among node positive patients in later years. Nonetheless, our findings corroborate a previous study 
(conducted between 2009-2010) demonstrating a lack of racial disparities in node negative women 
[24]. Because ODX is also commonly used in node positive women it is important to study uptake of 
the test in this group of women; to our knowledge, to our knowledge, our study is the first to describe 
racial disparities in ODX test use among a subgroup of node positive women.  
 Overall, Black women in the study cohort were more likely to initiate adjuvant chemotherapy 
compared to non-Black women. This is likely because Black women experienced larger, higher grade 
breast cancers compared to non-Black women, consistent with previous work in the Carolina Breast 
Cancer Study, Phase 1 and 2 [31]. Among node-negative patients, adjuvant chemotherapy initiation 
was higher among those who received ODX testing than those who did not; notably, this pattern was 
reversed among node-positive patients. Evidence suggests that among node negative women, 
patients are less likely to receive ODX testing if they have preferences against adjuvant 
chemotherapy, as the ODX test result may not influence the treatment decision-making process [32, 
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33]. However among node positive patients, ODX testing may be more commonly offered to women 
for whom providers wish to forgo chemotherapy [33], potentially explaining different chemotherapy 
initiation patterns by node status. Studies examining the cost effectiveness of ODX should stratify 
analyses by nodal status, as different patterns of ODX and adjuvant chemotherapy use may occur 
across these strata. 
ODX Use for Node Negative Patients 
 Tumor characteristics were associated with ODX use among women with node negative 
disease. Moderate tumor size, moderate/higher tumor grade, and PR positivity were associated with 
an increased likelihood of receiving ODX testing. These results suggest that, among eligible women, 
there is a subgroup of women with medium size and/or grade tumors for whom chemotherapy 
decision-making is more difficult, and in whom the additional information from ODX testing may be 
helpful. A prior study by DeFrank et al., suggested that in cases of uncertainty, ODX may offer an 
extra piece of information to make decisions about forgoing chemotherapy [24]. Perhaps patients with 
especially favorable or unfavorable tumor characteristics were more likely to forgo ODX testing, 
because the patient and provider already had enough information to make an informed adjuvant 
chemotherapy decision, even in the absence of the ODX risk score. 
 We did not find racial or SES differences in ODX test receipt among node negative patients. 
Perhaps this is due to wide coverage and availability of ODX testing for node negative breast cancer 
[6]. For eligible women who are uninsured or lack adequate coverage for ODX, Genomic Health (the 
makers of ODX) provides a financial assistance program [34]. This reduces financial barriers to 
access this test and may partially explain why race and SES are not associated with ODX use among 
node negative patients.  
ODX Use for Node Positive Patients 
 In contrast, our findings suggest a racial difference in ODX test receipt among node positive 
women. Specifically, Black women were significantly less likely to receive ODX compared to non-
Black women. In sensitivity analyses, this effect persisted across year of breast cancer diagnosis 
(data not shown). Unlike ODX testing among node negative patients, ODX testing for node positive 
patients is not generally covered by Medicare or commercial insurers, as the test is not yet guideline-
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recommended in the node positive setting. Because ODX is not widely covered for node positive 
women, concerns about perceived costs may act as a barrier to receiving ODX, despite Genomic 
Health providing financial assistance. Because SES and race are correlated, perceived costs could 
explain potential racial differences in receiving ODX testing. This may partially explain the observed 
attenuated association of race with ODX test receipt in the secondary model, which included SES 
covariates.  
Additionally, a qualitative study indicated that North Carolina providers are primarily ordering 
ODX among node positive patients within the context of the ongoing Southwest Oncology Group 
(SWOG) RxPONDER trial (S1007) [33]. Thus, low recruitment of Black women into this clinical trial 
may be a contributing factor for racial differences in this group, as a large body of evidence has 
demonstrated that Black women are less likely to enroll in clinical trials compared to Non-Black 
women [35, 36]. Future studies should test whether there is an association between race, trial 
participation, and access to new genetic technologies.   
Current medical guidelines do not recommend ODX use in this node positive subgroup of 
early stage, ER+ breast cancer patients. Thus, while Black women in our sample are less likely to 
receive ODX testing, they are actually receiving more guideline concordant care compared to non-
Black with node positive breast cancer. For this reason, differential receipt of ODX testing does not 
necessarily reflect a racial disparity in the quality of care. This paradox illustrates challenges that will 
accompany measuring disparities in the early adoption of new genetic technologies into clinical 
practice moving forward. 
 In addition to racial differences, women younger than 50 were less likely to receive ODX 
testing compared to those older than 50 years in the node positive group. Because younger women 
tend to be healthier and thus, tolerate chemotherapy better, it is possible that providers are more 
likely to move forward with chemotherapy according to guidelines [33, 37]. Alternatively, providers 
may be more likely to order ODX testing for older adults to justify not giving adjuvant chemotherapy to 
those who are frail or experiencing multiple comorbidities. 
 Finally, year of breast cancer diagnosis was strongly correlated with likelihood of ODX testing 
patterns in node positive women. This is likely due to accruing evidence for ODX testing among these 
67 
patients over time. The first major studies suggesting ODX’s prognostic validity in node positive 
patients were reported in 2008 among women receiving chemotherapy and endocrine therapy [19], 
and 2010 among women receiving endocrine therapy alone [17, 18]. In 2010, a randomized study 
demonstrated ODX testing’s predictive validity among post-menopausal women with node positive 
breast cancer (16). Thus, mounting evidence beginning in 2008 may explain why year of diagnosis 
was a strong predictor of receiving ODX testing in node positive women. Notably, we do not see this 
trend in node negative patients, as ODX testing had already been added to clinical guidelines by 
2008 for these patients [6]. 
Limitations 
 This study has several limitations. First, we were unable to account for patient preferences, 
which likely play a large role in ODX testing and adjuvant chemotherapy decisions. Evidence 
suggests that preferences around treatment for early stage breast cancer may differ by race [38]. If 
so, patient preferences may be a mediating variable between race and ODX use. Second, ODX use 
was determined through pathology report abstraction. It is possible that patients received ODX 
testing, but this information was not added to medical and pathology records. However, our rates of 
ODX uptake were similar to those reported in other studies and increased over time [22, 23]. Any 
data missing on ODX uptake is likely to be missing at random; if so, the effect of exposure 
misclassification would likely be non-differential. Third, our study was powered to observe 10% crude 
racial differences: however with the inclusion of covariates our models, in particular secondary 
models, were underpowered. Notably, with its oversampling of Black women, CBCS III presented the 
best opportunity currently available to examine racial disparities surrounding ODX test uptake. Fourth, 
our models did not include organizational or provider level characteristics that influence ODX use. 
Two studies indicate that organizational level factors, such as being seen at a tertiary medical center 
[23] or a community cancer center (versus a comprehensive cancer center)[25] may decrease the 
likelihood of receiving ODX testing. Of these studies, one found that being seen at a tertiary medical 
center explained racial differences in the uptake of ODX testing. Planned data linkages will facilitate 
exploring multilevel factors in the future. Finally, the inclusion of SES required redefining family 
income to include a “not reported” category: this demonstrates the challenges of measuring the 
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independent effects of SES, as non-random underreporting of these variables is common and may 
result in biased estimates [39]. 
Conclusions 
 Overall this study contributes to our understanding of racial variation in ODX test uptake, 
particularly by describing these differences across lymph node status. Racial disparities were not 
observed among women with node negative disease for whom ODX testing is guideline 
recommended and widely covered by insurance. This is heartening as more genetic technologies are 
incorporated into clinical guidelines for the care of cancer. Conversely, the observed racial difference 
in node positive patients suggests that newer applications of genetic technologies may be used less 
by racial minorities. This may occur for several reasons: (1) lower uptake of newer applications of 
technologies because of disparities in clinical trial participation, (2) less insurance coverage, or (3) 
unexplained provider and organizational differences in genetic technology use where racial minorities 
access care. Future studies should examine these factors’ association with ODX testing explicitly. 
Because ODX testing in node positive patients is currently not included in clinical guidelines, this 
racial difference does not describe a disparity. However, this poses an important question as we 
move into the era of “precision medicine:” How we will measure disparities in access to the latest 
advances in genetic technologies for cancer care? Moving forward, we should consider this question 
as we work to ensure that newer applications of genetic technologies are accessible to all patients 
who may benefit from the test.  
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CHAPTER 5. RACIAL VARIATION IN ADJUVANT CHEMOTHERAPY INITIATION FOR BREAST 
CANCER PATIENTS RECEIVING ONCOTYPE DX TESTING 
Background 
 Black women are less likely to develop, but more likely to die from, breast cancer compared 
to non-Black women [1]. This disparity likely arises from a complex array of biological, societal and 
health system factors, including access to high quality cancer care [2]. For example, Black women 
with breast cancer are less likely to receive guideline concordant cancer treatment, with mixed 
evidence about adjuvant chemotherapy [3, 4] and adjuvant endocrine therapy initiation and 
adherence [5]. While the vast majority of women with node negative, hormone receptor positive 
breast cancer are recommended to take endocrine therapy to reduce 10 year risk of recurrence, only 
about 15% of these women are thought to reap added benefit from adjuvant chemotherapy in addition 
to endocrine therapy [6].  
 In 2004, Oncotype DX (ODX) became commercially available as a tool for identifying which 
women with early stage, estrogen receptor positive (ER+) breast cancer are likely to benefit from 
adjuvant chemotherapy. ODX is a 21-tumor gene expression profiling panel that not only predicts 10-
year distant recurrence, but also estimates the benefit of adjuvant chemotherapy [6]. The test 
categorizes women as being at “low”, “intermediate” or “high” risk of recurrence; low risk-women are 
predicted to derive no significant benefit from adjuvant chemotherapy, while high-risk women appear 
to have improved recurrence-free survival if they receive adjuvant chemotherapy in addition to 
endocrine therapy. Thus current guidelines recommend that women with low ODX risk scores forgo 
adjuvant chemotherapy and women with high risk scores receive adjuvant chemotherapy [7]. Within 
the intermediate group, there is less certainty regarding the benefit of adjuvant chemotherapy in 
terms of 10 year distant recurrence; instead adjuvant chemotherapy decision-making can be 
individualized for factors such as patients’ preferences, age, and comorbidities.  
 There are several possible ways in which the availability of ODX testing may impact racial 
disparities in breast cancer outcome. ODX has the potential to decrease treatment disparities - 
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especially among women in the low and high risk groups - because it provides an evidence-based 
tool to guide treatment decisions. To date, little is known about adjuvant chemotherapy decision-
making in the presence of ODX risk information in a population-based study. The only peer-reviewed 
study to examine this question did not find racial disparities in the use of adjuvant chemotherapy 
among women with ODX; however findings may not be generalizable, as it was conducted within 
three urban, academic-affiliated hospitals [8].  
 Using a large, population-based prospective cohort study, we examined racial disparities in 
adjuvant chemotherapy initiation among women receiving ODX. To this end, we described racial 
differences in ODX risk scores, and we elucidated whether adjuvant chemotherapy initiation varied by 
race within (1) the low and high risk groups, with clear guidelines for adjuvant chemotherapy use, and 
(2) the intermediate group, where the treatment decision in response to ODX results is less clear. As 
more genetic technologies are used to manage breast cancer, it is important to understand how they 
impact treatment decision-making across racial subgroups.  
Methods 
Data Source  
 We used data from the third phase of the Carolina Breast Cancer Study (CBCS-III) (NIH 
8389741), CBCS-III is a prospective cohort study of 2998 women with invasive breast cancer across 
44 of the 100 counties in North Carolina. In collaboration with the North Carolina Cancer registry, 
women were enrolled using rapid case ascertainment. Notably, CBCS-III oversamples young (<50 
years old) and Black women, making it ideally-suited for examining racial differences in breast cancer 
care. Between 2008 and 2013, patients were randomly sampled from four strata: Black women under 
50 years old, Black women 50 years or older, non-Black women under 50 years old, and non-Black 
women 50 years or older [9]. For this study, we used data that were collected from the baseline 
surveys, medical record abstractions, and pathology reports to define demographic and 
socioeconomic, treatment, and tumor characteristic variables, respectively.  
Sample 
 Included women met the following criteria: a single breast tumor (n=2943), ER+ (n=2139), 
stage I-II (n=1786), HER2 negative breast cancer (n=1507), and ODX test results (n=578). Exclusion 
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criteria included: undetermined tumor grade (n=4), missing data (tumor size and/or PR status) (n=6), 
unreported employment (n=4) and family income (n=23) (Appendix 5). Our total sample size for this 
study was 541 women (Black=186, non-Black=355).  
Measures  
 Dependent variable: Our primary outcome was adjuvant chemotherapy initiation, defined as 
chemotherapy initiation following the primary surgery as determined from medical records.  
 Independent variable: Race was self-reported, and dichotomized in the CBCS-III as “non-
African American” (non-Black) (including 93.5% White, 2.3% Asian, and 4.2% other) or “African 
American” (Black), irrespective of Hispanic ethnicity. 
 Covariates: Covariates included clinical (comorbidities, age at diagnosis), tumor (size, grade, 
ODX risk score, node status), treatment (lumpectomy vs. mastectomy), and socioeconomic 
characteristics. Age at diagnosis was dichotomized (< 50 versus >50 years old). We calculated the 
number of comorbidities recorded in patient medical records. We considered five comorbidities that 
are clinically likely to affect adjuvant chemotherapy decision-making: heart disease, hypertension, 
obesity, diabetes, and chronic obstructive pulmonary disease. Tumor and treatment characteristics 
were abstracted from the pathology report and medical reports, respectively. Socioeconomic 
variables included: marital status (married/living as married vs. other), education (less than high 
school, high school, or college and more), current employment since diagnosis (yes, no), family 
income (<15K, 15-30K, 30-50K, >50K per year), and insurance type (insured, uninsured). 
Analyses 
 To account for complex survey design using population weights, descriptive analyses used 
weighted linear regression for continuous variables and weighted chi-square tests for 
binary/categorical variables. We compared the distribution of ODX risk scores in the sample overall 
and by race. We also graphed the kernel density of ODX risk scores by race. We compared sample 
characteristics by race and by adjuvant chemotherapy initiation. Per our data-use agreement, data 
were not reported for cell sizes less than or equal to 5 observations. For our primary analysis, we 
employed a modified Poisson regression to examine the association between race and adjuvant 
chemotherapy initiation. Modified Poisson regression estimates relative risk consistently and 
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efficiently with correlated binary outcomes, using sandwich standard errors [10, 11]. We addressed 
complex survey design through sample weights and design effects using Taylor Series 
Approximations. We also accounted for clustered standard errors at the provider level, and we 
conducted a complete case analysis (missing data, n=37). 
 We used the Institute of Medicine (IOM) definition of health disparity to guide covariate 
inclusion. Specifically, the IOM model for disparities states “the difference in treatment or access not 
justified by the differences in health status or preferences of the groups;” implying that race is a social 
construct [12] [13]. Thus, we did not include socioeconomic variables (marital status, education, 
current employment, family income, and insurance type) in our primary model, which measured the 
reduced form effect of race on adjuvant chemotherapy use. In order to observe the residual direct 
effect of race on adjuvant chemotherapy use, we also estimated a secondary model including 
socioeconomic covariates. This secondary model may provide insight into any mediating effects of 
socioeconomic factors on racial disparities. 
 A priori, we specified that we would stratify analyses by ODX risk category: low (risk score 
<18), intermediate (risk score 18-30), and high (risk score >30), because the evidence-based 
guidelines for adjuvant chemotherapy differed across ODX risk groups. Because so few women in the 
sample were categorized with high ODX scores, we lacked sufficient power to examine multivariate 
relationships between race and adjuvant chemotherapy initiation. Thus, we present racial differences 
in this group using only an unadjusted model. Finally, we present six models including unadjusted, 
primary, and secondary models within low and intermediate risk group strata. Analyses were 
conducted using STATA software (StataCorps, College Station, TX).  
Results 
Racial Differences in ODX Risk Score 
 Overall in our sample (n=541), 54.2% of women were in the low-risk group; 37.5% were in 
the intermediate-risk group, and 8.3% were in the high-risk group (Table 7). There were no racial 
differences in the proportion of non-Black compared to Black women in the low, intermediate, and 
high ODX risk groups (Table 8). Within ODX risk groups, mean ODX risk scores were similar among 
non-Black and Black women in the high (41.6 vs. 39.6, p=0.85) and low risk groups (11.2 vs. 11.3, 
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p=0.42): however, Black women had a somewhat higher mean risk score within the intermediate ODX 
risk group compared to non-Black women (23.5 vs. 22.3, p=0.04) (Table 7, Figure 7).  
 Within the low and high risk groups, tumor characteristics by race were similar; except in the 
low risk group where Black women were more likely to have higher tumor grade than non-Black 
women (Table 7). In the intermediate risk group, Black women had higher ODX scores and were 
more likely to have progesterone receptor negative breast cancer compared to non-Black women. 
Treatment characteristics were similar between Black and non-Black women within all three risk 
groups. Comorbidities, especially diabetes and hypertension were higher in Black compared to non-
Black women across risk groups. Age at diagnosis was similar across racial groups in all three risk 
categories; however Black women were slightly younger at diagnosis compared to non-Black in the 
low risk group. Socioeconomic characteristics were lower among Black women compared to non-
Black women regardless of ODX risk group (Table 7). 
  In bivariate analyses, women who initiated chemotherapy had higher ODX risk scores, larger 
tumors, higher tumor grade, younger at diagnosis, less heart disease and COPD, and less likely to 
have Medicare (Table 8). Among those with low-risk ODX scores, only 6.1% received adjuvant 
chemotherapy. Conversely, among women with high-risk scores, 80.1% initiated chemotherapy, 
given evidence-based recommendations to do so. In the intermediate risk group, about half of 
patients (45.7%) started chemotherapy (Table 8).  
 
 Table 7. Patient Characteristics by Race and ODX Risk Group, Carolina Breast Cancer Study, Phase 3 
 
  
Low ODX Risk Group (54.2%) 
Intermediate ODX Risk Group 
(37.5%) 
High ODX Risk Group 
(8.3%)) 
  
Mean (Standard Deviation) or 
% 
Mean (Standard Deviation) or 
% 
Mean (Standard Deviation) or % 
  
Non-
Black 
Black p 
Non-
Black 
Black p 
Non-
Black 
Black p 
 
n (weighted 
proportion) 
195 
(54.8%) 
93 
(49.8%) 
† 
131 
(37.4%) 
69 
(37.9%) 
†  29 (7.7%) 24 (12.3%) † 
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Oncotype Dx 
Recurrence 
Score 
11.2 
(3.9) 
11.3 (6.6) 0.85 
22.3 
(3.2) 
23.5 (5.9) 0.04 41.6 (7.2) 39.6 (13.1) 0.42 
AJCC Stage 1 (v. 
2) 
68.3 66.5 0.79 62.5 67.8 0.47 77.9 51.6 0.08 
Tumor size 
category 
  0.64    0.60    0.16 
<2cm 75.3 72.3  70.8 74.1   77.9 57   
2+ cm 24.7 27.7  29.2 25.9   22.1 43   
Combined grade 
  0.03    0.39    0.29 
1 42.3 26.3  23.1 32.2   * *   
2 53.2 65.2  57.8 54.2   * 25.8   
3 4.5 8.5  19.1 13.6   79.9 68.8   
PR Positive 96.7 97.3 0.79 89.9 72.7 0.003 67.8 55.9 0.44 
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Chemo Initiation 
5.9 7.2 0.69 46.2 42.7 0.66 76.5 94.6 0.11 
ET Initiation 92.4 93.1 0.84 97 94.4 0.41 92.6 84.9 0.42 
Radiation 
Initiation 
67.4 70.2 0.68 66.9 70.6 0.62 57 59.1 0.89 
Lumpectomy 
(v.Mastectomy) 
66.3 66.5 0.98 63.5 71.7 0.27 57 62.4 0.74 
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C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
Age at diagnosis 
57.4 
(8.7) 
54.4 
(15.6) 
0.002 
56.4 
(8.7) 
55.8 
(15.7) 
0.66 57.7 (9.8) 55.4 (17.3) 0.22 
7
7
 
 # Comorbidities 
0.7 (0.8) 1.1 (1.5) <0.001 0.5 (0.6) 1.0 (1.4) <0.001 0.7 (1.0) 1.4 (1.2) 0.02 
Diabetes 7.4 20.7 0.003 7.7 20.3 0.01 * 40.9 0.01 
COPD * * 0.62 * * 0.56 * * 0.59 
Obesity 14 21.3 0.13 8.7 18.2 0.1 * 31.2 0.07 
Heart Disease 4.8 * 0.19 * * 0.3 * * >0.99 
Hypertension 39.8 64.9 <0.001 31.1 59.4 <0.001 43.6 66.7 0.08 
 
*Data not reported for cell sizes of 5 or fewer. †p-value for weighted chi-square=0.23. Because of small cell size, we combined women who were 
diagnosed in 2013 (n=8) with women who were diagnosed in 2012, and women who had tumor size >5cm (n=5) with women who had a tumor size 
of 2-5 cm 
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Table 8. Sample Characteristics by Adjuvant Chemotherapy Initiation, Carolina Breast Cancer Study, 
Phase 3. 
 
  Overall Sample 
  Mean (Standard Deviation) or % 
  
No 
Chemotherapy Chemotherapy p 
 n 373 168   
T
u
m
o
r 
C
h
a
ra
c
te
ri
s
ti
c
s
 
 
Oncotype Dx 
Recurrence 
Score 14.4 (6.6) 27.6 (11.4) <0.001 
ODX Risk Group     
 Low 93.9 6.1 <0.001 
 Intermediate 54.3 45.7   
 High 19.9 80.1   
< 2cm Tumor 
size (vs. 2cm+) 76.9 64.2 0.01 
Combined grade   <0.001 
1 36.8 18.3   
2 55.2 44   
3 8 37.7   
PR Positive 92.3 86.4 0.06 
T
re
a
tm
e
n
t 
C
h
a
ra
c
te
ri
s
ti
c
s
 
ET Initiation 93.1 96.1 0.25 
Radiation 
Initiation 68.4 62.4 0.24 
Lumpectomy (v. 
Mastectomy) 65 68 0.03 
C
li
n
ic
a
l 
C
h
a
ra
c
te
ri
s
ti
c
s
 Age at diagnosis 58.0 (9.4) 53.6 (11.3) <0.001 
# Comorbidities 0.7 (0.9) 0.6 (0.9) 0.4 
Diabetes 9.4 10.3 0.78 
COPD 2.5 * 0.12 
Obesity 12.7 13.2 0.87 
Heart Disease 4.5 * 0.001 
Hypertension 40.9 38.9 0.7 
S
o
c
io
e
c
o
n
o
m
ic
 C
h
a
ra
c
te
ri
s
ti
c
s
 
Annual Family 
Income     0.98 
<15K 7.6 7.2   
15-30K 13.3 13   
30-50K 18.8 17.4   
>50K 60.4 62.4   
Insurance     
Private 79.2 82 0.55 
Medicaid 6.2 8.5 0.41 
Medicare 35.2 23.9 0.05 
Uninsured 2.6 4 0.41 
Married 69.8 70.7 0.85 
Employed (v. 
Unemployed) 49.7 51.3 0.78 
80 
Education   0.93 
HS & Post-HS 48.5 48.3   
College+ 46.5 45.7   
<HS 5.1 6   
Y
e
a
r 
o
f 
D
ia
g
n
o
s
is
 
Year   0.07 
2008 8.5 18.1   
2009 19.8 17.1   
2010 25.4 20.7   
2011 23.4 26.8   
2012/2013 23 17.2   
*Data not reported for cell sizes of 5 or fewer. Because of small cell size, we combined women who 
were diagnosed in 2013 (n=8) with women who were diagnosed in 2012, and women who had tumor 
size >5cm (n=5) with women who had a tumor size of 2-5cm 
 
 
 
 
 
 
Figure 7. Distribution of ODX risk scores by race, with reference lines indicating cut off points (at 18 
and 30 scores) for the low-, intermediate-, and high- risk groups[6]. 
 
Racial Differences in Adjuvant Chemotherapy Initiation in Risk Groups: Higher Treatment 
Certainty in Guidelines 
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 Low Risk Group: No association between race and adjuvant chemotherapy uptake was 
observed within the low risk group (Table 9). Higher ODX scores among those in the low risk 
category were associated with an increased likelihood of chemotherapy initiation compared to other 
women within this subgroup, holding other factors constant in both the primary and secondary models 
(primary aRR 1.35, 95%CI=1.17-1.55, p<0.001; secondary aRR 1.39, 95%CI=1.22-1.58, p<0.001). In 
the secondary model, being married was also independently associated with an increased likelihood 
of adjuvant chemotherapy uptake in the low risk group (secondary aRR 2.92, 95%CI=1.12-7.60, 
p<0.028). Finally, having high versus low grade tumors (secondary aRR 3.57, 95%CI=1.08-11.76, 
p=0.037) and having larger tumor size (secondary aRR 3.45, 95%CI=1.28-9.29, p=0.014) were each 
independently associated with an increased likelihood of adjuvant chemotherapy initiation in the 
secondary model, but not the primary model.  
 High Risk Group: No racial differences were found in the initiation of adjuvant chemotherapy 
among women in the high risk group, though a non-significant increased risk of chemotherapy was 
found among AA women (unadjusted RR=1.24, 95% CI=0.94-1.62, p=0.12). The small sample size 
precluded our ability to explore beyond the unadjusted model. 
Racial Differences in Adjuvant Chemotherapy Initiation in the Intermediate Risk Group: Lower 
Treatment Certainty in Guidelines 
 No racial differences in adjuvant chemotherapy initiation were observed; however higher 
ODX score (primary aRR=1.15, 95%CI=1.11-1.19, p<0.001; secondary aRR=1.15, 95%CI=1.11-1.20, 
p<0.001), younger age (primary aRR=2.00, 95%CI=1.39-2.89, p<0.001; secondary aRR=1.95, 
95%CI=1.35-2.81, p<0.001), and tumor size > 2cm (primary aRR=1.51, 95%CI=1.12-2.035, p=0.007; 
secondary aRR=1.70, 95%CI=1.22-2.35, p=0.002) were each independently associated with an 
increased risk of chemotherapy initiation across primary and secondary models (Table 10). Finally, 
being diagnosed in year 2012 or 2013 was associated with lower risk of adjuvant chemotherapy 
initiation (primary aRR=0.56, 95%CI=0.33-0.97, p<0.037; secondary aRR=0.54, 95%CI=0.30-0.96, 
p=0.036). In the secondary model, the lowest income patients were independently more likely to 
initiate chemotherapy compared to patients with higher incomes. 
 Table 9. Unadjusted and Adjusted Risk Ratios for the Association between Race and Adjuvant Chemotherapy Initiation in the Low ODX Risk 
Groups. 
 
  LOW ODX RISK GROUP (N=285) 
  Unadjusted Primary Model Secondary Model 
  cRR 95% CI P>|t| aRR 95% CI P>|t| aRR 95% CI P>|t| 
Black (v. Non-Black) 1.21 
0.47-
3.08 0.69 1.26 0.50-3.21 0.63  1.37 0.60-3.12 0.29  
ODX risk score      1.35 1.17-1.55 <0.001  1.39 1.22-1.58 <0.001  
Node Positive  
(v. negative)      0.81 0.28-2.29 0.68  0.77 0.20-2.96 0.70  
< 50 Years Age at 
Diagnosis 
     2.32 0.79-6.80 0.12  2.12 0.66-6.85 0.21  
2+ cm Tumor size  
(v. <2cm)      2.53 0.99-6.43 0.052  3.45 1.28-9.29 0.014  
Grade (v.1)                
2      0.82 0.34-2.00 0.66  0.87 0.32-2.35 0.78  
3      1.88 0.52-6.83 0.33  3.57 1.08-11.76 0.037  
Mastectomy (v. 
Lumpectomy)      1.65 0.70-3.92 0.25  1.61 0.69-3.76 0.27  
# of Comorbidities       1.3 0.76-2.24 0.34  1.3 0.73-2.33 0.37  
Family Income (v. <15K)                
15-30K           1.29  0.29-5.69 0.736  
30-50K           1.14 0.24-5.39 0.87  
>50K           0.58 0.11-3.17 0.53  
8
2
 
 Uninsured (v. insured)           0.8 0.17-3.64 0.77  
Married (v. unmarried)           2.92 1.12-7.60 0.028  
Employed (v. unemployed)           0.68 0.20-2.26 0.53  
Education (v. HS-HS+)                
College+ 
          2.86 0.92-8.9 0.07  
<HS 
          0.7 0.059-8.32 0.78  
Year                
2009      0.71 0.14-3.47 0.67  0.77 0.15-4.01 0.76  
2010      1.7 0.41-7.17 0.47  1.78 0.36-8.81 0.481  
2011      0.57 0.12-2.68 0.48  0.36 0.069-1.87 0.22  
2012/2013      0.38 0.060-2.41 0.30  0.34 0.044-2.58 0.29  
Constant 0.059 
0.034-
0.10 <0.001  <0.001 
 <0.001-
0.005  <0.001 <0.001  
<0.001-
0.002 <0.001  
Population N          1008 
#PSUs          190 
Design df                 186 
 
PSU= Primary Sampling Unit is the provider to account for provider level variation. Because of small cell size, we combined women who were 
diagnosed in 2013 (n=8) with women who were diagnosed in 2012, and women who had tumor size >5cm (n=5) with women who had a tumor size 
of 2-5cm 
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 Table 10. Unadjusted Risk Ratio for the Association between Race and Adjuvant Chemotherapy Initiation in the Intermediate ODX Risk Group 
 
 INTERMEDIATE ODX RISK GROUP (N=199) 
  Unadjusted Primary Model Secondary Model 
  cRR 95% CI P>|t| aRR 95% CI P>|t| aRR 95% CI P>|t| 
Black (v. Non-Black) 0.92  0.64-1.33 0.67 0.88 0.64-1.22 0.45  0.92 0.62-1.36 0.67  
ODX risk score      1.15 1.11-1.19 <0.001 1.15 1.11-1.20 <0.001 
Node Positive (v. negative)      1.22 0.82-1.82 0.31 1.12 0.76-1.64 0.56  
< 50 Years Age at Diagnosis      2.00 1.39-2.89 <0.001 1.95 1.35-2.81 <0.001  
2+ cm Tumor size (v. <2cm)      1.51 1.12-2.035 0.007  1.70 1.22-2.35 0.002  
Grade (v.1)                 
2      0.88 0.60-1.30 0.53  0.88 0.60-1.27 0.49  
3      1.086 0.72-1.63 0.69  1.16 0.77-1.75 0.49  
Mastectomy (v. Lumpectomy)      0.89 0.64-1.23 0.48  0.84 0.61-1.17 0.30  
# of Comorbidities      0.87 0.67-1.13 0.29  0.85 0.65-1.12 0.24  
Family Income (v. <15K)                 
15-30K            0.30 0.12-0.77 0.013  
30-50K            0.33 0.15-0.75 0.009  
>50K            0.43 0.18-1.012 0.053  
Uninsured (v. insured)            1.23 0.58-2.63 0.59  
Married (v. unmarried)            1.22 0.78-1.93 0.38  
Employed (v. unemployed)            1.31 0.94-1.83 0.108  
Education (v. HS- HS+)                 
College+            0.84 0.59-1.18 0.31  
<HS            0.74  0.26-2.13 0.57  
Year                 
2009      0.85 0.48-1.51 0.58  0.91 0.49-1.68 0.76 
2010      0.72 0.36-1.45 0.35  0.76 0.36-1.58 0.45  
2011      0.99 0.61-1.62 0.98  1.013 0.61-1.70 0.96  
2012+      0.56 0.33-0.97 0.037  0.54 0.30-0.96 0.036  
Constant 0.46 0.39-0.55 <0.001 0.019 
0.0054-
0.068 
<0.001 0.031 0.0086-0.11 <0.001 
Population N         698 
#PSUs         145 
Design df         141 
 
PSU= Primary Sampling Unit is the provider to account for provider level variation. Because of small cell size, we combined women who were 
diagnosed in 2013 (n=8) with women who were diagnosed in 2012, and women who had tumor size >5cm (n=5) with women who had a tumor size 
of 2-5cm. 
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Discussion 
 Overall, we found no racial disparities in adjuvant chemotherapy initiation across ODX risk 
groups; neither did we observe racial differences in mean ODX risk scores within the high and low 
risk groups. However, in the intermediate risk group, Black women had slightly higher ODX risk 
scores compared to non-Black women. The magnitude of this difference was small, and likely not 
clinically meaningful, corroborating a previous study that reported no significant racial differences in 
mean ODX risk scores [8]. Unlike that study, we did not observe significant racial differences in the 
distribution of women into ODX risk groups [8].  
 In our study, only 8% of women were classified with high risk scores. This differs significantly 
from the preliminary ODX validation studies, where 27% of women with early stage breast cancer 
were classified as high risk [6]. Notably, subsequent observational studies have found the proportion 
of high-risk scores to be similar to what we observed [8]. In a qualitative study, providers discussed 
being less likely to order ODX testing for more aggressive tumors because they felt that they already 
had the necessary information to offer adjuvant chemotherapy [14]. Thus, this may suggest reasons 
why women with high risk scores may be less likely to receive ODX testing in real world practices. 
 We did not find racial disparities in adjuvant chemotherapy initiation. There are several 
plausible explanations for this finding. First, we examined women with early stage, ER+, HER2- 
breast cancer who received ODX testing. Within this selected group, it is possible that women already 
have access to high quality breast cancer care that would attenuate racial differences in uptake of 
chemotherapy. Second, it is possible that ODX information mediates variation in the uptake of 
adjuvant chemotherapy by providing an objective tool to guide treatment decision-making. Third, the 
non-significant association between race and adjuvant chemotherapy initiation may result from our 
relatively small sample size, especially in multivariate models. Finally, studies of racial variation in 
breast cancer care have not consistently demonstrated racial disparities in adjuvant chemotherapy 
initiation. While some studies report underuse of adjuvant chemotherapy among minority and low-
income women [3, 4, 15], others have failed to find such disparities [16-18]. Furthermore, some 
studies suggest that racial disparities in adjuvant chemotherapy use occur not in initiation, but rather 
in delays [19-21], which was not evaluated in our study.   
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 Although race was not associated with adjuvant chemotherapy initiation across risk groups, 
there were interesting findings within the low and intermediate risk groups. Despite guideline 
recommendations to forgo chemotherapy for low ODX risk tumors, a small subgroup of patients 
(6.1%) still initiated adjuvant chemotherapy. Within the low risk group several factors were 
independently associated with adjuvant chemotherapy initiation. Higher ODX score was associated 
with an increased likelihood of chemotherapy initiation. This may reflect that ODX scores are being 
used along a continuum; if so, within risk groups, physicians may perceive some women to be at 
higher risk than others. In our secondary model, other tumor characteristics, including larger tumor 
size (>2cm v. <2cm) and higher tumor grade (3 vs. 1), were each independently associated with 
increased risk of chemotherapy initiation, suggesting that such tumor characteristics play a role in 
adjuvant chemotherapy initiation even in the presence of a low ODX risk score. Finally, consistent 
with previous literature, being married was associated with an increased likelihood of adjuvant 
chemotherapy initiation among women in the low-risk group. It may be that women who are married 
have more social support and resources to pursue additional treatments [22].  
 Interestingly, population weighted estimates demonstrated that 19.9% of patients in the high 
risk group failed to initiate adjuvant chemotherapy despite guidelines. Small sample size limited our 
ability to investigate factors associated with adjuvant chemotherapy receipt in this group. Qualitative 
analyses suggest that women who forgo chemotherapy in this group typically do so because of 
patient preferences [14]. 
 Within the intermediate group, about half of women received chemotherapy. Race did not 
influence chemotherapy initiation: however, similar to the low risk group, the ODX risk score did. Not 
only higher ODX score, but also larger tumor size was associated with adjuvant chemotherapy 
initiation. Taken together, tumor characteristics appeared to play a major role in directing adjuvant 
chemotherapy decision-making within the intermediate risk group. Younger age was also associated 
with higher risk of adjuvant chemotherapy initiation in the intermediate group, which is consistent with 
studies demonstrating that younger women tend to get more aggressive treatment [14, 23]. This 
could be due in part to better overall health and tolerability of adjuvant treatment, patient preferences, 
or other differences in tumor characteristics. Interestingly, having an annual family income below 
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$15,000 was associated with a higher likelihood of adjuvant chemotherapy initiation compared to 
women with higher incomes. Two potential explanations for this finding may be that (1) low income 
patients are more likely to be seen by providers that prescribe more chemotherapy within the 
intermediate risk group or (2) patient preferences regarding chemotherapy vary by socioeconomic 
factors, such as family income. Finally, being diagnosed with breast cancer in 2012 or 2013 was 
associated with a lower likelihood of adjuvant chemotherapy use, perhaps indicating a change in 
practice patterns over time. 
 This study has several limitations. First, while CBCS-III is a large, longitudinal breast cancer 
cohort that oversamples Black women, we were underpowered to fully explore racial disparities in 
multivariable models, particularly in the high risk group. Second, we were unable to account for 
patient preferences, which likely play a role in ordering ODX testing and subsequent adjuvant 
chemotherapy decision-making [24]. Third, we lacked data on organizational and provider 
characteristics that influence adjuvant chemotherapy use [8, 25, 26]. Finally, we conducted a 
complete case analysis under the assumption that data were missing at random. If this assumption is 
violated, then estimates may be biased. However, we did not observe significant differences in race, 
ODX risk score or chemotherapy initiation between observations with missing and non-missing data 
field(s). 
 Our study adds to the literature by investigating the uptake of adjuvant chemotherapy among 
women receiving ODX testing by race within a large longitudinal, population-based cohort study of 
breast cancer patients. Our findings suggest that racial disparities in adjuvant chemotherapy use do 
not exist among this group of breast cancer patients receiving ODX. As more genetic technologies 
are incorporated into treatment decision-making, it will be important to understand how these tests 
are being used across racial subgroups. Future research should incorporate organizational-, provider-
, and patient- level data into studies that seek to understand racial variation in oncology treatment 
decision-making. 
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CHAPTER 6. BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE AMONG 
ONCOLOGISTS: A QUALITATIVE STUDY 
Background 
 Once viewed a single disease, breast cancer is now recognized as a heterogeneous disease 
with distinct biological subtypes (1). With this nuanced recognition of tumor biology, we better 
understand the interaction between tumor genetics and treatment response. As such, genetic 
technologies are changing the landscape for breast cancer treatment. 
 Oncotype DX (ODX) is a 21-tumor gene-profiling panel test that estimates 10-year risk of 
recurrence and benefit of adjuvant chemotherapy among early-stage, estrogen receptor positive 
(ER+) breast cancer patients, thereby improving treatment decision-making (2). Specifically, women 
with low risk scores are recommended to forgo, and women with high risk scores to take, adjuvant 
chemotherapy; research on chemotherapy benefit among women with intermediate risk scores is 
ongoing (3). Evidence suggests that ODX reduces adjuvant chemotherapy use among women with 
low risk scores, saving patients from significant costs and harms of adjuvant chemotherapy overuse 
(4-6).  
 Today, ODX use has been incorporated into standard practice. Some private insurers began 
reimbursing for ODX in 2005, and CMS followed in 2006 (7). Although clinical guidelines began 
recommending ODX in 2007 (7), fewer than half of guideline-eligible women are receiving ODX 
testing (8-11). Reasons for its low use are not well understood. Because treatment decision-making is 
a nuanced process, secondary data are unlikely to capture the complex factors related to ODX use 
and subsequent adjuvant chemotherapy decision-making. Thus, this study sought to better 
understand provider recommendation patterns for ODX, and to identify factors that influence ODX 
test use at the organizational, interpersonal, and intrapersonal levels.  
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Methods 
Study Design  
 We conducted semi-structured telephone interviews with oncologists across North Carolina 
(NC) The interview guide was motivated by a conceptual model (12) in which barriers and facilitators 
influencing providers’ use of ODX could occur at the organizational, interpersonal, and intrapersonal 
levels. We conducted interviews until theme saturation was reached (estimated ~15-20). Interviews 
took ~30 minutes and were conducted by one author (MCR); a second author (AB) listened, identified 
areas for probing, and took notes. All interviews were digitally recorded, professionally transcribed, 
de-identified and transferred to Atlas.ti (Berlin, Germany) for analysis. 
Table 11. Participant Characteristics.  
Characteristics Mean  
Provider 
Gender (%Male) 53.3  
Race (% White vs. Non-white) 86.7  
Oncology Specialty (% Medical 
vs. Surgical) 66.7  
Years of practice 15.8 + 7.8 
Number of ODX ordered per 
month 4.4 + 3.4 
Patient Mix 
Medicaid (%) 20.7 
Uninsured (%) 10.5 
Non-White (%) 38.1 
Breast Cancer Patients (%) 56.4  
Breast Cancer Patients/wk (%) 25.1 +13.9 
Breast Cancer patients with HR+ 
breast cancer (%) 68.1 
Practice 
Academic Affiliation (%) 73.3 
 
Procedures  
 We used purposive sampling to identify NC surgical and medical oncologists who practice in 
community or academic settings through the: (1) NC Oncology Association and NC Medical 
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Licensure websites and (2) contacts with clinical partners. Providers were emailed or faxed a 
recruitment letter, asking those interested in participating to contact the researchers. Providers were 
eligible if they saw >5 breast cancer patients/week to establish care, undergo treatment, or for follow-
up. Once we scheduled a phone interview, providers completed an electronic informed consent and 
brief demographic survey. We gave providers $100 gift cards for their participation. 
Data Analysis  
 We used template analysis which combines inductive and deductive approaches to 
qualitative analysis by allowing a priori codes to be modified, removed and augmented (13). Template 
analysis follows several steps. First, our initial coding template applied the domains of the conceptual 
model (12), including “attitudes towards the innovation”, “organizational facilitators/internal 
marketing,” “social usage” and “personal dispositional innovativeness” as a priori codes. We applied 
the initial coding template to the first five interview transcripts using Atlas.ti. Subsequently, the initial 
template was revised and emergent thematic codes were added in a hierarchical fashion to create a 
final coding template (Appendix 6) that was applied to all transcripts: MCR and AB coded all 
transcripts. Consensus was reached on coding for the first five transcripts to ensure agreement 
across coders; coders’ analytic files were merged using Atlas.ti. Data were analyzed and organized 
by: provider recommendation patterns, as well as factors that influenced ODX use at the 
organizational, interpersonal, and intrapersonal levels.  
Results 
Provider Characteristics 
 After interviewing 5 surgical and 10 medical oncologists across 10 health care settings, 
theme saturation was reached (Appendix 7). Provider characteristics are presented in Table 11. On 
average, participants ordered ~4 ODX tests/month and had practiced for about 16 years. They saw 
an average of 25.1 breast cancer patients/week and estimated that ~70% of their patients had 
hormone receptor positive breast cancer. When asked “among my peers, I am usually the first to try 
out new medical technologies for clinical care” on a Likert scale (1=strongly agree; 7=strongly 
disagree), their mean score was 3.3 (viewing themselves as somewhat innovative).  
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ODX Recommendation Patterns 
 Factors influencing provider recommendation for ODX testing crosscut organizational, 
interpersonal, and intrapersonal levels. Providers typically determined eligibility for ODX based on 
tumor characteristics, age, comorbidities, and patient preferences. Though variation existed, most 
providers felt that patients with HER2 negative, ER+, stage 1 and node negative breast cancer were 
appropriate candidates for ODX. While a few providers restricted their use of ODX to Stage 1 only, 
the majority considered Stage 2 breast cancers. Overall, this aligns with current clinical guidelines 
recommending ODX for HER2 negative, ER+, stages 1-2, node negative, >0.5cm tumors (14).  
 Providers were less likely to use ODX for women who may not be candidates for 
chemotherapy due to extensive comorbidities, advanced age or life expectancy <10 years. Young 
age seemed to influence ODX test use in two ways. First, one provider mentioned a bias towards 
adjuvant chemotherapy in younger women, making ODX testing unnecessary. Second, two providers 
mentioned a lack of validated data for ODX test use among premenopausal women, resulting in less 
use:  
I do acknowledge that even though the original publication of the Oncotype 
validation tried to say that age really wasn’t a factor...I'm still not totally 
convinced of that. I think that there is some reason to doubt that it functions 
in quite the same way in younger women. Those patients oftentimes will 
decide to take chemotherapy anyway; not often but a handful. 
 
 While many providers felt that most patients are open to receiving ODX, patient preferences 
played a large role. The vast majority of providers reported being unlikely to order ODX if a patient 
expressed a clear preference against chemotherapy because the test result would not provide 
actionable information. Several providers stated that prior to ordering ODX, they discussed patient 
preferences so patients understood how the ODX risk score might inform their decision about 
adjuvant chemotherapy. When a patient’s preference towards chemotherapy was not aligned with 
how the ODX score could influence treatment decisions, providers often did not order ODX. 
 The most variation in ODX testing was in node positive disease: Currently, ODX testing in 
node positive disease is not guideline recommended; however, new evidence suggests it may be 
applicable [14]. Twelve providers mentioned ordering ODX for node positive patients less frequently 
than in node negative patients. Many providers referenced only using ODX for node positive patients 
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in two major ways. First, providers used patient enrollment into the RxPONDER study (15) to 
motivate the use of ODX among certain women with positive lymph nodes. While women with 1-3 
positive lymph nodes were eligible for the RxPONDER study, some providers only ordered ODX for 
women with 1-2 positive nodes. Most providers were comfortable recommending ODX among 
patients with otherwise favorable histological (e.g., lobular) and tumor (e.g., low grade, small size) 
characteristics. Second, providers commonly reported ordering ODX in node positive disease to find 
evidence to forgo chemotherapy in elderly, sick, or frail patients. Many providers expressed no 
hesitation in using ODX among women with micro-metastases. Hesitation around using ODX testing 
in node positive patients largely came from lack of evidence that ODX predicts chemotherapy benefit 
in this population.  
Organizational-Level Factors 
 One organizational challenge to ODX testing resulted from departmental silos (surgical 
versus medical oncology; pathology versus oncology). Providers mentioned that departmental silos 
were more common when ODX was first introduced, suggesting an organizational learning curve:  
I think how it was working before is we would call the pathology 
department…my nurse would have to walk up there, get the blocks herself, 
get the Oncotype kit, fill out all the paperwork, and mail it. Now we just call 
pathology and they mail it. They kind of leave that whole step out. 
 
Several providers indicated that having a single nurse or staff member responsible for ordering ODX 
might address this challenge. Furthermore, provider roles in ordering ODX shifted to a more 
organized process over time:  
At present, just the medical oncologists are [ordering the test]. When the test 
first came out and before we actually formulated the multidisciplinary breast 
group, we had radiation doctors ordering it and surgeons ordering it...And so 
it wasn’t really being used appropriately in every instance. It was nice 
sometimes to have the results available right then when you talk to the 
patient. But that wasn’t appropriate in all the situations. So [now], we 
basically have an understanding that it should be done by med oncologists. 
 
 Overall, multidisciplinary teams seemed to facilitate decision-making about which patients 
would benefit from ODX and provided an optimal organizational structure for ODX use:  
It’s actually very simple [to order] because we have a multidisciplinary clinic 
where we have a medical oncologist and a surgeon working side by side all 
day long every day. So, we literally just walk over with the path report, say 
‘Ms. X has just come back from the operating room for a return cancer 
operation.’ We decide what to do and move ahead. 
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These multidisciplinary teams appeared to reduce departmental silos as a barrier to test use. 
 All providers, except one who could not recall, had at least one interaction with the Genomic 
Health Marketing team. In general, Genomic Health representatives and/or resources seemed to 
facilitate ODX use through: (1) training for ordering and using ODX, (2) offering support around 
coverage/reimbursement for ODX, and (3) providing educational materials and current research 
results around its effectiveness. Providers also indicated that easy online ordering and results, 
website resources, and printable test reports facilitated use of ODX. 
 Ten providers discussed insurance coverage. In node positive patients, insurance coverage, 
outside of clinical trial use, was often seen as a barrier for using ODX. Providers noted that insurance 
policies did not “keep up with the science,” referencing new studies that demonstrate effectiveness of 
ODX in node positive disease. Notably, insurance was no longer viewed as a barrier for women with 
node negative disease. This suggests that if evidence accumulates for using ODX in node positive 
disease, clinical guidelines and insurance coverage may change accordingly. Until then, several 
providers noted that Genomic Health offers payment assistance programs for eligible patients for 
whom insurance does not fully cover the cost of ODX. 
 Organizational factors identified as barriers to ODX use delayed, rather than prevented, 
sending results to Genomic Health. One provider noted:  
The biggest delay I’ve seen is from insurance companies making approval. 
And most end up doing it. Like I said before, very few have said “no.” But 
that’s usually the biggest delay is them dragging their feet to approve it and it 
adds another week or two. …this isn’t as big anymore...  
 
Another provider elaborated how these delays influence the patient:  
It’s not something we typically order off of the core biopsy because we just 
don’t have all the answers yet. […] So, once surgery is completed and you’ve 
got a pathology report then there’s still a delay … and so it drags things out 
for the patient. And there’s an anxiety associated with that.  
 
 While delays were not viewed as compromising treatment trajectory, they were inconvenient 
to patients and increased their anxiety. Two providers emphasized that these delays can be 
particularly difficult for patients living in rural areas or travelling long distances for care.  
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Interpersonal-Level Factors 
 Providers discussed physicians’ normative beliefs and roles on their use of ODX. Overall, 
providers believed that there was greater buy-in for ODX compared to alternative tumor gene profiling 
panels. Several providers referenced consensus around ODX use for managing early stage, ER+ 
breast cancer. Because medical oncologists typically ordered ODX, discussed ODX results with 
patients, and ordered adjuvant chemotherapy, the ODX recommendation often came from them 
rather than surgical oncologists. While medical and surgical oncology roles were sometimes well-
coordinated, discordant beliefs and disagreements occurred between surgical and medical 
oncologists who used different criteria for ODX recommendation. For example, one medical 
oncologist stated:  
One [surgical oncologist] doesn’t order it. The other one does, and it drives 
me nuts because they order it for HER2 positive patients. They order it on a 
four-millimeter patient.... It puts me in a bind. [...] I never would have ordered 
it or even brought it up.  
 
One surgical oncologist discussed introducing ODX to patients before they see their medical 
oncologist, because ODX is not used across the board: 
 I will discuss Oncotype as part of “this may play a role in determining 
whether you benefit from chemotherapy.” And I do that as part of my 
discussion as the surgeon so that it puts it out on the table and then [they] 
can force the issue with the medical oncologist. I work with a wide variety of 
medical oncologists. And while it’s now more in the standard, it is not 
completely embraced across the board.  
 
Some providers mentioned that ODX recommendations beyond node negative patients are becoming 
more common, but norms vary across health care settings: 
I traditionally order Oncotype in my node negative, ER positive patients. I 
know across the United States there’s been more of a push to use Oncotype 
in the node positive.  
 
There are people who use it kind of emphatically in the one to three lymph 
node group. I think I use it still more sparingly until we have prospective data, 
which we should have soon. 
 
Intrapersonal-level Factors 
Most providers referenced attitudes and beliefs when discussing ODX use, which we grouped into 
three categories: attitudes towards ODX, perceived barriers, and perceived research gaps 
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Attitudes Toward ODX  
 Overall, providers had positive attitudes towards ODX, because it provided clinically relevant 
results that providers and patients could use to make treatment decisions, saving some patients from 
a major treatment from which they were unlikely to benefit:  
Quite honestly, [they] used to be frustrating discussions for all of us, because 
we knew that there was a significant portion of the ER positive node negative 
disease that we were giving chemotherapy where we probably were not 
benefitting patients at all. 
One provider noted that test results helped frame discussions with patients regarding their future 
health and survival:  
It’s oftentimes the case in early stage breast cancer discussion that the 
focus…very quickly, goes to the local, regional management. And that’s fine 
to some degree. But it can’t come at the cost of patients losing sight of the 
importance of the systemic therapy. Ultimately, … the discussion I think 
helps to put the issue and the problems they need to think about in the right 
context. One of the strengths is [that it] quantifies their risk in a way that for 
most patients is quite reassuring.  
 Some providers mentioned that patients are increasingly familiar with ODX when they enter 
their offices, facilitating patient understanding of the test and results. Providers saw several other 
reasons for using ODX over alternative tumor gene profiling panels. For example, ODX does not 
require fresh tissue (like Mammaprint), making it more convenient and feasible, especially in small, 
rural communities. Two providers noted that the receptor status information that ODX provides is 
useful to ensure that patients’ tumors are properly classified. 
Providers’ Perceived Barriers  
 Providers discussed frequent difficulty with communicating the purpose of ODX testing to 
patients: 
I'm always talking about genetic testing and I think sometimes they can 
confuse Oncotype DX testing with genetic testing with BRCA 1 and 2. […] 
Either they're very overwhelmed or I'm not explaining it clearly enough or it’s 
not concrete enough at that point in their process of their treatment. 
 
Furthermore, explaining risk of recurrence and risk reduction was challenging because the nuances 
involved often led to “information overload.” One provider reported that low risk scores can result in 
misconceptions about the need for other risk reduction strategies. For example, women with low ODX 
risk scores may interpret the result to mean that adjuvant therapy is unnecessary, when in reality 
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endocrine therapy is still recommended. Patient misconceptions occurred not only about the test and 
its interpretation, but also about its perceived cost, which can be a barrier to testing. To overcome 
patients’ misconceptions, several providers emphasized the need to discuss ODX across multiple 
visits.  
 Overall, providers discussed that low risk patients forgo chemotherapy and high-risk patients 
receive chemotherapy. Discordant chemotherapy decisions were rare, and often resulted from patient 
preferences. However, intermediate risk results posed a challenge to providers. Providers often 
created rules for navigating adjuvant chemotherapy decision-making in the intermediate ODX risk 
group. About half of the providers created their own cut-off points within the intermediate group for 
recommending adjuvant chemotherapy. One provider stated that as a rule, s/he recommends 
adjuvant chemotherapy to most patients within the intermediate risk group; another provider rarely did 
so. About 1/3 of providers used “old fashioned” clinical and tumor characteristics (tumor size, grade, 
age, comorbidities) when recommending chemotherapy in the intermediate risk group. Because there 
is no definitive evidence of benefit to chemotherapy in this risk group, providers emphasized the 
importance of patient preferences in decision-making. Most providers used a combination of 
approaches for decision-making in the intermediate risk group: For example:  
It’s a joint decision about whether or not to give chemotherapy […] if it’s 
towards the low end of intermediate, I'm comfortable not giving 
chemotherapy. If it’s towards the high end, then I'm more likely to 
recommend chemotherapy--but add into that also such things as age. 
 
Perceived Research Gaps 
 Providers offered ideas about future research needs including (1) what patients understand 
about ODX and (2) how to best communicate ODX testing and results with patients. Providers also 
reported a need to better understand the predictive validity of ODX among premenopausal women, 
pointing to weaknesses in current studies that underrepresent younger women. Because women in 
validation studies were taking endocrine therapy, one provider discussed the need to understand 
ODX’s predictive validity when patients are not prescribed or appropriately taking this therapy. They 
also wanted more studies of ODX effectiveness in real world settings and that consider additional 
patient outcomes (e.g., survival). Several providers desired more information about managing women 
with intermediate risk scores and hope that the TAILORx trial will soon close this research gap (3). 
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Finally, oncologists voiced a need for genetic technologies that not only describe which patients 
would benefit from chemotherapy, but also which chemotherapy regime would be most effective.  
Discussion 
Our findings contributes to current knowledge by providing a rigorous, theory-driven, 
qualitative study examining how multilevel factors influence ODX recommendation and use among 
providers. We elicited how organizational, interpersonal and intrapersonal factors have influenced 
ODX use and explored nuances across node positive and node negative breast cancer patients.  
Prior research indicates that the diffusion of genomic innovations is influenced by multilevel 
factors (16). Currently only two qualitative studies have examined provider and system-level factors 
that influence the use of ODX in clinical care, one of which focused more broadly on barriers common 
to both BRCA and ODX testing (17). Together, these studies indicated that characteristics of the test 
(i.e., interpreting intermediate results)(18), use of multidisciplinary teams (18), test coordination 
(including reimbursement) (17), and patients’ out-of-pocket costs (17) created barriers to genetic 
technologies in clinical practice. Furthermore, oncologists worried that testing could be used 
inappropriately(18) or delay treatment (17). Overall, our study found similar results; however, most 
providers in our study viewed multidisciplinary teams as facilitators to ODX use. Previous studies also 
indicated that costs were a barrier for ODX use. While we found this to be true for node positive 
patients, costs were rarely reported as a barrier for node negative patients. Furthermore, it is possible 
that stage of adoption and insurance coverage of ODX varied across study settings (19).  
Organizational factors, including departmental structure, workflows for ordering tests and 
insurance policies, were discussed frequently by providers in our study. The extent to which these 
factors acted as barriers seemed to decrease over time, suggesting that organizational barriers may 
be especially critical to address when first adopting of genetic technologies. Furthermore, providers’ 
normative beliefs have changed over time to embrace ODX in the node negative setting; with 
increasing evidence, beliefs are beginning to shift in node positive disease.  
Research evidence was viewed as essential to provider acceptance of ODX. Respondents 
sought evidence from research among real world patients; cancer registries and health information 
technology will be critical to evaluating these technologies. Because patients demonstrate poor 
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understanding of ODX and its interpretation results (20, 21), future research should examine best 
practices for how providers communicate this information so that they can optimally use results from 
genetic tests to help patients make informed treatment decisions. Equally important, guideline support 
and insurance coverage for these technologies will be important in facilitating their use. Rapidly 
incorporating these technologies into insurance policies and practices may present challenges for 
policy makers. It will be imperative that financial barriers do not preclude low socioeconomic patient 
subgroups from accessing these technologies and contribute to existing disparities in access and 
quality care.  
The main limitation of this study is generalizability: (1) we only included NC providers, (2) 
respondents may differ from providers who declined to participate, and (3) while saturation of themes 
was attained, the sample consists of 15 provider perspectives. 
ODX represents an example of the successful genetic technology that has reshaped breast 
cancer care for women with early stage breast cancer. As such, it presents an important model for 
incorporating a genetic technology into the standard of cancer care. Our findings highlight the 
importance of multi-level factors in the use of ODX testing. Moving forward, studies should examine 
how the identified organizational factors influence uptake and use of ODX, controlling for provider-
level variation. As more genetic technologies become available, our findings can facilitate their uptake 
across providers and health care settings. Finally, more evidence is needed to truly understand the 
effectiveness of ODX in treatment decision-making and outcomes (22).  
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CHAPTER 7. DISCUSSION 
Conclusions 
Race and ODX Use 
Findings from this study provide insight into how the ODX test is being incorporated into 
cancer care. While racial disparities were not detected among women with node negative breast 
cancer, a racial difference was detected among node positive patients: Black women with positive 
lymph nodes had a 46% decreased chance of receiving ODX testing compared to non-Black women. 
We offer several hypotheses as to why ODX may be used differently among node negative verses 
node positive patients.  
First, ODX is widely covered for adjuvant chemotherapy decision-making in node negative 
patients and has been incorporated into clinical guidelines; neither is true for node positive patients. 
Thus, the lack of insurance coverage for ODX testing in node positive may play a role in the observed 
difference in testing. Notably, when SES factors such as education, family income, and insurance 
coverage were included in our models, the racial difference in receiving ODX testing among node 
positive women was attenuated and no longer statistically significant (aRR: 0.54, p=0.006 vs. aRR: 
0.68, p=0.172). SES factors appeared to partially explain the observed racial difference in receiving 
ODX testing, but sample size constraints limited our ability to fully control for SES factors. Because 
ODX testing in node positive women (outside of clinical trial settings) is not aligned with current 
medical guidelines, Black women were actually receiving more guideline concordant care compared 
to non-Black women.   
Second, ODX testing in node positive patients may be ordered and covered within the 
purview of clinical trials. The RxPONDER trial has 23 recruitment sites across NC, and during 
qualitative interviews, several providers discussed their infrequent ordering of ODX testing in node 
positive patients, except in the case of clinical trial enrollment. Given known disparities in minority 
participation in clinical trials [1, 2], we may be observing a racial difference in ODX uptake that is 
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mediated by differential clinical trial enrollment. Future studies should examine this explicitly, as 
clinical trial enrollment may be a potential intervention for ameliorating racial variation in the uptake of 
new technologies early in adoption. 
Associations of Covariates with ODX Use 
In total, fewer than half of women who were eligible for ODX per current guidelines received 
the test. In addition to race, associations were detected between covariates and receiving ODX 
testing, including (1) tumor characteristics, (2) age, and (3) year of diagnosis. First, among node 
negative patients, women with medium-sized (2-5 cm), grade 2- 3 grade, and PR+ tumors were more 
likely to receive ODX testing. One potential explanation for this finding may include the role that 
clinical uncertainty plays in the use of ODX for chemotherapy decision-making. During qualitative 
interviews, oncologists discussed using ODX test results to reduce uncertainty in treatment decisions. 
In circumstances when the tumor had particularly favorable characteristics or seemingly aggressive 
characteristics, providers expressed being less likely to order ODX testing, as they were already fairly 
certain that chemotherapy would not or would be beneficial, respectively.  
Second, young age played a role in ODX test receipt in node positive women: qualitative 
interviews revealed that providers felt less certain of the validity for ODX among young women. In 
particular, among node positive patients, providers discussed ordering ODX testing more often 
among women with comorbidities or frailty due to older age to see if they could safely forgo adjuvant 
chemotherapy. Because young women tend to be healthier, providers discussed being less likely to 
order ODX and more likely to move forward with guideline-concordant chemotherapy among node 
positive patients.  
Third, among node positive patients, year of breast cancer diagnosis influenced ODX uptake: 
This aligns with Roger’s theory of diffusion [3], and previous work [4] demonstrating that the use of 
genetic tests increases over time, following an s-shaped curve. Node positive patients were more 
likely to receive ODX testing in 2012/2013 compared to 2008. Reasons we did not see the same 
effect in node negative patients may be due to timing of insurance coverage and guideline 
incorporation, as the first set of women enrolled in CBCS-III was in 2008. By this time, ODX testing 
was widely covered and had been included in NCCN and ACS guidelines among node negative 
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patients. This finding also aligns well with qualitative findings, in which providers described the 
barriers of ODX testing as being ameliorated over time.  
Additional Qualitative Factors That May Influence ODX Use 
 Provider interviews yielded a rich set of multilevel factors that influenced ordering ODX 
testing for adjuvant chemotherapy decision-making.  
Organizational Level Factors 
Organizational level factors appeared to be particularly influential in ordering ODX. Silos 
between surgical oncology, medical oncology, and pathology departments created barriers for 
ordering ODX in a coordinated, timely fashion. While this did not appear to dissuade ordering ODX 
testing, providers reported that these silos resulted in delays that were not clinically important, but 
may impact patients in terms of anxiety. Multidisciplinary teams that met to discuss patients during 
tumor board were viewed as easing the coordination of ordering ODX testing for patients. 
Furthermore, some providers delegated a nurse to order ODX tests. Genomic health marketing was 
often credited for providing up-to-date clinical evidence regarding ODX testing as well. Streamlined 
processes in conjunction with easy online ordering and training through Genomic Health seemed to 
facilitate ODX test use.  
Providers also discussed how insurance coverage and supportive clinical guidelines have 
facilitated test use over time. Again, this further explains why we may see differential patterns of ODX 
testing across nodal status. While currently, insurance policies and coverage support ODX testing for 
node negative disease, this is not the case for node positive disease. For these reasons, providers 
discussed lower use of ODX testing in patients with node positive disease, unless they were looking 
for additional information supporting non-use of adjuvant chemotherapy (e.g., in a frail patient) or 
were ordering ODX testing in the context of a clinical trial. Interestingly, descriptive analyses in our 
quantitative work suggested that the ODX testing has increased over time for node positive patients 
to levels similar to those among node negative patients. 
In addition to favorable guidelines and coverage, provider typically referenced Genomic 
Health as a facilitator for ordering ODX tests. Genomic Health was mentioned by all but one provider 
as providing educational materials, training, easy online resources, and help with insurance coverage. 
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This support was often referenced as a facilitator for ordering ODX tests among providers. 
Interpersonal and Social Usage Factors 
Providers discussed how ODX ordering practices among their peers, especially referring 
providers or others on their care team, influenced how they order the test. For example, some 
surgical oncologists ordered tests or discussed ODX testing with patients due to concerns that peer 
medical oncologists may not offer the test to patients who may benefit from ODX risk results. Other 
surgical oncologists discussed never ordering ODX testing, as they defer to medical oncology. 
Furthermore, providers discussed norms around ordering ODX tests within their clinics with the 
acknowledgement that not all provider groups order the ODX test and use the ODX test results the 
same way. This suggests a role for interpersonal factors and social usage of ODX testing in whether 
providers accept ODX testing within particular clinical situations (e.g., node positivity). Furthermore, it 
became apparent that variation in ODX testing exists across providers and health centers. Providers 
discussed that norms, especially around ODX testing in node positive patients varies by region, 
clinics, and individual providers. This information demonstrates why it was necessary in our 
quantitative analyses to control for provider level clustering. 
Intrapersonal-Level Factors 
 Providers described overall positive attitudes towards ODX testing compared to alternative 
gene expression profiling tests, such as Mammaprint, citing greater evidence for ODX testing 
including its inclusion in clinical guidelines. Here again, we see how time may influence ODX uptake, 
as it takes time to generate enough evidence for its subsequent incorporation into insurance policies 
and clinical guidelines. Providers also perceived patient knowledge (including misconceptions) and 
difficulty explaining the complexity of tumor gene expression profiling as challenges to incorporating 
ODX testing into clinical care for patients. Providers discussed their personal communication styles 
for describing ODX testing and results to patients: While these communication results fall outside the 
aims of this dissertation, communication styles for describing the ODX test and test results were often 
discussed. 
ODX Test Results and Adjuvant Chemotherapy Decision-Making 
Overall, we did not find racial variation in adjuvant chemotherapy decision-making among 
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women who received ODX testing. Women in the high-risk group showed a non-significant racial 
trend, with Black women being more likely to use adjuvant chemotherapy compared to white women; 
however, our sample size is too small to reach a clear conclusion. Secondary analyses utilizing 
propensity score analyses showed that Black women were 25% more likely to receive adjuvant 
chemotherapy in the high risk group in two models. (Appendix 1)  
Some previous literature found racial disparities in adjuvant chemotherapy [5-7]; however, 
our findings are consistent with recent literature that has not observed racial differences [8-10]. There 
are two potential explanations for the lack of racial differences. First, women receiving ODX testing 
may differ from women who do not receive ODX testing. So, while adjuvant chemotherapy was not 
associated with race among our cohort, these results may not generalize to patients who do not 
receive ODX. Second, our results may reflect literature that has not observed racial differences in 
adjuvant chemotherapy initiation with or without an ODX test result. Future studies could examine 
these hypotheses directly. 
High and Low Risk Scores and Adjuvant Chemotherapy 
Interestingly, we found that the vast majority of women in the high and low risk groups 
received guideline concordant chemotherapy (i.e., low risk score did not receive adjuvant 
chemotherapy, high risk score did receive adjuvant chemotherapy). Within the intermediate risk 
group, about half of women received adjuvant chemotherapy. Risk score distributions across non-
Black and Black women were similar; however, Black women tended to have higher risk scores 
compared to whites in the intermediate risk group. Furthermore, risk scores among node negative 
and node positive women were similar (Appendix 8). 
The high- and low- risk ODX scores present clear adjuvant chemotherapy decisions that 
cross cut all patient populations. Overall, the vast majority of patients with low risk scores did not 
receive adjuvant chemotherapy (93.9%); in the high risk group 80.1% received adjuvant 
chemotherapy. This corroborates qualitative findings that suggested discordant decisions (e.g., 
patients with low risk scores initiating chemotherapy) occurred less frequently, and typically resulted 
from patient preferences. Again, this was a rare event, as patient preferences were typically 
discussed prior to ordering the ODX test. Almost 20% of high-risk patients did not initiate adjuvant 
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chemotherapy: qualitative data also corroborate this trend, as providers discussed guideline 
discordant decisions to occur more frequently in the high risk group due to patients “changing their 
mind” about adjuvant chemotherapy preferences.  
Among patients with low ODX risk, higher ODX score, higher tumor grade and being married 
were independently associated with an increased likelihood of adjuvant chemotherapy initiation. In 
qualitative interviews, providers discussed ODX as a continuous score, acknowledging the actual risk 
score (rather than risk group alone) may influence decision-making, though this was more often in the 
context of the intermediate group. Similarly, higher tumor grade was associated with an increased risk 
of adjuvant chemotherapy. Among women in the low risk group, being married was also associated 
with adjuvant chemotherapy initiation, suggesting that social support may lead to higher rates of 
treatment [11]. 
Intermediate Risk Group and Adjuvant Chemotherapy Use 
Within the intermediate risk group, there is unclear evidence of benefit from adjuvant 
chemotherapy. Thus, providers and their patients with intermediate risk scores must engage in a 
more complex decision-making process. No racial differences were observed in chemotherapy 
initiation within this risk group, and about half of women in this group initiated chemotherapy. In 
qualitative interviews, providers viewed intermediate risk scores as a major barrier to ODX use. To 
mitigate this barrier, providers created decision rules for women within this group; these rules varied 
across providers, but the majority reverted to traditional factors such as tumor characteristics, age, 
and patient preferences.  
In our quantitative analysis, larger tumor size, higher ODX score, and younger age were 
associated with adjuvant chemotherapy uptake in the intermediate risk group. Young age was 
associated with adjuvant chemotherapy among the intermediate risk group, aligning with qualitative 
data where providers questioned the value of ODX testing as they were more likely to move forward 
with chemotherapy. We also found that lower income was associated with increased chance of 
receiving chemotherapy. Reasons for this result are unclear, however provider or organizational level 
factors may play a role. Further research would be necessary to understand how income is related to 
chemotherapy initiation among women receiving ODX testing. 
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Policy Relevance 
Overall, a complex array of factors influences the uptake of ODX testing and its use for 
adjuvant chemotherapy decision-making. Fortunately, racial disparities in ODX uptake were not 
observed in women with node negative breast cancer, nor was adjuvant chemotherapy decision-
making in the presence of ODX results associated with race. This suggests that in guideline-
concordant applications of ODX testing, women are equally likely to access ODX testing and 
subsequent adjuvant chemotherapy. Interestingly, Black race was a predictor of lower ODX testing 
among node positive patients for whom guidelines do not currently recommend the test. One 
interpretation is that Black women are receiving more guideline-concordant care. Alternatively, newer 
genetic technologies may be accessed less by Black patients. For the latter, interventions to increase 
the uptake of new genetic technologies should target minority patients during early adoption of tests. 
Before developing such interventions, future studies should seek to uncover reasons for the 
differences. A key to better understanding the source of this variation may lie in examining (1) 
racial/ethnic disparities in genetic technology access through clinical trials and (2) multilevel factors 
associated with the uptake of ODX testing across patient populations.  
Despite barriers, the uptake of ODX testing represents an example of a successful genetic 
technology that has reshaped breast cancer care for women with early stage disease. Hopefully, we 
can apply the lessons learned from patterns of ODX uptake to newly emerging technologies as they 
are being disseminated to patients across providers and health care settings. In addition, rapidly 
incorporating these technologies into insurance policies and practices will be critical for policy makers 
and payers.  
Limitations 
This section addresses limitations to the current study, and offers recommendations for future 
studies that address these shortcomings. 
Aims 1 and 2 
Five main limitations arose in our analytical models for Aims 1 and 2. First, we were unable to 
include patient preferences in either primary analysis. Ideally, the IOM definition of health disparities 
would have us control for patient preferences, however no such measures were available. It is 
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possible that patient preferences for ODX testing and adjuvant chemotherapy initiation vary by race, 
acting as mediating variables. If so, our estimates for the effect of being Black on ODX test receipt 
and on adjuvant chemotherapy initiation may be biased. This is possible, as evidence suggests that 
patient preferences vary by race [12]. In this scenario, instead of describing the direct of effect of race 
on ODX uptake and adjuvant chemotherapy in the modified Poisson models, we would be estimating 
the reduced form effect of race on ODX test receipt. Given that racial variation did not occur in 
adjuvant chemotherapy initiation, we would expect that patient preferences across racial groups were 
either similar or did not greatly influence adjuvant chemotherapy initiation.  
Second, qualitative results demonstrated the importance of organizational and provider level 
factors on the receipt of ODX testing, however we were unable to control for these factors in our 
quantitative analyses. Future studies should utilize data sets linked to organizational (e.g., American 
Hospital Association) and provider level data (e.g., American Medical Association).  
Third, our definition of ODX testing assumes that if a patient received ODX testing, the results 
would reside in pathology or medical records. If this assumption was false, we would underestimate 
the proportion of women who received ODX. While this is possible, uptake of ODX testing was 
consistent with that reported in other studies [13, 14]. Furthermore, if we are missing some data on 
ODX test uptake, it is likely missing at random, and given our dichotomous dependent and 
independent variables, the effect of misclassification would likely be non-differential. 
Fourth, data for income and employment were often missing, which was particularly an issue 
in Aim1. Studies indicate data on SES are not missing at random for women [15], creating potential 
bias. Thus, we created categories for missing income and employment data in Aim 1 and 2 (however 
these categories were dropped from Aim 2 analysis). Furthermore, race, ODX test receipt, and 
adjuvant chemotherapy initiation did not vary between the analytic sample and individuals with 
missing data.  
Finally, despite analyzing data from one of the largest longitudinal breast cancer studies of 
Black women, our multivariate analyses were underpowered. To gain power, we also used propensity 
score analyses to control for baseline characteristics. These models produced similar associations 
between race and our dependent variables. This strengthens the conclusion that, despite low power, 
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we have captured existing racial disparities, controlling for clinical and treatment characteristics 
(though power is still limited in the Aim 2 for the high risk group model). However, one restricted 
propensity weighted model and one restricted propensity matched model found a statistically 
significant increased likelihood of adjuvant chemotherapy initiation among Black women compared to 
non-Black women with high ODX risk scores. Using national datasets that are linked to ODX test 
uptake would not only increase sample size and power, but also generalizability, as our data were 
from a single Southeastern state. Furthermore a larger sample size would allow us to include not only 
race, but also ethnicity related information. 
Aim 3 
The main goal of this aim was to understand multilevel barriers and facilitators to ODX uptake 
in clinical practice. One advantage of using qualitative methods is the richness and depth of the data; 
however, this comes with a tradeoff for lower generalizability. Using purposive recruitment, it is likely 
that providers who agree to participate in this study differ from those who declined participating. 
Moreover, we tried to elicit providers’ opinions on why patients’ ODX uptake and chemotherapy 
initiation may differ by race or SES; however, providers were reluctant to discuss race as a factor 
associated with treatment decision-making. Our results be vulnerable to social desirability biases. 
More directed techniques (e.g., vignettes) could attempt to better isolate provider perceptions or 
biases on ODX uptake, adjuvant chemotherapy initiation, and race.  
Future Directions 
Understanding how genomic technologies influence racial disparities in cancer care 
processes and outcomes will be imperative moving forward in the era of precision medicine. This 
study provides a foundation for future research, including: 
1. Extending research to other genomic tests used in cancer care (e.g., Oncotype 
DX colon assay). 
2. Extending research to the use of genomic testing outside of cancer care (e.g., 
genetic testing for drug response, health risks, and carrier status). 
3. Informing decision-makers (policymakers and payers) about reimbursement for 
genomic tests under different insurance structures (e.g., high deductible health 
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plans) 
4. Developing interventions (e.g., genetic counseling, educational) that increase 
access to genetic/genomic testing 
5. Evaluating interventions that optimize how ODX test results are communicated 
and used in clinical practice. 
6. Developing decision tools to help patients and providers (including genetic 
counselors) make decisions around genetic/genomic testing that align with 
patient values 
7. Helping health care organizations develop infrastructures that facilitate access to 
genetic tests that improve the process and outcomes of care for their patients 
Additionally, several more specific research studies would extend this dissertation research 
focusing on (1) multilevel factors associated with ODX test uptake, (2) the interaction of time and 
organizational barriers to genetic technology use, (3) leveraging national data sets, and (4) racial 
differences in adjuvant chemotherapy completion. 
Qualitative findings demonstrated the importance of multilevel factors on ODX test uptake. 
Future studies could investigate how provider and organizational level variation affects ODX test 
uptake. Using large linked data sets would provide a good platform for conducting these analyses. 
For example, the Integrated Cancer Information and Surveillance System (ICISS) data provide multi-
payer claims that can be linked with SEER data as well as provider and organizational level factors. 
Leveraging powerful data sets such as ICISS to conduct multilevel analyses would provide valuable 
information about the diffusion of this technology into clinical care. Accounting for provider and 
organizational variation, as well as factors such as the use of multidisciplinary teams and clinical trial 
enrollment (e.g., RxPONDER and TAILORx) would be interesting organizational factors to consider. 
Another important qualitative finding was that organizational barriers appeared to dissipate 
over time, suggesting the importance of interventions during the early adoption of new genetic 
technologies. More investigation focusing on organizational practices over time would provide 
additional insights in how the use of these technologies changes over time. Prospective data 
collection on how structures for ordering and using new technologies would better elucidate this 
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process and identify targets for interventions that facilitate the incorporation of genetic technologies 
into clinical practice. Furthermore, while this dissertation uses one of the largest Black breast cancer 
cohort studies in the nation, sample size remains a limitation. Aim 1 and 2 analyses could be 
reconstructed using larger datasets, such as SEER-Medicare data linked with Genomic Health data. 
The National Cancer Institute is currently conducted such analyses, and results from their studies will 
provide the power required to investigate associations between multilevel covariates and outcomes 
[16]. 
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APPENDIX 1: PROPENSITY SCORE ANALYSES 
Background 
 In cases where there are large differences between treatment groups on observed 
covariates, usual multivariate techniques may be inadequate for addressing unbalanced 
characteristics of the groups. We can account for multiple observed covariates across two groups 
(i.e., Black and White women) using a single measure, the propensity score. Propensity score models 
provide unbiased average treatment effects, assuming no unmeasured confounding [1]. The 
propensity score is the probability of being treated (e.g., being Black) given a set of covariate values. 
This score is particularly helpful when there is limited sample size: Propensity score models not only 
decrease bias, but also increase precision when properly specified. The two most common 
approaches to propensity score application are weighting and matching [2, 3].  
 Propensity score weighting is appealing since it allows you to retain your full sample. 
However, average treatment effects can vary across propensity score weighted and matched models 
if propensity score overlap is insufficient and there are extreme observations [4]. In such cases 
weighted models may give a large amount of influence to outlier values, which may or may not be 
representative of the population of interest. Because of these concerns and potential differences 
between weighted and matched estimates, we conducted both propensity score-weighted models 
and propensity score matched models and compared results across models. This ensures that our 
propensity-weighted models were not biased due to sensitivity to extreme observations.   
 Because we had limited power in some of our primary models, these propensity models 
allowed us to control for covariates using one measure rather than multiple covariates, increasing 
power to detect clinically significant differences in the association between race with ODX testing 
receipt and adjuvant chemotherapy initiation. Thus, these models acted as sensitive analyses for our 
primary models, which used modified Poisson regression techniques with sandwich standard errors.  
Methods 
 We used STATA commands and methods created by Lunt for the implementation of 
propensity score weighting and matching [5].  
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Covariate Imbalance 
 Literature demonstrating racial differences in tumor biology and overall health among breast 
cancer patients suggest that propensity score models may be a tool for controlling underlying 
differences between Black and White women [6]. We confirmed that imbalances existed in our data 
by baseline covariates across Black and White women. Results demonstrated that covariates were 
imbalanced across racial groups in Aims 1 and 2 (Table 1-5).  
Calculating the Propensity Score 
 We used a logistic regression to model the association between tumor and clinical 
characteristics with race. The Hosmer-Lemeshow goodness of fit test was used to test the 
specification of the logistic models used to predict the propensity scores. All models passed this 
specification test (p>0.05). We then calculated the linear predictor (log odds of the propensity score) 
to compare the distributions of the propensity scores across Black and White women (Figures 1-5: 
Distribution of Log Odds of Propensity Scores across Racial Groups). The calculated propensity 
scores and linear predictors were then used for propensity weighted and matched models. 
Weighted Propensity Score Models 
 We used standardized mortality/morbidity ratio (SMR) weights to facilitate a counterfactual 
estimate of the average treatment effect [4]. Using SMR weights, we estimated the outcome of 
interest among Black patients, assuming that they had the characteristics of White patients. Next, we 
rechecked the balance of the covariates with the SMR weights: for each model, all covariates (i.e., 
year of diagnosis, tumor size, tumor grade, progesterone receptor status, mastectomy, age at 
diagnosis, number of comorbidities) included in the propensity scores were balanced with the 
propensity score weights (results not shown). Then we regressed race on our outcome variables 
using the propensity score weight. In SMR weighted models, patients treated against prediction are 
included and are assigned a particularly small or large propensity weight: these extreme weights 
often result from unmeasured confounding and can lead to biased estimates. Thus, we excluded 
them from the analysis using trimming: we trimmed the 5th percentile of observations with particularly 
large or small propensity scores and recalculated the average treatment effect (excluded patients with 
propensity scores outside of the 5th-95th percentile). 
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Matched Propensity Score Models 
 We used Greedy matching techniques for our propensity score-matched analysis. This 
technique matches a set of Black women’s propensity scores with a set of White women’s propensity 
scores: Greedy matching uses the best match available; once a match is made, it is not reconsidered. 
Best matches are made until there are no more possible pairings [7]. Parson’s Greedy matching 
technique first matches on 5 digits, then 4 digits down to 1 digit. One potential downfall to this 
approach is that match quality may decrease after a certain point, because the technique insisted on 
finding a match for each observation with Black race. We set a caliper of 0.1; this excludes poor 
matches from the analysis and improves the overall quality of matching in our analysis [8]. We then 
rechecked the balance of the covariates after setting the caliper, and we found our covariates to be 
balanced (Table 1-5). Then we regressed race on our outcome variables using matching with the 0.1 
caliper.  
Results 
Aim 1 
 Because both weighted and matched models yielded similar results, we present propensity 
weighted analyses as this technique retains the full sample of women. Racial differences in ODX 
testing receipt were not found among women with node negative disease, however differences were 
found among women with node positive disease. Black women were 13% less likely to receive ODX 
testing compared to White women (ATE=-0.13, 95% CI= -0.22, -0.030 p=0.01) (Table 6).  
Aim 2 
 Propensity score weighted and matched models yielded different results. Likely, weighted 
models were vulnerable to extreme observations. Racial differences in adjuvant chemotherapy 
initiation were not found among women across ODX risk groups in propensity score matched models 
(Table 7). Racial differences in adjuvant chemotherapy initiation were uncovered among women in 
the high risk group in our propensity score weighted model (Table 8). AA women in the high risk 
group were 25% more likely to initiate adjuvant chemotherapy compared to non-AA women 
(ATE=0.25, 95% CI= 0.051, 0.46, p=0.015. 
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Conclusions 
 Results from our propensity score analyses corroborated findings in our primary modified 
Poisson regression models for both Aims 1 and 2: While there were no racial differences in ODX 
testing receipt among node negative patients, Black women were less likely to receive ODX testing 
compared to White women with node positive disease. There were no racial differences in adjuvant 
chemotherapy initiation across ODX risk groups. Furthermore, propensity score weighted and 
matched models yielded similar findings across all analyses.  
Propensity weighted models for the high risk group in Aim 2 suggests that AA women are 
25%-28% more likely to receive adjuvant chemotherapy compared to non-AA women. Racial 
differences are only observed after trimming and restricting results: this suggests that among this 
select subpopulation of patients, AA women are more likely to receive guideline concordant 
chemotherapy compared to non-AA women. Overall, results from these models suggest decreased 
ODX receipt among AA women compared to non-AA women with node positive breast cancer, but 
not node negative breast cancer. Furthermore, race does not seem to influence adjuvant 
chemotherapy initiation; however, AA women may be more likely to initiate adjuvant chemotherapy in 
the high-risk group. 
Limitations 
 Propensity score models can only balance the “treatment” groups by observed variables, 
which are included in the model. Furthermore, propensity score analyses are as good as the 
variables used in the propensity score estimation, that is, the treatment variable, race, must largely be 
a function of the observed characteristics. Finally, propensity score models assume balance on 
unmeasured confounding, which we cannot confirm. 
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Tables 
Table 1. Means by race and standardized differences between baseline characteristics by race 
demonstrating differences in covariates across racial groups with node negative breast 
cancer in Aim 1 before and after propensity score weighting. Standardized differences 
measure effect sizes between two groups independent of sample size. Yellow indicates 
imbalance across racial groups. 
 
Aim 1. Node Negative: Baseline Characteristics: 
unbalanced without propensity scores 
Baseline Characteristics: balanced 
with propensity score weighting 
Variable Mean in 
AA 
Mean in 
non-AA 
Standardized 
Difference 
Mean in AA Mean in 
non-AA 
Standardized 
Difference 
Age <50 0.4 0.45 -0.1 0.38 0.38 0.016 
Large tumor 
size 0.03 0.03 0.03 0.03 0.03 0.024 
Small tumor 
size 0.69 0.78 -0.197 0.7 0.69 0.013 
Medium tumor 
size 0.28 0.19 0.193 0.27 0.28 -0.024 
Tumor grade 
1 0.31 0.38 -0.163 0.48 0.5 -0.034 
Tumor grade 
2 0.48 0.45 0.052 0.21 0.19 0.041 
Tumor grade 
3 0.21 0.16 0.131 0.31 0.31 0.001 
PR Positive 0.81 0.9 -0.237 0.82 0.84 -0.062 
Mastectomy 0.34 0.39 -0.109 0.33 0.33 0.003 
# 
Comorbidities 1.18 0.6 0.607 1.2 1.33 -0.137 
Diagnosis 
2008 0.1 0.1 -0.006 0.1 0.1 0.025 
Diagnosis 
2009 0.18 0.21 -0.091 0.18 0.17 0.024 
Diagnosis 
2010 0.24 0.25 -0.028 0.24 0.25 -0.022 
Diagnosis 
2011 0.28 0.22 0.123 0.28 0.29 -0.013 
Diagnosis 
2012 0.18 0.21 -0.066 0.19 0.19 -0.005 
 
 
Table 2. Means by race and standardized differences between baseline characteristics by race 
demonstrating differences in covariates across racial groups with node positive breast cancer 
in Aim 1 before and after propensity score weighting. Standardized differences measure 
effect sizes between two groups independent of sample size. Yellow indicates imbalance 
across racial groups. 
 
Aim 1. Node Positive: Baseline Characteristics: 
unbalanced without propensity score weighting 
Baseline Characteristics: balanced 
with propensity score weighting 
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Variable Mean in 
AA 
Mean in 
non-AA 
Standardized 
Difference 
Mean in 
AA 
Mean in 
non-AA 
Standardized 
Difference 
Age <50  0.55  0.58  -0.063 0.52 0.5 0.044 
Large tumor 
size  0.02  0.02  -0.023 0.02 0.02 0.016 
Small tumor 
size  0.44  0.52  -0.167 0.44 0.43 0.007 
Medium tumor 
size  0.54  0.46  0.173 0.54 0.55 -0.011 
Tumor grade 1  0.17  0.26  -0.205 0.17 0.22 -0.117 
Tumor grade 2  0.44  0.50  -0.116 0.44 0.44 -0.013 
Tumor grade 3  0.38  0.24  0.309 0.39 0.34 0.118 
PR Positive  0.79  0.93  -0.404 0.79 0.8 -0.044 
Mastectomy  0.49  0.55  -0.126 0.48 0.49 -0.028 
# Comorbidities  0.98  0.56  0.437 1.02 1.11 -0.096 
Diagnosis 2008  0.13  0.13  -0.001 0.14 0.11 0.082 
Diagnosis 2009  0.24  0.18  0.152 0.25 0.27 -0.027 
Diagnosis 2010  0.19  0.23  -0.105 0.2 0.2 0.006 
Diagnosis 2011  0.25  0.25 0.009 0.27 0.28 -0.023 
Diagnosis 2012  0.13  0.22  -0.220 0.14 0.15 -0.024 
 
 
 
 
Table 3. Means by race and standardized differences between baseline characteristics by race 
demonstrating differences in covariates across racial groups with low ODX risk tumors in the 
Aim 2 sample before and after propensity score weighting. Standardized differences measure 
effect sizes between two groups independent of sample size. Yellow indicates imbalance 
across racial groups. 
 
Aim 2. Low ODX Risk Group: Baseline 
Characteristics: unbalanced without propensity 
score weighting 
Baseline Characteristics: balanced 
with propensity score weighting 
Variable Mean in 
AA 
Mean in 
Non-AA 
Standardized 
diff. 
Mean in 
AA 
Mean in 
Non-AA 
Standardize
d diff. 
Node Positive 0.15 0.13 0.05 0.12 0.15 -0.073 
Age < 50 0.43 0.5 -0.14 0.41 0.4 0.023 
ODX Score 11.32 11.65 -0.08 11.41 11.5 -0.022 
Small tumor 0.73 0.75 -0.04 0.73 0.74 -0.01 
Medium tumor 0.27 0.25 0.04 0.27 0.26 0.01 
Large tumor 0 0 . 0 0 . 
Tumor grade 1 0.62 0.53 0.18 0.29 0.29 -0.002 
Tumor grade 2 0.3 0.41 -0.24 0.63 0.61 0.037 
Tumor grade 3 0.08 0.05 0.1 0.08 0.1 -0.069 
PR Positive 0.97 0.98 -0.03 0.97 0.97 -0.011 
Mastectomy 0.34 0.4 -0.13 0.33 0.34 -0.022 
# 
Comorbidities 1.06 0.59 0.55 1.08 1.12 -0.046 
Diagnosis 0.16 0.09 0.22 0.16 0.14 0.068 
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2008 
Diagnosis 
2009 0.19 0.19 -0.01 0.2 0.2 -0.016 
Diagnosis 
2010 0.15 0.26 -0.28 0.15 0.16 -0.007 
Diagnosis 
2011 0.27 0.25 0.04 0.28 0.25 0.06 
Diagnosis 
2012 0.2 0.21 -0.02 0.21 0.25 -0.098 
 
 
 
 
Table 4. Means by race and standardized differences between baseline characteristics by race 
demonstrating differences in covariates across racial groups with intermediate ODX risk 
tumors in the Aim 2 sample before and after propensity score weighting. Standardized 
differences measure effect sizes between two groups independent of sample size. Yellow 
indicates imbalance across racial groups. 
 
Aim 2. Intermediate ODX Risk Group: Baseline 
Characteristics: unbalanced without propensity 
score weighting 
Baseline Characteristics: balanced 
with propensity score weighting 
Variables Mean in 
treated 
Mean in 
Untreated 
Standardize
d diff. 
Mean in 
treated 
Mean in 
Untreated 
Standardiz
ed diff. 
ODX Score 22.97 22.07 0.248 23.01 23.34 -0.089 
Node 
Positive 0.1 0.2 -0.294 0.09 0.09 0 
Age < 50 0.4 0.49 -0.165 0.36 0.38 -0.038 
Grade 2 0.53 0.57 -0.094 0.51 0.51 0.005 
Grade 3 0.14 0.22 -0.203 0.15 0.2 -0.14 
Grade 1 0.33 0.21 0.281 0.34 0.29 0.116 
PR Positive 0.78 0.92 -0.395 0.78 0.83 -0.147 
Mastectomy 0.26 0.43 -0.358 0.27 0.27 -0.003 
# 
Comorbiditie
s 0.92 0.46 0.575 0.97 1 -0.034 
Diagnosis 
2008 0.08 0.13 -0.163 0.09 0.11 -0.051 
Diagnosis 
2009 0.19 0.23 -0.09 0.21 0.18 0.073 
Diagnosis 
2010 0.25 0.23 0.043 0.27 0.27 0 
Diagnosis 
2011 0.29 0.19 0.247 0.31 0.33 -0.03 
Diagnosis 
2012 0.11 0.22 -0.286 0.12 0.12 -0.003 
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Table 5. Means by race and standardized differences between baseline characteristics by race 
demonstrating differences in covariates across racial groups with high ODX risk tumors in the 
Aim 2 sample before and after propensity score weighting. Standardized differences measure 
effect sizes between two groups independent of sample size. Yellow indicates imbalance 
across racial groups. 
 
Aim 2. High ODX Risk Group: Baseline 
Characteristics: unbalanced without propensity 
score weighting 
Baseline Characteristics: balanced 
with propensity score weighting 
Variables Mean in 
AA 
Mean in 
non-AA 
Standardized 
diff. 
Mean in AA Mean in 
non-AA 
Standardized 
diff. 
Node Positive 0.08 0.07 0.062 0.08 0.06 0.078 
Age < 50 0.5 0.53 -0.065 0.5 0.63 -0.246 
ODX Score 39.13 41.4 -0.246 39.13 39.83 -0.076 
Small tumor 0.54 0.77 -0.477 0.54 0.79 -0.523 
Medium tumor 0.46 0.23 0.477 0.46 0.21 0.523 
Grade 2 0.25 0.17 0.202 0.25 0.18 0.169 
Grade 3 0.71 0.77 -0.13 0.71 0.71 -0.007 
Grade 1 0.04 0.07 -0.109 0.04 0.11 -0.29 
PR Positive 0.63 0.63 -0.017 0.63 0.76 -0.271 
Mastectomy 0.42 0.47 -0.099 0.42 0.32 0.199 
# 
Comorbidities 1.33 0.67 0.664 1.33 1.66 -0.323 
Diagnosis 
2008 0.17 0.17 0 0.17 0.11 0.144 
Diagnosis 
2009 0.13 0.2 -0.201 0.13 0.11 0.039 
Diagnosis 
2010 0.25 0.23 0.038 0.25 0.23 0.056 
Diagnosis 
2011 0.38 0.23 0.306 0.38 0.48 -0.224 
Diagnosis 
2012 0.08 0.17 -0.249 0.08 0.07 0.03 
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Table 6. Average treatment effect (restricted and trimmed) of AA race compared to non-AA race on 
ODX test receipt among node negative and node positive patients. 
 
 
Treatment Effect of Race on ODX use with PS Weighting: Restricted & 
Trimmed 
  Node Negative Node Positive 
ODX 
Average 
Treatmen
t Effect P>|t|  
 [95% Conf. 
Interval] 
Average 
Treatment 
Effect P>|t|  
 [95% Conf. 
Interval] 
AA  
(v. non-AA) -0.068  0.060  
-0.14, 
0.0029  -0.13  0.011  -0.22, -.030 
constant 0.48  <0.001 0.44, 0.53  0.27 <0.001 0.20, 0.35 
 
 
 
 
Table 7. Aim 2. Average treatment effects from the propensity matched models with restriction and 
trimming. (ATE=average treatment effect, p=p-value, CI= Confidence Interval) 
 
AIM 2. Propensity Matched Models 
LOW RISK ATE p 95% CI 
Black 0.014 0.765 -0.076, 0.10 
Constant 0.083 0.008 0.022, 0.14 
INTERMEDIATE 
RISK 
      
Black -0.044 0.675 -0.26, 0.17 
Constant 0.46 <0.001 0.32, 0.59 
HIGH RISK        
Black 0.29 0.040 0.015, 0.56 
Constant 0.74 <0.001 0.58, 0.91 
 
 
 
 
Table 8. Aim 2. Average treatment effects from the propensity weighted models with restriction and 
trimming. (ATE=average treatment effect, p=p-value, CI= Confidence Interval) 
 
AIM 2. Propensity Weighted Models 
LOW RISK ATE p 95% CI 
Black 0.0036 0.92 -0.066, 0.073 
Constant 0.071 0.001 0.029, 0.11 
INTERMEDIATE 
RISK 
      
Black -0.0356 0.71 -0.23, 0.16 
Constant 0.46 <0.001 0.35, 0.58 
HIGH RISK        
Black 0.25 0.015 0.051, 0.46 
Constant 0.75 <0.001 0.54, 0.95 
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Figures 
 
Figure 1. Propensity weights by race (White=non-AA, Black=AA) among node negative patients in 
Aim 1. 
 
 
Figure 2. Aim 1. Propensity scores by race (White=non-AA, Black=AA) among node positive. 
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Figure 3. Aim 2: Propensity scores by race (White=non-AA, Black=AA) among women with low ODX 
risk scores. 
 
 
Figure 4. Aim 2: Propensity scores by race (White=non-AA, Black=AA) among women with 
intermediate ODX risk scores. 
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Figure 5. Aim 2: Propensity scores by race (White=non-AA, Black=AA) among women with high ODX 
risk scores. 
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APPENDIX 2: RECRUITMENT LETTER 
 
[Date] 
 
Dear [Provider Name]: 
 
 I am a PhD student from the Department of Health Policy and Management at School of 
Public Health. For my dissertation, I am collaborating with faculty from my Department, as well as 
oncologists from the Lineberger Comprehensive Cancer Center (including Dr. Katie Reeder-Hayes) to 
better understand how Oncotype DX is being used by oncologists to make treatment decisions when 
caring for women with breast cancer. We are reaching out to medical and surgical oncologists, such 
as you, who have expertise and experience with breast cancer patients. We seek your insights into 
the ways Oncotype DX testing is being used in clinical practice. We hope that you would be willing to 
complete a brief questionnaire and participate in a 30-minute phone interview to provide your insights 
and to support the work of a UNC doctoral student. If you see at least five breast cancer patients a 
week (to establish care, undergo treatment, for follow-up, etc) and are interested in participating, 
please simply reply to this email. Upon your reply, we will schedule a time for the interview via phone 
to discuss Oncotype DX; we would also provide a link to the brief (less than 5 minute) questionnaire 
that asks for descriptive information about you and your practice. As a token of our appreciation for 
your participation in this study, you would be offered a $100 VISA gift card. If you have any questions, 
please feel free to contact me by email (mclarker@unc.edu).  
 
Thank you in advance for your time and consideration.  
Best regards, 
 
Megan Roberts 
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Megan Roberts 
CCEP Pre-doctoral Fellow 
Department of Health Policy and Management 
Gillings School of Global Public Health 
University of North Carolina at Chapel Hill 
McGavran-Greenberg Hall, CB# 7411 
Chapel Hill, NC 27599-7411 
717.448.3247 
mclarker@unc.edu 
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APPENDIX 3: INFORMED CONSENT AND SURVEY 
Before completing this brief survey, you must provide your informed consent below. Please 
read the information below: After you review the information below, you will be asked whether 
or not you voluntarily agree to participate in the study. The survey should take no more than 5 
minutes to complete. 
________________________________________________________________ 
University of North Carolina-Chapel Hill 
Written Consent to Participate in a Research Study  
Adult Participants: Oncologists 
Social Behavioral Form 
________________________________________________________________ 
Consent Form Version Date: March, 11 2014 
 
Title of Study: Understanding racial disparities in the diffusion of Oncotype DX in breast cancer  
Principal Investigator: Megan Roberts 
UNC-Chapel Hill Department: Health Policy and Management 
Phone number: 717.448.3247 
Co-Investigators: Morris Weinberger, Stephanie Wheeler, Katie Reeder-Hayes, Stacie Dusetzina, 
Michaela Dinan  
Funding Source and/or Sponsor: CCEP Pre-Doctoral Fellowship, UNC Lineberger Comprehensive 
Cancer Center, Megan Roberts 
Study Contact telephone number: 717.448.3247 
Study Contact email: mclarker@unc.edu 
________________________________________________________________ 
Information about this study  
The purpose of this study is to understand how oncologists use Oncotype DX testing to help make 
treatment decisions for breast cancer patients. We will interview breast medical and surgical 
oncologists about this topic. For this study, we are interested in what you think about the benefits and 
challenges of Oncotype DX testing for providing care to women with breast cancer.  
If you decide to participate, you will be one of up to 20 oncologists in this research study. Your 
involvement will include completing a short (~5 minute) survey and participating in a 30-minute 
telephone interview. With your permission, the interview will be audiotaped, and the interviewer will 
take notes on the discussion so that the research team can learn about your thoughts on this topic.  
 
Possible benefits from being in this study 
 
Your participation in this study will increase our understanding of how Oncotype DX may be used to 
improve cancer care for women with breast cancer. You will be offered a $100 VISA gift card for 
taking part in this study. 
 
Possible risks from being in this study 
 
The risks and discomforts related to this study are minimal. We will take great care to protect the 
confidentiality of the information you provide. The audio recordings and notes from the interview will 
be kept confidential, which means that the information will be kept in a secure, password-protected 
computer that will be accessed only by the principal investigator of the study team. All data will be 
de-identified.  
 
You will not be mentioned by name in any reports, articles or presentations that result from this study. 
In the event of publication of this research we will not disclose any personally identifiable information.  
 
Your contact information will be kept confidential as required by law and will be kept in a separate, 
secured file. Your name and address will only be used to send you the $100 VISA gift card. Federal 
Privacy Regulations provide safeguards for privacy, security, and authorized access. Except when 
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required by law, you will not be identified by name, address, telephone number, or any other direct 
personal identifier disclosed outside of the University of North Carolina. 
 
For UNC employees ONLY 
 
Taking part in this research is not a part of your University duties, and refusing will not affect your job. 
You will not be offered or receive any special job-related consideration if you take part in this 
research.  
 
Withdrawing from the Study 
You can withdraw from this study at any time, without penalty. The investigators also have the right to 
stop your participation at any time.  
 
What if you have questions about this study? 
You have the right to ask and have answered, any questions you may have about this research. If 
you have questions, complaints, concerns, or if a research-related injury occurs, you should contact 
the researchers listed on the first page of this form.  
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights and 
welfare. If you have questions or concerns about your rights as a research subject, or if you would 
like to obtain information or offer input, you may contact the Institutional Review Board at 919-966-
3113 or by email to IRB_subjects@unc.edu. 
 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
Title of Study: Understanding racial disparities in the diffusion of Oncotype DX in breast cancer  
 
Principal Investigator: Megan Roberts 
 
Participant’s Agreement:  
 
Do you voluntarily agree to participate in this research study? 
 
[Drop down menu] YES, NO 
 
Please complete the following brief survey:  
 
1. What is your gender? 
a. Female 
b. Male 
 
2. What is your age? ________________  
 
 
3. What is your race/ethnicity? (circle all that apply) 
a. White  
b. Black 
c. Asian 
d. Hispanic 
e. Native American 
f. Other_______________________________ 
 
4. What is your role in patient care? 
a. Medical Oncologist 
b. Surgical Oncologist 
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5. How many years have you been in practice since completing training (all residency and 
fellowship training)? ________________  
 
6. Among my peers, I am usually the first to try out new medical technologies for clinical care 
(including screening technologies, new diagnostic and prognostic tests, and therapeutics) 
<strongly disagree, disagree, somewhat disagree, neither agree or disagree, somewhat agree, 
agree ,strongly agree> 
 
 
In order for us to better understand the patient population that you serve, please estimate the 
following:  
 
7. Approximately what percent of your patients are insured by Medicaid? ______% 
8. Approximately what percent of your patients have no insurance? _____% 
9. In terms of your patients’ racial/ethnic background, approximately what percent of your 
patients are (these figures should add to 100%):  
a. White   ________%  
b. Black   ________%  
c. Hispanic  ________%  
d. Other   ________%  
 
10. Estimate the percentage of your patients who have breast cancer __________________%  
 
11. Estimate how many total breast cancer patients that you see in an average week? 
__________________ per week  
 
12. Estimate the percentage of your breast cancer patients that are hormone receptor 
positive?__________________%  
 
 
In order for us to better understand the practice in which you serve, please estimate the 
following about your practice setting:  
 
13. Describe your practice setting: (select all that apply) 
a. Public 
b. Private 
c. Academic Affiliated 
d. Non-Academic Affiliated 
e. Urban 
f. Rural 
g. Suburban 
 
 
14. How many other providers in your practice treat breast cancer patients? __________________  
 
15. In a given month, estimate how many times you order Oncotype DX for your patients. 
______________ 
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APPENDIX 4: SEMI-STRUCTURED INTERVIEW GUIDE 
 
 Oncology Clinicians—Interview Guide 
 
Oncotype DX Use in Clinical Practice 
 
I. Introduction  
 
Hello, I’d like to thank you for your time and interest in our research project. Your participation 
is very important to us. My name is Megan Roberts and I’ll be talking with you today about the 
use of the tumor gene-profiling test, Oncotype DX, in the care of early stage breast cancer 
patients. Your opinions as an oncologist are extremely valuable as we try to better understand 
factors affecting the use of this test in clinical practice.  
 
I will be audio taping our discussion, because I want to make sure I don’t miss anything. I will 
ultimately summarize the comments of all oncologists that I have interviewed. I want to assure 
you that your comments will be kept confidential and that nothing you say will be connected 
with your name or your patients. We are interested in your ideas, comments and suggestions. 
Please feel free to share your thoughts and talk candidly during the discussion. 
 
 
II. Personal Attitudes and Beliefs 
First, I would like to hear about your personal thoughts about how you use Oncotype DX 
testing in your own practice. 
 
2. Think about last month, how often would you estimate that you ordered ODX testing for your 
patients? * 
If NO & surgical oncologist, Start w/ #7. 
3. When you recommend/order the test, at what point following diagnosis do you typically do so? 
 
4. How do you (your team) decide which of your patients should be offered this test? For whom 
would you recommend ODX? * 
  PROBE IF NECESSARY: 
a. Do you ever use ODX for your node positive patients? Why/why not? 
b. Do you ever use ODX for your patients with DCIS? Why/why not? 
c. Do you ever use ODX for your patients with metastatic disease? Why/why not? 
d. Among your patients who you feel are eligible for this test, which of your patients do 
you think benefit most from having this test (e.g., clinical characteristics, age, family 
history, etc.)? 
 
5. Do you discuss with your patient whether they should have Oncotype DX testing? If YES, how 
do you discuss with your patients whether they should get Oncotype DX testing? 
  PROBE IF NECESSARY: 
a. Do your patients ever refuse to get Oncotype DX testing? If so, why? 
i. What role, if any, does cost influence Oncotype DX use for your patients?  
1. IF YES, Do you explicitly discuss costs with your patients? 
ii. What role do patients’ preferences play in determine whether or not your 
patients receive Oncotype DX testing? 
1. Have you noticed any racial, cultural, educational, economic 
differences in your patients’ preferences regarding ODX use?  
b. Are there alternative tests that you believe are more useful for your chemotherapy 
decision-making? If so, which ones? * 
 
134 
Now, I’d like to transition into discussing how you use the Oncotype DX test result for your 
patients. 
 
4. How do you discuss the Oncotype DX result with your patient? * 
PROBE:  
a. Do you use the Oncotype DX chart that Genomic Health produces with your 
patients? If so, what is useful about the presentation of the results? What do you 
think could be done better? 
i. Do you provide your patient with a copy of the Genomic Health report? 
b. What are the challenges and strengths of using Oncotype DX test results in your 
treatment decision-making? * 
i. Do you have patients who you worry won’t be able to interpret the results? 
(e.g., age, race, education, etc.) 
ii. Is the waiting time for a test result ever a problem? 
 
5. How does the Oncotype DX risk score influence your (your team’s) treatment decision-
making? 
PROBE:  
a. How do you handle intermediate risk scores in terms of your decision-making? 
b. Do your patients interpret intermediate risk scores differently? Are there any patterns 
(e.g., racial or cultural or SES or rural/urban) that seem to influence how the score is 
used in their decision-making? 
c. Are there times when a patient of yours with a low risk score may still have 
chemotherapy? 
d. Are there times when a patient of yours with a high-risk score will forgo 
chemotherapy? 
 
6. Overall, how do you feel that the availability of the Oncotype DX has changed the way that you 
treat breast cancer? * 
 
 
Now if we step back for a moment, I would like to talk with you about how Oncotype DX is 
being used among your colleagues in your practice. First, please think about your 
colleagues…  
 
III. Interpersonal Factors 
 
7. Now that both surgeons and medical oncologists can order the test, how do you coordinate 
who orders the test for a given patient? 
a. Do the opinions and practices of other oncologists that you work with influence your 
use of ODX?  
i. If YES, How? May need to move up for those who do not may ODX orders 
 
IV. Organizational Factors 
Now I’d like to discuss practice-level factors… 
 
8. Are there things about the way that your practice is set up that makes using Oncotype DX 
especially difficult or easy? 
PROBE:  
a. Ordering the test 
b. Filing and getting reimbursement from insurance companies through Genomic Health 
 
9. Has a representative from Genomic Health been to your practice? 
a. IF YES: Have you found the information or services they provide to be helpful? In 
what way?” 
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VI. Closing 
Thank you very much for participating in these interviews. Within the next two weeks you will 
receive a thank you letter with $100 visa gift card in appreciation for the time that you took to 
speak with me today. (Confirm mailing address) (Give providers the opportunity to deny $100 
VISA gift card if they choose.) 
 
10. Is there anything else you would like to share with me today? Are there any challenges with or 
strengths of this test that you feel we haven’t discussed? 
 
 
 
THANK YOU VERY MUCH! 
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APPENDIX 5: INCLUSION/EXCLUSION CRITERIA, AIM 2 
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APPENDIX 6: CODING TEMPLATE 
 
Appendix 6. Final code template and code definitions applied for analysis. 
Code Template Code Definition Code Frequency 
Attitudes/ 
Perceptions 
 
Provider attitudes about Oncotype 
DX use 
 
 Cost Cost of ODX as a barrier or facilitator 30 
 Speed/Timing Speed or timing of ODX test to result 18 
 
Perceived 
Patient 
Preferences 
Provider’s use of patient preferences in 
ODX use 
57 
 Biopsy Results 
Clinical characteristics that influence 
ODX use 
84 
 Age Impact of age on ODX use 48 
 
Uncertainty 
Around 
Chemotherapy 
Role that uncertainty plays in using 
ODX 
18 
 
Perceived 
Benefits 
Provider perceived benefits for ODX use 27 
 Comorbidities Impact of comorbidities on ODX use 22 
 Geography 
Impact of patient or practice geography 
on ODX us 
6 
 SES Impact of patients' SES on ODX us 7 
 Research Gaps 
Areas where data are lacking around 
ODX use and subsequent 
chemotherapy decisions 
13 
 
Alternative 
Tests 
Use or reasons for non-use of other 
tests as alternatives of ODX 
17 
 Positive Node Role of positive nodes on ODX use 36 
 Stories 
Clinical vignettes to demonstrate ODX 
use 
12 
Barriers  
Factors that prevent providers from 
using ODX 
51 
Facilitators  
Factors that promote providers’ use 
of ODX 
53 
Communication  
Provider discussions with patients 
about ODX 
 
 
Pre-test 
Communication 
Provider discussion with patients about 
using ODX 
59 
 
Post-test 
Communication 
Provider discussion with patients about 
ODX test result 
50 
 
Perceived 
Patient 
Knowledge 
Provider’s belief about patients' 
understanding of ODX 
28 
Decision 
Making 
 
How provider's use ODX to make 
chemotherapy decisions 
 
 
Intermediate 
Risk Group 
How providers communicate results and 
make chemotherapy decisions in the 
intermediate risk group 
35 
 
Discordant 
Decisions 
Why chemotherapy decisions may 
discord with ODX results 
24 
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Organizational 
Factors 
 
How structures and policies 
influence ODX use 
 
 
Organization of 
Practice 
How the organization of the practice 
influences ODX use 
47 
 Guidelines 
How insurance and clinical guidelines 
influence ODX use 
39 
 
Genomic 
Health 
Marketing 
How marketing from Genomic Health 
impacts ODX use 
19 
Social Usage  
How peers and social norms 
influence ODX use 
 
 
Physician 
Roles 
How physicians' roles influence ODX 
use 
47 
 
Normative 
Beliefs 
Providers’ beliefs about how other 
providers use ODX 
17 
 
Motivation to 
Comply 
How providers' change ODX use based 
on their beliefs about how other 
providers use ODX 
13 
Personal 
Disposition to 
Innovativeness 
 Providers’ tendency to be innovative  
 
New 
Studies/Clinical 
Trials 
How participating in- or evidence from- 
clinical trials influences ODX use 
18 
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APPENDIX 7: THEMATIC SATURATION 
 
Appendix 7. Thematic saturation occurred before 15 interviews: No new themes emerged following 
the seventh interview. 
Theme Emergence Provider Interviews 
Super Codes Codes 1-5 6-10 11-15 
Attitudes/ 
Perceptions   
  
    
  Cost X    
  Speed/Timing X    
  
Perceived 
Patient 
Preferences 
X 
   
  Biopsy Results X    
  Age X    
  
Uncertainty 
Around 
Chemotherapy 
X 
   
  
Perceived 
Benefits 
X 
   
  Comorbidities X    
  Geography X    
  SES  X   
  Research Gaps X    
  
Alternative 
Tests 
X 
   
  Positive Node X    
  Stories 
X 
    
Personal 
Disposition to 
Innovativeness   
  
    
  
New 
Studies/Clinical 
Trials 
X 
    
Communication         
  
Pre-test 
Communication 
X 
   
  
Post-test 
Communication 
X 
   
  
Perceived 
Patient 
Knowledge 
X 
    
Decision 
Making   
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Intermediate 
Risk Group 
X 
   
  
Discordant 
Decisions 
X 
    
Social Usage         
  Physician Roles X    
  
Normative 
Beliefs 
X 
   
  
Motivation to 
Comply 
X 
    
Organizational 
Factors   
  
    
  
Organization of 
Practice 
X 
   
  Guidelines X    
  
Genomic Health 
Marketing 
X 
    
Barriers   X     
Facilitators   X     
 # New Themes 27 1 0 
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APPENDIX 8: ODX RISK SCORES BY LYMPH NODE STATUS 
Appendix 8. Kernel density of ODX risk scores by lymph node status.
 
 
 
